var title_f19_30_19936="Benefit clopidogrel over time";
var content_f19_30_19936=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F53809&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F53809&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 521px\">",
"   <div class=\"ttl\">",
"    Benefit of clopidogrel in CURE increases over time",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 501px; height: 286px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Impact of clopidogrel compared with placebo on the incidence of cardiovascular death, MI, or stroke in the CURE trial of patients with a non-ST elevation acute coronary syndrome within first 30 days (left panel) and, among those who were event-free at that time, from 31 days to 12 months. In both time periods, clopidogrel therapy was associated with increasing benefit over time (relative risk 0.79 and 0.82, respectively).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Yusuf S, Mehta SR, Zhao F, et al. Circulation 2003; 107:966.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_30_19936=[""].join("\n");
var outline_f19_30_19936=null;
var title_f19_30_19937="Radiation field stage I HL";
var content_f19_30_19937=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F66021&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F66021&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 503px\">",
"   <div class=\"ttl\">",
"    Involved-node radiation for a patient with stage I Hodgkin lymphoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 483px; height: 246px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Patient with stage I Hodgkin lymphoma involving the left neck. The gross tumor volume (PET + node) is displayed in red.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Yahalom J, Hoppe RT, Mauch PM. Principles and Techniques of Radiation Therapy for Hodgkin Lymphoma. In: Hodgkin Lymphoma, 2nd ed, Hoppe RT, Mauch PT, Armitage JO, et al, (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2007. Copyright &copy; 2007 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_30_19937=[""].join("\n");
var outline_f19_30_19937=null;
var title_f19_30_19938="APBU with stone";
var content_f19_30_19938=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F63089&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F63089&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 485px\">",
"   <div class=\"ttl\">",
"    Anomalous pancreaticobiliary union with biliary cyst and obstructing stone",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 465px; height: 361px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A) Endoscopic retrograde cholangiopancreatography (ERCP) shows obstructing stone. B) After sphincterotomy, a balloon is inserted through the papilla and inflated upstream of the stone. C) Contrast injected into the duct demonstrates successful removal of the stone and resolution of the obstruction.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: ERCP in Paediatric Practice: Diagnosis and Treatment, Isis Medical Media LTD, Oxford University Press, UK 1997. Copyright &copy;1997 Oxford University Press.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_30_19938=[""].join("\n");
var outline_f19_30_19938=null;
var title_f19_30_19939="Diploid-triploid mosaicism";
var content_f19_30_19939=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F66227&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F66227&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Diploid-triploid mosaicism",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Diploid-triploid mosaicism. Note the skin syndactylies.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of John Tolmie, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_30_19939=[""].join("\n");
var outline_f19_30_19939=null;
var title_f19_30_19940="Equipment for removal of ear foreign bodies";
var content_f19_30_19940=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F86351&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F86351&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Equipment for removal of foreign bodies from the external auditory canal",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 367px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFvAfgDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDaTKggAFuxPGamjcIAskY64x/Wq6buhbIPPTp709UbLFpBkc4PQ/WtzAtiUBRiMDGKbM0LOQBhsZAqpGdgwzhNx6ZzTuOXBdjjHPr7UhkrOUU4Qg5/MVMJYxGdgLfpiqSAltzs34GpUAYYzlfTPNAyd+CCpGcZP/16GHmIrMNp9KYHxk47YyR3qEyPJwPug8kdqYFuMYbBJB6Zx1FTx5GeQR1P/wBaqyK4iHUnpnOSak3OqkleRxigCx5g5G3PGQGHBFMLICMhvp6fjUa7yflbaScYqdYssMkE45x/OgQxpVLHZnHcAVIQ8YzOdy44x2+lKm1P9XguD0xzT3KuNpXJHPSgY2PLEkqGB9ewqdIGCDZnPbPQUyGDAxIRk9uxFW4+MHcMDsOlMCEyYIRTuYnv0qaNBg7wefQfzqFlG/eW5HTninkuV2lifbOCaAJWARlKY9zTXZW+8SxHp3qJXCZLckcfhSY3EndkHpxyKQx/mOW2pt69ew+tZWrQSzS6cz42JdDcV7ZHH6irrK0W3BJz/CR2pimQ7DICynnb1FXCbhJSRM480eVizs8blmU7T2HT8arC9iMgTzAxJwPr6VDreogs0CHDdXPUj2FZ9hbq7Gd3CRQ/OSe+Ow96zR1ww9488iz4hj8tornaqgfIxXv/AJ5qpevHf2Ed0g/ewDa/Byy9qtvcpqiTW6hhkbuRjB9ayrWSe0ysgAz8kiMuQR71tBtr0PFxlP2M3zrSW/r3NnS7rfZxMvzsCRuP6CsO1sfNuNZ0yEhDIvmxsOCQf4SfT/GukSFNqiFAsLYIwMdawLOWR/E13cojhbeMo0X8TKOOB61pRu3Nra1/u2/E3a5YQT1e39fIveG5IpNLi8mIBo22uued3cmtJmOSpG3ucnOPasfwmnmWFw5ZVMkhJTuvufzrV8pmcZZgB3znP0qMUrVpGuHd6aCKQ4YEMSD94d6mXPylh1PGOtQDciNkkg5AwKjAcpkNjHVSea5zYtibAKAHK9/QU5XbbnOQOme1QwMWiyeD2zzmkmcy8NhhnAx1OPWgCZbmUPuUnA4Ix/Wra3GCwIzgdao70ZAAOCMc/wAqWJZCzZ+7gDp0pgW0lBkG4k+3tStkElmHP8Hcmq43gN5eMdyPWhlwRh+SOuKAJ2CoF4OTjmo3wroJSwPYVGJyJQBkkeg4pwyXDFTgDA+bke1AhxVlBzlgO2eKW3HylmIXPamzI+Mq5U4+9jpTbcErsAyuMg4OaBiSShT83ykngiopplc7ZA3fkfpUzxI+wSMFwPvdzUjwMyFeCF6H1oArRuoA2r8hHXvSBpGwTwoOQM/lxUgUl1cA7VHAxxVpQpU7MbvT3pgVIWdhlR1yPemXDhCoX7x9RUrsynIXkc5zTmYvs3cnqAp5oAgi+QqSHyw5IHepwByzdMZGKRCFjO9vm7EdxTJFMp2YwOuR2oAHlUgfIGqJGBkKNjjks1PZVC+Wq7iehUdKjILYPQcjk9aBDnUb13MpHXIpEVDIGZfnXIBx0z1pdqsOOSO1MuZJbaymZMMdpG7qaL2Gld2KF3fsZvLtyDtOM46n0FM1JkmjDI5N3AAxC/rzUWnIXS5lHDpGQuam0WNPs7EgGQng4/SmnZ3N8RRhKm4DtKETo1xt3Sk5dQcbj2rG0ybDacSMDzpeB/Bn+A++a6OBBZQSrarvk5cRk9D6Cue05S8dgxMeyW6Z5MHlZOymuujZqT/rZnmOMoRjF7m8XchuQhHX1qZCzRY3E46+uaVog7NwQwPSoizqxG4Buu3/AOvXGdYu5HJDKT656GoZrpFUgNg9jTck7vNOCeQfSovswYuB1PUk0AM8xiwb5un8IoqxsS3TBbJHTNFAFdpGVSB9369aeyswDo652/SmERhdzLwf4B/OpowOVXC+g/rSJGxbZGwCc45FWUBVCCMgepqsqoJf4gR6DrU6uGAQPlc8nHP0oAcAhVtgGcZwDSQJwOBzz2/Oo2kXzCqqVIHWnBRJll3A9SWGKAJQqCToct68YoERyvA5H51CPkk+Ykqeg61MY9ybg5UDseooAl+UFRjac4wTUpUF1bduC9agikC/NxwME7etSiQSJlflQ9/amMcQGwcdep9DUyhgy4XjH3s1GZVJGDnHBzUi+YCACMZoATayfPInzY4I4/OnqrYAPJIztzjFIm4vsk5XOQ2atKkS4XcMjpjmgBQ5Y8rtHTOOabApy4bOOgB7mlaRCjAZOO+KYXJVdznOOg5oAezIGxtGBj8PpRIhOSxyo5461AEZyFIJXgk5/wA4qxNGcMSwIPKgdqAI3lAy6qwHHNMZg8uBlTjJbsafGxEbN82SOmOKgLpyQhOOoH9aBkrF3UBf4ckA9apXskkMLyKx+UZxjoamDqB8oP4VSvcvbXCjeAV3Y6UmVGzauYW8vKvmsSSevXFausN5NpBCjDyQckDufWsm22C5TzOFyDxWnrMOVifOVyQQB0oex6FRv2kUT6Vtgt1kEYZm/iI5x6U7VbYuy3ESbh0kX+tJo9zug2AMzJ19cetaDuhQN5mATkEdc/SqUuV3R5uMo+25oTLAjWO3gQkhSoAHeuaO0+MpGt8hUAWQqRzxzn1rfeRJ49krHcQV3qcEZ7iuW8PR2yapdWF6rfaPmRZM9sdPrjoa6sNa1SXWz09f8jmrLlUIdLov+GMy3eoyrIGt2ciPA6nOa3FiKgmPg55Dds9q5vww/wBm+22pyDFLtLD+IdBk+tdKsjBerEkZGO1Z4q3tNNtPyRph/g18/wAyOU5JUZ+Xrg1C0TE8k4A5BHT8an4Kq0WNx4J6VM6ZiK5yo7+tc5sV4IQMfxL6imNEq/cAyWyT6VZVyUUFjz93IxTFijkyZCxI7e9AEKKMFUwTjginqVMoZmIOMYNCxmMFh36/ypsMDH5zICOcqOp+lAC7nYbWXafyFLEcPgL83YmpH3KmD0HHTmojncFI+YHigCfKsNp4HTgc0j7AMKcr3FQJKACvIIPBFOUbHyr5I54oAeXXyRuAVcYIJ6Gm5B+dMmQ9D64oZm2ZRlJ7CmOVVR5jd+QooAllKna+AWzzjnmlaUI4IDhep9KrmQAlUUDnHFNaUAMjFifUdhQBZE29iEyRjIz3qMSPy6ZcdxnGKrqPLTAfknhqliDYwCcnue9AEgcfNv2nI7UiAKQQdqY6Y6U0ZQlUALL/ABVKE8yNVUBSO/8AepgRs4VlZR8ueCTnFB+WTbGPlbkkd6Rd0agcFepGKUElcgZHYE4oAcrKABsxjj61A8gZyWToPXk/hUgBUsQx5OAe9RyF34bAxx05B9aBAzI2RGSCexHFRzKJLZkAIJG1jnpSOjE7FcYz1HanPGWPyN0HOehoGjEtn+yXLwyj5W+Vhjr71btLeaKSRrV4ih+6Gz09Knns4Zm2y7TkcODyDUKad5a4Fy4PbBoOn2qlrez6lmA3C7pJRG0mDhV6E9gK5izkaCC0d9gWa7MrHPCkfwn0PNbz74IXLNJLKoLKrHB47VygRp9LgkdhHJd3m4Ko6AdTXVhtn8v6/X5Hn4nVq3mdsHjy2WJ6dTioHmUvtG4qD36Cq0cfR9xBHT3+tSghy4LAY6ehNchsKJELEk5x+WKauWPJHPeq8ibX4BIz35FX4iCiEAAg46cUwEaJVk+ZVC4/E0UXBHlsM5kJyCDmigCDYEBZgAe+B1piKCQ7tgZ9e9TM25Gyg6dj1qBNpQgkjPPPagksMhwOc8fn701fkY7mwvpt5NMWcrHt3AMOM4pFYx4ZgrA9iKQFgoXj3qAPqOtIssq9fmUdvSntKCgAxj0Pamq4Tapxt7ntigBSp+9vAJ5zjpUok5Ksy4A6nvSDy5AQDkYqK2WMnBII6YJzQBZUcFlyw6cf0pXHynY37peSh5GajR9hI2bU6dalXLMNx+XHTFMYoUFMHAOOF65qe3jXZltw2njnpUKlVxvGR/Or0aFtqqpIxQBFu4OEBHUHNTQIQysy4Pr60yKIRE534B5zyKdINnzKQFJ696AFlQb2KjI/2aRIwiqNwGT2B4qWFgS6kgEe9NDIOJMA9sUAOn3qgXksDwy9aqF2AZjz2xVmS42BQoBHbNV1nBJJC57UDANII8dFIxgUwqVJDMQcckdacZdmcKSOtVztHzuzAtzgjpSAkIKj5Hzn+VJsEiESEkdOelNZ/N4TIPvR5oG1WBBFAHP3ES2s7KeVHTB6ir1pcieL7PN0IwrE8MPf3FWL62FyNroQOoYD7v0rNl02e1PmDLL13L/nrSO6Mo1oqLdmWY9Lljy0VyobjBXP61LDbXaTpJLc+YqclR2qMT3sIUrErA8cAj86khu5HlQyW5Qk4cg9B70EzdTrZ/cXpAiK0jZwoJOOcdzx3rk9Nu47rxE17tbyWYsT6ADr+ldWBG7YQ4/usetcpZYtfEV7pjIj2tzlcA42ZGf611YWVlO29v8AhzzMQruN9rk/huf7VLqEo/1sj7xnoMn0rptu4/Pww4/3q5TwpMYbma05KJu4PO0A9fr2rozM6fMwAyMbj6VOLsqmm1kPDNuGu92W0ZgwUkA5yOcZppaR5SpDL6HGcVni4Ktk5J75NTxXXmMWXIByK5rnQXycL8zA54+lJ9p+c7nU7R0Wqcb4JJOcfw9hRMyEKVUAY5yadwLpnVFGB8/Qe4p0ZAcf7PJYHpWd54TB+8uMjAyaUzh9hz+7B/nQIvSSSOmwnluBx+lQeVKCSrMSeOeAKaZSExt3jrjNTq7ug3cAHORTAesYWL5yGP8AI1NbwhgHLEdxUaSDoNppRtB25wG6egoARod8nyqhPO0jjj3qnLHmRTt4BxzVqQ+VjKHk8EU5wQ6hPmzySaAKDl0TcgyT2NVJmmYMWQgjrg9a1HjwD5e4n06VD5LbsdTjtQBUjmJCkk4H3fepIZSWIUYyOh7Ch4SzhWAyASPYU2RAVzJubsOcUhlnzdkZznrz6VOJt6KcHOKqAoQAH3HoTj+dJGXDtjcOmGY8UxFwM5XLLgqMDnORRGGkP7w4B7VWjkZGbJZsdfapdrh/lUFWHTvQBLuDJkHJB6E4zUcuQqk4APTB70m8qTyAR2NNkZGj+U8N2P8AMUwFI8uEkgYY9+lRMfKiyzDGevanMyMhRwX7EdM01cDBBDAdAegoEMDLE4UrjPWiVMNvIX157mkabHVcYPU8gUgZjNuC7lJxycYpDBo/MIcbScYXHP41l/2Og02C1JHmRyiZpB/Ec5IHpnpWm8nzdCpPGAeKSXJiGOh67upqozcdiXFPcjRNrkKnTkZ/lSOMAHYWb0A6U1GbeGfLLjtzV+MQvt2Ej+lIZRKOUOOM9sVKP3cWMM23kjPWplh3zA5AHIytJJEu/CsR6jFAFNSXXIbaCc+ooqUALiPBK9BiigCJyD82/b6D3qNsvkhSG/WlmkUQqi5DMc5I4qB5H6Hnnrn+VIkeJFDKBww7mp/MLKA5VwT/AJxVeDdu3Srt44Y9Kmj8t8hyN/YdqBjt37xgisvbmkTywG3qznp9Klj+WIMpyRwc0PMgk3MUXd69TQAKfLTaiYz+lPjWR2y2AvXKnrSI7SEAnPsKlQhAdoLf59KYhVBR85yD+ODU0bqFxIQBnOR3qMqzONmF709F3ygsCMcgEdfxoGWIogWDH7o6f/qqZAxlBDD1HY5qHhR97LdcDpVlWARQMNnt3+ooAASGYgkk9Seh/Cmlhu2yEEjoMU2eUICGIJ9OmKQTM4BJAHHyCgCVCuSoUEsfyqGSTBOGXJ+6R60kkqDmMYaqssmcY27xzg0gHp96QqvXv1pjNgEbAAOvvUT3GWIWTaRwcjioJLkkbJCBjuOc0rjLTySDaYirD27iopJEBw7Dpwc9Kz3vpGOEUYHSkecOuTyRxjHUUrjsW3mYMBlhgcA0RSsyFjguc9az0ZySD1Xp7ipgGVju25IzwaTdgSNKGSMx7Q3J7A96cW24QNz165xWXAdrY3EAHncOlSux3bgyke3U1PMVY0fthEoCvkYO7JqFpDgtkGMnrVBbkR4wvH8QHNSmcu2VX8R2ouFizMz7JGt1/eBCyA/xEDpXMeE4mlv57+feWjyWc9j1P6V0MUwkbk/MuMEnpWR4ZO2bUbjYVt55iEUjrgnOfzrroVFGnU72/U560OacPUb4XjSe4vb6PILyMEI44JyePyrbMcmGMh3J2FYGhF7e+1WODiCOXaibc8nn8MVsGaRxg4wT27VOKlep8l+Q8OrQ+b/MCVZCAQeOBikGVcCcjGOAD0NNABJXjkZ696a8RDBiOvT61zm5aaYKArng84AzikSTMgzyOucd6rBthJAGSOvoamZpFEYHyn+7607gWBIsrEMNuOASe1TAnG1tpA5z2NVshQrDG8H7uOAKTyzIoaTgf3egNNMRa2xxqTu2jpj1qxEqqV3HoMgdqpRyO+RGqhFx1Ocj2qyZiDzlhjHIpiJwF3scAgjketPEhZFRBxj06VVUgZYvweOfWp4HBiCowJzzgdKYE8KMuCMYxkZFLIWiTKkAeuKjidTuD5yB1B6Gk4UrsI6dM0AJlyxDt8wHGR/Wo5vvnbjdj8ascrgbSw/ukVG64csw+gFAFAyjALjae2KiLELu3BgB26YqzJEJR0A74FVGZd4UDbjjA7n396QxVJlJKg49KmYBYuQoI9CTzSKFiBPzIPXHFOjYeSWLbu+KAHwu/Kpgkdc96SFpEYqdw56+lNjy23YFYZ5I7VO0xJK7OD05pgI3zHGF3Z4NMJRD91ic4zTy52kBDk+gpDJtg2sBu9SO1AhjqDjcQCeM9ajyWXBUde3ANSswK5XIyM+tQeYXYAjtgAUAORlRCJjG23oB2+tDO7IF2rnp1zSMikcocgdzxVVQVJP3PpzmgCddqpjaAccgHmhAW3FD8p9e3rTkyQGUbvQmpSqoN4xz37/SgBoaJFUhAxAyfeozdqpPyAITk7fX3on+VSSqnsp6014WwgAB9S3egC+k6gZXnH86fEPOLMxQDPQd6yGkjiucKCM9cetNWQq2QTtB7U7hY3vJyu2Ixl80Vmw3LYUvwvvRTuKxVX7m7O5z1GOlRldrgnqeSeuKiDOkgG75c8kCnSfvW+6eB+dIkU/MjYkO7pg02ON2bdKQCPzomEkZBI5PYCo0DueVB2dT0/SkMsHcF2mRmU4PJzxShRtOxsj1PNRIPkJYk57DrTo0UxgqSvfnvQBJAZg2FPJ7+1T5CDYW3E+nFMEiswRDhhyQBipI/n+ZwOByTQBYhWRXGPk4yOeTV1S2CZgxXqDiqaozFSFDLj5exqwx/dgb+RwAR0pgTr8pU8kYzjvUbzFZAwJCjjGKYJdqfOMkcnFU7idN3UbR09aLgTXLruUt5jg85UdKjknVxwDwOnpUDXShWbJ5HQGs1rqMPgBiD39am4y4LlmDIAyoOgPSq5mORzz+o+lVJrotkqTuFN84Texz09qVxlpZl5BLFCOpPeiRweMHIGM1UODyp27TnFTCQlflPPfjp9KQDFBTG5W69BUmcD5eF7c81JHIrZ3Dcze3NWreydgZJsrGBkYWh6DWpFboVR2kJI/h46VMVVgPlJHqD0q4sZQqc/IR0x0pptyqnceD1yO1ZXbLsQLFgMQzHPqajkVQwIU/QfzqbyHxtQbmB464ApTaPIimZiM56dRQrgVvITDFRxnJI9aURsvyshx1JqZ1McbBeMdCRTRHIRwx245x3piIiIlKgLtUnB44pruQSEbjOcjjn1qV0LOF2/L6gY/OkNm7OTt47D1p2AaXGFAOC3UAYBPrTNpWT5nZMjIIXirJiVUyp+Ycc+vpUzwoIgzNk9s1QiiQMEBXGfTpUq5TChe/YVbhBCfuhuB796cyec3zlFdR9OKAKxdAhO356FTJDOeR39Ke7MXwgEgPXaKeilgQCMdOR3piIElA3OYm3HpnuPpSSyRkKzZZsggHoMUoMe7dIcgdjyQaY4Vk/djv0oGH2shDhCrenXNSQyLwSrg45BHSo3Cpwp4HQ4zzmlMilixGG7gjGaBFksgwAcqTkZ9fanupX/Vnr74/Ws3flyYVJyRgL2qV23hY1dQ/t0FO4FyIyLncwds9SeB/jU29l2gtuIPOBmqCyFSFO3noe5qXzeFw+HPqelO4GiWZuEwWOOpp4b97lgBz1xzVDzVC/OTkddtSeY/UnAxxk0wLUyA4jRsjPPoKqSwmN/7/AH/+vTxMyptDcE5NNd/MzvIAxjPr6CgClIQj/vHIBPfn9KfHKrHBb5c5Ge9LLHGp2sA2e+elVyrLIdnQ8A1Ix8kXlfMEAB6DP3algVkZmZtxPr2FVg5WNleTJ7Ec/hSIruyoSVXHzA0AXpJBH8+7rjpzinEK4J34GQSM8VGCXAXIK9M45qZFLRMrbSvfB71QiHYu8EdOp9KjYgkKjgA88jmrIjCwvuGFzwT0P/1qZgtHgAYPIOaAK5jHVjtDcHJodSkZEQAToRnOKmyFYqwyR054qDBc/IGI5GOlIB+5hGp/E4606MApuZgc5I45+lV/IdiSSQOAPepgVVghK56ZFMQ9YWlGWI247dRTSqqDvZn9vWojKIv9YzFexxnFWUUMu6UqVHOc0AU2KS7s5wDwAM1JFAwUMhT3BFPnMTNhCMjGQOAR71Nj5SWLIp6EHrQBSlh+YMCxfP3W5oq5uyQDjtg57UUWAoAqF4HI9KLd8S7iML09abKxVQoUEHoc80xDgYfIOO1MgdNIC5YHC+/9KpsF4w20deSavhVfkAscdT2qrNGPNKt1I5PakMfESVG8koO9WFIIyqlgOpxxVOBmR9uWPPGBkVcUO0LZUjnjB4/GgBo2mXCcDHQevvWhbRnZjbtXryKrW0JK/MoUDuO9XnUpwdwTGeDimJlpdirtKAMBnP8ASmGVTFkHHcYHBqs92kSAeZ83QcZNZl9cyONwbbt6gfdIpNjLdxcbZSMsVx2HJrLmutuGlBKHgeoqjc6gWYIGAPr0qg80kp5bJxjA6VDZVi/LcsA2xjjOSMVEswcZxz34qOLfKoVuh6H1qzBbqhG9ixPb0FMCInrsGc+oqS1Q53uM9gauR2+RhACMZ5H8qspaGRiAGA7/AF96LBcprEA2GLEN7ZqRYAAG4xnrV2GB97qoO3oDnFaEOmyTqEJK8Z9MUW0Ao6fCZ5AGChB95gOntW7cKFiVImIUjjipIbP7OoCBcgdfU1JGWbIADgdAQOtZSd2apWKFvDKGJ4dO2BSNHgkOzNnjg9Kv7cEnoMZGahZcsTkjNAMrBCirImSoA4pZW2tlyBkcYpdpYDflVHQZp5VgpCHOBjng1SRJX8wErwCScBiKcmAxBwVDdcUwysGbGcj1FSR4dN2Rz1A/pVJCuE7JG+4DAAwTjNIq7n3uGTPPPpTJJC0jAgZxgHsRRJKQRgttAzt6miwC3YTGEKswGQcVEq7wCxAX6ZxSqQGAxlSM5xipHZGRllJwBwcYoERy7lUAD5c8EVBcRho8qCSvA/2h71biVN52kgYyA3qac2wOEXOQM5PenYCkXSNAqYGDkH1qNJCCWXJ3Hn0FXGWI5yRuJ+n4VCIdr71+bA5X0pWArTOpIXO0Hnd60D7hL4GOMY4NSTRbjxxkcYNOWLeAJWBC9T3zQMqsNhjAO3nPWky07dQCDgkjBqedFB4kDBsYzyQfSmGO4RWT5sdckc0AIkaqWKdW4xjHFImAxQAhj0J56dqYfOD5YBSOdx4wPpT18xSHLrICOQetAEu5dgB2jPY+tIxQMGbYUP3ieoNQSzbc7E+XuvahWJQN5YJ9ulFx2LCyoWKblIP3SR0x61ahut6nGPl4XNZ6Y2hhF84/iPpTd8mDz8ueSP4adwsauU8tCMMx96cmwg7gdynpnkVRgDFmLE47NVjb5g+ZiARj5uv400xWJdsRBxn0YZ6+4prxqqEblbBI680qk7dmMEdMGmTyL5bDyyGI647UAUdjFwJMKq9Pf6nvUiksCc4PXPY1GyEjBJCdTkdfwpQWC8ggdQM9KQy1DMAc8Zxk1M0vzbIyM9zVKB1zyrBRnORxUzbWCCNNoxyD3poRacbF+Zyw7YqPJabAyqjoRTTLhACMf7R4BpfNDrGoLE9vlxTELt+9tJIHbuPeo1KkgnIJB5PFG8OH28AHvTYyZBwsikcYxQA0gxr98ZPY1GIzMpwHGO/tVkJvKA7Qw7EdKsKqhSpIHcDtmgDPaMwRHAYn3PUUiyfIxbgHChfWrUmVUZALE9RwKY+1gq7cEjJGP60CIlKhf3bHJ+971LI4ZY1Xcf7pz0+tQZTzQSGI9OmDUq5kYRK6Ac8dyfWgBmJc4VcDPPPBoqZWcKQdrDp0wBRTAzsZfBGOMAGkcELyRuA5A7VKkiHoq5PPPFRupJY457kjgiggIpmMYCsFBPeops5yNuOpPtTkkG7aEGB6GmT4fIUcexpDGecA2FyUHpVmKZ1iG3ODznHT61VCAtmMgY6GpYipXEmee+e9AGjbyFovMxgevrT728W3jBZlx2Hesu5v2jRdhUHGCtZE92JnI3Et3waG+wJF67v1DMzLww6msua7aTALZDdh3rI8RavDptpsmYSXDnCpn9TXHP4hnyf9LlUeiHArO5R6PHayylfLRnA6c1rWuluEDyLtI7k4xXj39uSysB9quGJ9ZD/jXT/8I5r1j4fh8UQ3E624G9/IcvLbLnh5EP3kPtn3qZVY01eRUYubsj0eG0V3KiM56g5yDWtaaUCjeaAp7EntXOeDPFMOt6ZJ9pWKO+t8CZYT8rg/dkT/AGW/Q10cOoRsxVmkfA4zW6a3RDTTJFtUjJRTuJ6461KsYQ7XXkDPFNWZWBck7jjkCrKyytIqKocEcL3NJhYS3tDPKpiDB8fgfcitj7MkcIBcZ6ljT47Z4AAgBcj5jnionQgFJDknqtc86l9EbxhbVla5uMYCg46EqKb8gAK/iOxPrStEcsoyD2zUaRsg3BlznkCpTG0aF3psohjaN42hcZBMir/M4qu9hKABvsgF45u4uP8Ax7muT8UpY6hp8mnX1u72ZcSYBwd4PBz+dcdHo/h2Gf8A5B+7HzAu5JFZqsP2dz1n+zLgnLfZt2O11Fgj/vumnTXKndLa5zyPtkI/9nryNtM8JGR1/wCEetNxyd2WJz+dV207wsMD/hHLTrjcVbn9a1VYl02etPpzKQTNYZ7/AOnwj/2emG0TcDJeaauBgj+0If8A4qvIzp/hwswj8OWbY9I2/wAajlstCRQF8M2bH18k/wCNP239W/4JPsz17ZAMbdS0nng7tRh/+KpQlmQPN1nRVYcc6jCeP++q8aktdGVzs8NWfHPEdQG0sRkL4etM4HWDOKftf6t/wQ5D2lzpiMAmtaCqZ5zqUP8AjUfm6YjEjxD4e65+bU4uP1rxgWsRLbPD9njHGYOaa9qzKGj0CyXPGDAKPavt+H/BDkPbGutBRM/8JN4f9T/xMI+aYmoeHgSzeKfDTH31BOleIf2XdSnCaTaoc4H7pRUqeGdQkc/6Hbrg/wB0fpxS9rPov6+8ORHtx1Lwx28WeHVIGMDUFP8ASo/7W8L4Ak8X+HeOB/pw/wAK8PPhTUy5Hkwr15ABFA8L6pj5Uh/LrR7Sfb+vvFyo9qbU/Cu5iPF3hzaRjH23/wCxp0Vxod63lWPiLw/dSHosV+m4+wDYrxZfDGpgLxDkjPIqGfw9qMJYT2lvMPTaDTVSfVf194cqPdpdLvLZBJLbuIM58xV3L/30Mj9aq+axRogoYdDg/wAq8h0O4bS5/wDQb7VtEmHQ2U5Cfih4Nd1YeI/FDRq32jQfEEZHIvYPstwfbzExVqdxWN94GVP3rbc8c81XW1cv04HcHv8ASsTXPGxs4oY73QL3SblySwedLiFx/wBM2wDnPr2rNh8ZWkuA1xPGOv3Mfyrnq4yFOXKz1sHlFbFU1Vi1ZnVC1aMtvRgc5IznOacUbYSqbQeMVjwaxa3YDRXkcw6EPLgn8DVv7RbvFhI43Y8go/b161n9cT2R2LIpL4p/h/wS4sAVlyTnt7UmQGwrMo6HHf3qEtIAG3GRfR+D+ff8acJ0ym7zIcdAw+X8xW0a8JeRx1srr0tldeWv4bkySGINxkt6d6RZirDzFDDGRzyPoaRQh+cbSRzlMGop0bd/sEZWtk7nA4NOzLouFI+TqDnOOQKmEhkQ5BBPTIrL3lWHRAcfMB1qcXRDbVXcuMDH9adyHAtfKM/Ptx0yOhqrI6hlK5OBg7RjNT8g7tykD+8O3pTI/mDYC+mF6ii4rBGqbl2l1PXYe9JvI3CNOPUnHNNVWRhJJ1P8WOtKjZYEnjI6imJoniAaFsAlM8j3/wAKeiDYRHJhhnjOSaakMaRtITgn36fhUaxHflflPdv89qZJNGpWRtrAnGDilik+dmkYrjjJ7VKoVNrq4HYgDk0rNGRxkr2PPFMRDJJ+9+YeYBnoME1GXRFJyw46E0jAocjO4j5SRVRmZdwO7k9BzikBZhmnVVChPL75ODUpkVyCCoK8EE/1qnFBI+/eyhV5UVNGqE4D5xyR2x70wFnOM5Hy464psRKLlcbRxkjmpJAHXEajcMH6UrRHcNzAcY9sUCIkkzyCwYdAB1opxCrIfuFRycjGRRTAxbW5E0XGDn0rQjO63XexPYgGuEjmktpstlcfxCpvEWuzW+iiGx3tcXBKEjgqnc/0qb2RNjeudW0+2nZftcZI4OPmx7cVlS+K9KF4bVZpWlxuYRxlgo9z2rz2VryKCSVogkcaliT2AqtoVjfNYi424a6PmsT1OelK7Hc9KPimyjztimY/gKrSeKoScpbMPqwrkRpt8x5fFOXSJz96Y/nS1C50EviMOR+6HHYtVK+199mIVWNiOW7/AIVkX+nfYrSS5ebITnGa5y4vix4NJvoNBrt41xecsSFHr3rOLn1/So5Zd0jN1JP503fUoZueF7E6jq9vbbtqySohPXgnn9K+jdF1D7FqqIB5lqPkMT874+jKR9O1eD/CeJ73xrYWidWLSev3VJr3a50ia3EMy4AY7Tk8EHiubFpNKLNKV020ebatpw8A/Faaxjc/2Y0imFhyDaz8oR/uvXpCxFVIYD0Pr9a5742aS9/4f8JapGGa4Edxo8smc/MgMkWff5TWloepx6jpVhekgtPCkjcdCQM/rW2Elelyvp+T2/z+Y6695S7m6NscYWIMGxn14rr/AA9pxS0W5lwXkHC+i/4mue8N2g1TU1gYO0SL5j4HVR2r0eaFEGEXHHYcDHaitUsrDpQvqYckYX/VhwQf4h0+tVRHvbc6/Nz9K1p8NHhUxkfSs1oiV2rgqOQd1YxZrJFGZWJATKryMnpVSUMUJXkk46Ecir8jqjbQflGRgCq5ZgcOvQcY5AFaEHO3OnvcNhgfXFV5dFiADAL7k810FyUD7wGDAcjGMVCY8MpYKVI4FTyod2c//ZcKPiFOSOcjrQmlgqWdASDggcgVuIu19owRj8qRtqgKhxnr35rRJEMxE0xVBcLxnjjFK1iJVKiPaRzg1sk7TknKeuKjJCxhiQc9WHUD6VSSIuY40yONMPGGYj0qX+z02APGuOo4rUAjX5QxfI698fSolYFlUcIMHkVQjP8A7PhViQhwOrelNGnbnxhVVjj5q1MhPvttJPftSSujbeQo/ve3pTQijLaBSCEJIOBmkkhPB44544x+FaWSACrZBHy5/iqHys/PnnvnrTsBT8lmQMcbSMYHH41F9jymZNpKjoK0A6DYY/3isudw7VDtZnZWO3oOe/0oEVVt1kBwnPTk85qkzWjwszhnCgyfKOcd+PwPHXit1I1QZAY5OPpXIajJHYeIT8j7Wl85yjffB6DHqDn8DW9Cj7WXKtzOrU9muZli80aC6hZ4xGysMhlG7P41hT6PLaOTbsV/HIrdgnfRtQubZY91u48wR79uPTaO5wcEd8VsXFszqTnr0GO3+NRVo8ln0ew6dTmunujzy/vLpLYx3G2eA9UcZH5Vx140ZlJhj2A/wg8V6zqOlJPEPKXGfQ1xOr6GQZGQYHTrXDWpc+56OFxc8O7wdjkvOG7BOD71NHcuh+ViD9abe2TxEbhnj8qokFCACcenauCeGR9Dh87e1RfcbsGtX0JHlXcw57OTz/WtGHxbqiYBui46fMAf/wBdckJSOCPY4qRZge4NYuk4nrUsbSq7NM7SHxjcg5khhY+oBBrTt/HHQPE4X0D7h+tediQHv+f+f0p4bPf+v/6/pSXPH4ZNG0lSqr34Jnp0Xi+ykVd4cHGeV6n8O3vV228RacXDRyRg5wPmK/jzXku8j6/n/wDro89vX+uf8a1WIrr7Ryzy7BT3hb0PbbfWLSRgwYO2Mgh1PFTPdxHoj465K9vwrw4XLDueT9f/ANdWINUuIz8k0g+jH/JrRYyst1c55ZLg5bNo9u8+CZCIXycc89PwqSKc5Ktn2B715Da+J7pJE8yUuV6Enn867bRPFsFwix3AVX6b/X6iuiljYy0noeTjMknT96i+Zduv/BOsQ+Y/UhgO7Zz9Km8obG4ypPPPTFVYZVkh3o6uP4duCKW5kkiTJbcD2BrvTvqeDKDi7MkYuN2cE9MdjUbSsrFTuwRwp9arpdPvJBypxk+3pRMyugILcnAP9KdyLFrajRZLMGbsOaFwItrAMR0OetVC+I8Engfez0pQGKA7iVU5yv8AT1oEWI4gzh93K87SakcDfyQUzk8c5qJnJIxIQT39qkiIG09SDk4Pb1piFkkK7dm05GSD1+lPDGRsHYFxkHvTXQu3LFU+8CByPamugJLbWAHQ56UwEw4myCTH35opEwqc/cJ4NFAjDuLSG4UswUqP5fSvNfHuqnQ9bjtrQDaYAxz7k1v6H4xgAmTV5BDEGxFIR39DXnvxR1C01LxQtxY3Szw/ZkXcvYjOQazck7WBK5V1LxNcXlhNbvgJINpx6ZoXxRdxxJHG4CIoVRjoBXMyEbTg0maVx2OjfxTfHjzfyqF/Ed6w/wBcwrBNJSuOxrzazc3ClJpWZD2Jqm9zkmqnGfWl/CgC+DlA3tmgYH+J/wA/5/OqySYUCnCX3pgem/AAKfippiMPvQXAx7+Wa+jNUSWVZrbC5RQ6kc4GK+Y/gVerbfF3wy7dHnaE/R0Zf5mvrG5m23yoA0YjBTJ6kjkHFcWNdnFrsb0VdNHOeOLCRvhzJI/3bXVbG/HfAdljY+/DGvP/AANmPRzZ7hmzuJ7fn0WRgM/hXqXiy8ef4W+IoW6W9rAwHGARNu4/KvKvDCK1/rgVtr/2pPx04LA/1q8G+i6q/wCKQVV7vz/Q9m+FcWRqU0hB4SPI/OuzulG3bnJ9e9c98M4Qug3QTBb7R1x7Vv3O8Eh1wfQ8/lSrr3iqWxRmjZV+QZPpnJFZ1zByASEPXbng1oTybQSiEA8571RLsJCGAxjOc5rJGzMy4XJDFSGz6ZJqpsLJwenOTxWhdzDfkBiMct0rPnZHIzkL0OD0roi7mEkRKpkUFgodQe/H0qJoxIhBGGPJ/wAKWV0LqqMzA8DtTGVWY/OSqnOB61Qit5RDA7ueoB4z9aayiJgyDkrkjNWLhRjdk7h1qF1yTnbyeTVIlkb4K/ulLc85NQyMUIBUE45OaeCicg9O9RPEAxYg4HUZ61RDI4mx825iO2TxQzEyH5gVxjbu61NFAoY5Yr7N2qIpGj7Ced2Tk8fWqEIyDaGfpn7v/wBekaSPOAQDVGxnW/aa5QvGm4xKpkypVe+OmTn+VXPK4CoN27v2HpVSi4uzJi1JXQSSBcZIwOnr+VRpc+Y0iLuMkT7SByaqLKYdQa1dkJdAycdx1/8A1VSuJnh1mGbokybW2L96nGN3YxqVuRcy6OzLGjXLRXU9pP8AMAxC4bhfarVtftJL9lmUrPEcA54cdjn1xVHVvKtrtXjKoWw7nHLe/wBeKbrRxcwXSOAJwDj3HU1rZSs+5y+0lRvFfZf4M6NroRW7yTkEICSccgDvXDX041rXlez+ZSFEYcbfcg/rzXW2Dvc20ckoAOeQBw3tWBZSrpHiaaxQI0cx+UlMkZ5A9vSujCPkc3b3ktDSu1VjGz91sTxEsc3iKwiDE4UK20ZYZPp1rrJx5o2Acj+I1x2lxm38UTi4kEkrofLZj1BHA5744rqlYRQhtpBHBzUYjSMIdLfmaUNZTl5/kVLkMMM43vnqOlZV3YrMgYqAx7VsPnZ9/jPT1PpULI0uQjEg85I/rXI0dJxOr6HGyufLJ+lcnf6MyoTGOh5r1K6i2KSGHuOtYl7BHIG2gDdzg96ylBMuM2jy6azdH9cdqqum1sbeR3ru7vS87iV+YVz2oWEkbEpHuB4PtXPKm1sdMKzRi7cIDnJ/nTd5U9xVhoGQf1qCRdp5OaxdNdT0qOYVIdbiiU9+RThMp68Hpz/n9KrMMvxxS7Wxzgis3S7HpU8zjL4i2Np6HP8An/PApxXqSenXP+f0qgCV6ZHvTJZ3243VHs5PQ7Fi6fLzFh2JYsM0+G8eJhhjWSZ5R/HxTBcHPLKfxrX2Da1ON4+0ro9A0LxTcWbriQ47g969E0jxFa39oTICp+6eMj614HDJMxHlxu3+6pNX7XVZ7d9pLo4/hPBH4URVWh8G3YdT6rjdKqs+/U99lmtPJDi5UqOCo6n04pkZWf5oWVkBwc54PoR615Rp+vzmB5ZHDeWQFz6mr+g+K2tL2Vp5MxS43A8jI6Grhjpc9prQ56uRU/Zt0pXl0v8AlseqQQmKVcsG9VFTlhEdirlc8nFcLL4qR5srIUhHyp5fRvUnPWtew8S282I5HRwRjgbSR7g/0NdEMbSk7XPOqZJiYQUrJ+X9aG/Mybh+7GQeCe9ORchj8q5GemeKgtpYLghVlWUYyoIIYfnV9YwhDLhu3SuuLUldHkzhKD5ZKzIGj2FX35ibGPY1LJIPLwo3EcEDoR60OiAA47k5btTCVCPk/P0HXFUQRNIiDZsJHbPOaKQuN+QMHp60UAYOp23hdrDF1aWbWaDIcfKAD33A/wA814T49utBuNVRfDFoLe1hUo7qTiVs/eAPPtXQv8O9fuWEU+oWos1PDGRiP++MVa1/wHp9j4RuW08yXGpQEStM38aj7wC9hjn8KiSb1YlZHlpNJu460YPpSYOcVBYuaTNG00bTTAAfmBqwBUG2p0cbQD1oAjkOGpu6nzYIBH0qLFIDZ8J6kNJ8T6RqBYqtrdxTMR6KwJ/TNff2ueEV1BjcWmoiMSAuu5OMHkcivzqHpX2L8JvF+sa54C0q7t7h/wDRIPsMp3BgrxAAMwPqpU+/NRW5PZ3mr2/X/hl944817ROl8caY2j/DfxZDK8csjWtsmUJwS0mB171474XYjU9YJwM3sjYPrXqfxY1R4fA8EV5IhudUvog23vFCN5P5gfnXjHhKcs7yvkedI0h/E1lhbOTcdtv1LndQSf8AXQ+kPhXeFrC+tWI3q6yrjuCMH9a6u9/eDGcY54rx3wXrv9larDcLlomGyQ9wp6165dSYQyAjBG7dngiiune5dJ9CqU2cEYYngjniqFwHiLAqOnBA5FXpQ3JikxxnGOR9KzJFd2csxPOck8f59qwNzNmBZWZ+FHtzWXdOyW1w6xCRgp2RFioc9hnsK3rjlDuGUwRuxzWJOcgKyL5Xb1z61pBkSRzttfeIUd1m0HSA4/u3sxDD15FPk8Q6jCD5vhliemYLwEf+PJXQxMpbktx8uT0AqKVWLgEEqT0xkV0WvsY7bnMHxjax7hfaDrEa9Cwkhcf0qGbxl4eCjzn1a3J/vaeXH/jrGulurRWj3DbhTkqBmqUtlbzyKXiV0xgrsGc/SklIV0Zdv4o8LzqgOtrCQc5uraWL/wBlNXo9d8OPgw+KNDfHAX7TtJ+u4Ckl8PafMp82zj9iUxWPdeC9MkHMSx5PZqpORLsdJA9vd8WmoafcqeoS8iOf/HqzvE1nfQ6XKLSzmmkl+QmEeaVH/Ac1x1z8O9MebCR7ieTlQwH5iuO17wXJYX8i2N49uAFx5R2YyO+3Fb4dSlUS5bmVaUYwbbPYtD0S7h0iEGzuIyCch4WXv1PFWghtiARtxwc8c/SvH/Dul+IHLJba/qUToMjF5Mu4e3zY4rojD8QbfIt/EupMo6A3O79HBorykqj546io8rguV6HUa1aNHf2dwRGeuQvtz/I1X1uFmgtrqKNkUNtxjoD0NchfeJviHpyh57iK8EZ63FpDLgdP7oqNfiB4sisjHc6Lo0kHUp/ZpTP4o4pRqpJO2xjUoOTnG/xHerGb2JJDsR+5C5IHQjHuKq6XGs0ctnLtaEEhHPOO/Hv3rhYPixc2soM/hfSt4/uy3EXB9txq1D8T9OjbzJ/DMkJkO7NrqJx74DxmqVSKvqZypylyt2ut/Q7+yhktIfL85ZOeijAH4muTuJGn8YFQyMRIuD2AHb3pT8TtAurZkOk61AzD5ZI7i3kKn1AO3NVdB8VeDrW/EstzrIkGflewVyCe52SVvhq0IuU5PW2mhVWg+WNOC0v3NDW7gf8ACUQyRLho1U56bu/Wusd2b94gyw4C9a4xda8Jy6wbyTxEyoX3+VLpc6HHpnBFdNF4i8KXA/deKdGjJ7zytEf/AB5BRXnBwhGLvZF0YSU5ya3ZK3n4bcvyniq8k0mWRBgDofWr8U+k3WBa+ItEuO4EeoRZP5kVZXR5bgE24hfHeOeJ/wCTVy6HQc1LvkJ+Xd/Wq8lqCPl2hjz0rrY/D15tJa0n3Z6LEW/lVO60q7hkO+0uM+hidf1IosByl1bZAUDBI5IHesm6sW2HYNxPrXX3kOwBZWSM56Gs+c2xjyJogeeNwxUtDuef3lgwbbsUnnPHFY91ZEZ4G3vXok1usqsUKsfVSKzJ9PZUzKgyR0ArKVO5ak0eftAVyCAQKZnYvFdPPYL0CkE9Pasm4tBknb09KxcLG0ahmkHjOKakMTuN8YYd/erbQmMAHJJ9abDEyseM1FjRVWtja0SDTkbMthbv7smf5121jNbwGPy7O2Gfu7YV6fl1rgLOUo4BycHHFdLp90FUeme9dNOXQ55ttncxzruOwKg7kAAU26s7DUYv9Ptbe4H+3GGJ/HrWJBeeWigjdu6A1oxXaBgQc8ZIHatkzO9tTl/EXgNrm5EugG2trVsCSFyw2N3Ydcj2p7fC+0ltdsWpXQvSPld1URlv93qB+Ndja3W9su+CegzjAq4skYYLkspGTnvUKlC7dtzqeOr8qjzaI8A1F7m1byJI3UxZQ/KcZB5qpHqsiHBb8M19HT3AkRMDKdQSM1UaC1uXH2mztphzkPCvJ/KsPqUNj0P7cq9jxSw8U3FvgJMwA7E5H5V6f4P8baPeaZHFqWt2ttqAJVobpWh4zwAxBDfpWrJofh+aVd+h6cWPQmEDkemKuahbaffNH/aFnaXG0grviDMpHQg44rSlh/ZNuLOXG5i8XFRcdi00m52yvQ4AFOKhgWJUbR8xPA/KoGk8rO2U724yBzj0zVfO5lIAbjJFdJ5hPM26MqQQPXrRWf8Ab1SR1cSARsRIMdAOrD1A4orRUZvaJHtIrqU5GEg43ADoMdaYIljBkYYB6qfSmPOkKsAc47nrWZcXhn+UE8nkE1ncdjzjxL4Jn/tGaXQoxLauxbygcGInsM9RWPceC9aiiMr2yqFGTlx0/OvWAFClADgngryc0zWZFttOcynaNvJPFQ1ZaFXPEJLKdGw4APpmm/ZHHUit2+VXkYxncAeTVJlHTFZczKM8WpP8WPwpRbY6t+lXFGCetIQMmi4FF4GAOORUBBB561rgAcmopYEfll59qdwMyvTfgj8QW8F61Lb37zHQr7AukjAZkYfdkUHuM4OMZBrgktYj1DH8auWthEzAhM/U07pq3cD2v4leMbfxPqER0+ZTbxxfZ7WNcnyoycs7H++3fHQCqeiWvlpGQ4CDgA8ZrkNEt1i2hEA9fpXb6epEZOR7bhRRpKnGyCc3N3Z1Fk4hQENkHvmvSPBmuh4ha3UgZkH7nd/d/u/hXk1u4AAf5cdMcDNatpI52luGznr09xVSjzKwRlyu57N9oWTcVIKnjPXJqrJKoL7mAA+7x0rC0TWEvYvKlfFyo5I4z7gVoSyYAZRvPr3rjlBp2OpSTV0SOwkcgk464JrMuwiSZLD0xnOKmlkUDGRk9Pb1qlcFc8BuPXniklYbYbmY4DYI/WoS0jqyq3yk9ckVDHIwUsu5R23DtUayySHKkMAeB6VtFmbRaUqkfLMXPc9KQBVhwpHmA7j2x7VRaY5KuVLcnaDwKeHQxYPyHvk9fatUzMlkZSN5clj0AbgVTeU+YcMBzyw7VK6ZRHU8H+EjrUE8EjQlUzvPP1pksc0vyNjYWA42nO2ud8YSQNYQoCBOzZAXv9a3Fh2ApIWz7DmuYsFbUNev8AFk5QnopHA/rXVhY+/zvaOpz137vKuuhT0S3vBfRz28bCEd2O0cdcntXby7MZ3E5yRjtSQxRxRCLG0Lzj+p9TSq6S5VTn0J708TiPbyvawqFH2MbXKZtI7qAgBmV1KE5BrnrFTDKkMzbRv2kZ6Hp09K6sl4DgocY5UHqa5rVkMOptIVKxz/ADZAzjsazp2bszLFuUEqken5Mp69olqmGWJWUsQ2V7H+QB/nUKeHbLVNNMRtog0TAA7eRXQfZnu9MdFO6aI5U5xlfQ/UVmWlwbSZRkCFzhjnG2qUbxa6o55TUKqk/hkilL4H0zywhgEbdAVON3vXKSeDbT/hKZLdHdU+6RnJ6etetvHthL/6xAu4EHr34rktMB1LW5b5VWK3Vy+W5wfQ1VClGSnKS0szsrTa5Yx7o4fVPBQg16KK3uCkcoBBJwRzzmtG58ETncY7sMB/eHSuntzDf+Kw6qHgjIX2wO9dKBbtIwY8segHT8anEUIxUE1rYdGblKbW1zxi/wDB1+uW8uCZR14H+FZo8NyAnOmJuHog/pXu5t43mw2Np49KqT2ARm2qCxPBxwa5fZ9mdFzxZdOvYOYFvoSD/wAspXT+RqRNV8QWTfudY16EjptvpR/WvZjYxZyycBf4hjP0qJ9MgfDCLKgfxCj2b7jueV2/j3xlAP3fivWgPR5Vf/0IVbX4l+OAOfEjSr6T2UL/APshrt9T8P2MyFZLeNXJyDisl/BVi6llyP8AdPFLlmthXRzh8f8AiKQn7XH4cvT3+06dED+iikbxpcSri48MeGH7Zt1eI/8AjsgrUk8BxncUuHxnoRmqUvgqUfcuBj0KUnz9h3Kf/CSWpJM3hWbJ7watMv6EtVWfV9GmcGTTNdth3Ed0sv8A6HHVt/CF9GcgROG6VTfw1qMaMfLG3PUPik3Lqh3fca89lcAtHAxXJZd0mCF6DPPr39aQRIPl+zy7sgHEhP8AnP6e1V5dCvo+GtXz1qu9heRcvDMuMnIXuRj+VRfuguaCeUig/vlGM59OeT0/D2q1BeLGTiZwQDwSvX3/AA61zzJcRgf60Dj16DpTWknAA8xuBj6DNLmSHc7OLVICNrySgAnB2g9Bnsf09OavwaramIj7Th2x8zRtx9CK8/8AtNwrbhJ168D8PypftdwMjCNnuVHrn8Ofy7YqlUEeoxajZcEX9ucAHDOc+3b8q14dShePalzA5Jx8sq89/wCVeM/2nP8AxRQtgliNuBk9RwenfHryCKBqRBP+jqeMfePP19c/555qlVCx7jFPhRJuV0GOFdTwRxgA1Ms6ttZTtQ9VPWvHvDEk91q9uVg2okivLIZPujv9T/P2616Zp1wlzGZouYyxCcdAOM/ia2g+ZXIbSdjYYIY/3bHOfTOKWWWOG2keRSQuM47DufwqkZvs5jyc+YdpPHB7A1WmuI/t0lnLu2yrlGznaT1HvWiRnOaRqRvFIihWZt3Ke/vSMHVztUcjop61z8FxM+nyW8XMtsd6N0IwecVq6Xe/a41LMdwHzEDGabiZ066k1F6N/wBMzUmdvFkSqzSQsoV0zlSCMH8PWiorOGKy1+5tbdVEkqFoZDyVJGcfSiuiq/hSdlZfMmmtZN9zFmndvlYHHXFRSSGJZXXllXdtPHFQ6fKZbSSRwDLOzEEHnA4A/CnWqNPLZSOcKwMTn+lczg1JrsVKqrJrr/maWnSxzSqT/dDqM/eH/wBaszxndBNPmVicyfKqrzk06d3gEax4V7diG55Kmub8V3xmgYB+Cw24NS7XSCnOUou62/r8znmX9+Bn7qDf9agZMkmrMRLXEyAfeAJ+tI6kE5FYVHqbQWhUOM00qD0NTOuRx1pm0qATipuWM296ADUh5GQKcFLYxQBHGvzdOtbmm2xIBwQPas+CIZ57V12hQZiGQpB7elXDUTJbK38sKTkH6cV1NhypUhgMDnt+FU44CvyhVJ6gGrcO9W+VM/XjFbIk1vugFFZgO56VetpHYc/TJrMt5ZFzvUcdDuq1DKx3BsE8H0oGbNrdtDIGZiOeCvaur07VIruEAlhKvXPH4iuDV2ChWb5s5IHQVfs5yr+YHYMvIOOamUVLcqMnE7hsEDbhCR/F1IrNuNT0q1lMV1q9hazgAtFLKFYA9Dim6bqX2tljdR5qjPP8X0qrr3h3TdaUjU7C2lkHO/HzAexHNc8otG6lcjuPEWgLJtfxDpgz1+ckL+OKf/amjTsgtdc0p+2RcqPx5xXI6l8K9MbP2S6v7Zj0Cy7lH4HpXP3XwtuYzth1mbd/dljB/lQk+xLbPVY4UlYNBc2swxgiO5jbd+tPXTrjDN5TFuwClhj+teMT/DvWYTmDULV1HXdDjFVj4X8V24LQTwFRxlHK1SfkSz2/7PcRjzHjlUKfutGRj/CoC7B+BhScn2rxyK28d2eXRpCR3W6Y/wDs1T/8JF8RLdcbr4Jj/lm2f6mqUiWesXDM0ocFtue1Yui2vla3qzjO8SKRnj5Tzn6V58/j3xnasBcreNjtJGG/9lp0XxP1yGVpDYWPmsu1nktASRnODwO9aQqqKa7oiUOZp9j1VtzSfOwUdiP5ULPFG+WcRjOBnivLT8Wr4Am5sLA7uDth2fyakHxUtZZN11otuxxgFZpV4+maSkjWMbvXY9Q86OeR40lLMO/86r67byTWAk2kNE2QAO3euEs/ifpUbh10ZVwMHF5J/VTWovxW0iRCj6bhSMEfaicj8UqoySd0Z16UZxcVszU0+5WGcB3+QjBJPA98U3VoIoZ8xtlZMPg84Jrmv+Eu8PuTshvFBP8Az8xf1WtWLxxpTwCH7JPMigBMyxnH4gVt7WKd0eXHC1ZU/ZT+TOw0+RRbxvnIAGMjoRxiues82fiO8sSN8UpLqG45PP48VCPHOnmNU/s+8AUdBImazLnxbp8msxagsF7G8YA2YQ7sepp0qkE5KT0a/wCGOydOfLG2rVv+CbGkQjStaurR4lYycxMDyoPOPx6VrSMqSbwQpH3lA6+lcLrvjnSJNWtLiaK8gaMDgKHwM9SQeBXW2Ws6brhkfTpA02NzQSDa4X1A7j3FFepGryyT1tr8iqMHDmjbS+halYyjfwD1B61LGpKsjPnocnr/APqoU7AJNgUe5zU8QCybiu3PJ5rE1Ko6gjcccDPepGKhcyHBwD+FSt9wIQG55J4zUI8tTvCoUzzkc0DI1zIcYIB6ZpxiAUZYMu0ZCjA/CpBNGxYAqQe44OfSh5QUKx/czxx3oERSRmHO4BQTxheoqOdY3xtTB6HPNPcu6kMAwHoaaCGUfKwA7NQBB9nVGXoe4JFV5LZS4ZkA57jpVmVwzhBwoPBznFE0nljDMSAeMnk0hmXLCjyFQdxHGfSqz24A2hQ7euMVrbQWDA53cGoVAEz9CV4B9qVgMeWCNgQUUn+6VFVhpkLbswR++VFdC8a9gCGP3qh27iVVQmO/rRYDlpdDtnbBt0AHqKpXHh2zBBCc56g9K7R7cYzgZHYVTW0Dzb5B8nQegqXFDTOLuPDsG9ViByc9+lVh4ZYuAhYk+tegizjy2R8pH8VLDaKMYGOOtT7OIXOGk02fTLJ9jESPlRx19f0rpfDTTQadbI2CvOMDvmrWt2yS2Ds52CMEhj0HbH41S8JuGk+z+UzQMcsfT3PpXdSpKVB8vRnLOo4VlfZmxqXmzWDNGyjDK3HPQ1VvElR7a+cgbWKOo/hNb628ciFAQQRtwoqjp8ccsE1rNjerEFW5yR/L/wCvWUdhVo3du/5rVFK9gQCO+t3GXfB+XAOeufrV6ysfs8ryRSERyDITsPWq9tDi5lsrgbInG0hj0Hbn1rQ0i3ktVmjuslVO1CT+tVJWRlSlzzu1/wAB/wDBOY053vPE8lxCCII8sxPsP88UVpz28aeJ5IEj/c3EH7xV4yeufb8KK2rcj5b6Kysa0lJc1t7nK+GbO4lgxLE6xryrEYHXpV65RfIuLYAeZG+5fwrfkaKCI9MAfKBXJa1cCC/SYjKOvQevcVhOfPNtaXJnD2dNX1S39GZdzI9w6yxAjAKyYPX0rndZjIVHYDKuMe9bSuIbx4o2/dtyvv6CqWqweYIGkY+XvAcCs7XmrFUXam77oyrdClzOnrg5PWnSQtknGc1es7dhPcrLhpN+Dgdu2KneEbMYGaxqR1+46IPQw3j2vjaaZIgHr+Fbf2Xg9N1RfZMnnBrPlaKuZCrkZAqeGIkev0rR+wndwPl9qljsxkjpTsx3K9tCuRn71dTo6HaAx2/WsS3t90m0Hd7mtqwOG+ZXAHY/0rWCsSzqLZUwpXBkI6ntVry9sXzAK2eWA4qvp7ho1ZE4HGTWnDE0iuzMfnGcitBFZpFXqQR2IFOYh1RioDZ4xxT3iaL+E47470oAjIJzz34NAx1sMNhAxwenpV5Z2UgFQVbgnHIqkk4DEDHPOKd5545C5znnoaANWC6JXEa7SOpU10FlqS7cMPnwASO1cdBOzHaPl/2uxq1E5RuJWVsZ5oauNOx1/nozAyAeZ6n096ezKyMBgfT+lYdldorjzWG7GAaum43naNxbqSBgCsrWLuWJYlJSQA9OPcVTuVExG0ADOParUcgLDzAWxweeKbJGomLY+XoMc4p2EU3s2KAIw5654FVhC2M7Rkdh3+lapjL5YsdnfFNEKbw6vtXGMHvRYLmS1ik02842A9ADnNRTafbeZiZAGHQFe1ahZtpKyK6dj71X1GYfZ2cFg5G0Z4p2CK5mkcfqOl2t1MzGBGjBIUFBjFZ58KafdThPsaDuWC9K6Ji2SeCB6DpWto6p9mctnc5wyrwPanY9CpalDQ4HU/B2k8wQW2wL95wxzn0rJXwJbyuBbvMMdSDmvQtTyb2XeQW3Y4/SrlrCEgUnCgjJOMZo5UZTtCmu7PHda8CXNtE0kE/mbPvKVIOK5p9Jv7eQbYZG/wBzvX0LJCxUM+w54/Cudk0n7LfCWB8w55B5xTjFWseXV51JSjqup5Is11Cdsitj0btUsOpRyymEuUlzwrcEn2PevTNS0SO6hLGHCk8n/wCvXluuaQRqcqW4DqDhcHrjvU06UpN+RrOooWuay3KhJBNEsjMMZYYI/wAaitb+eyuIri1k8ueEho2AwVP+HtVSM3Pl/Z2QG5jxnecZQ9/rUU5Ppweh71m7o0PevDOq23iDSob6Mtv+7LGT/qpB1B/mPY1fknESZWQsN3Oa8P8ABXiJtB1Ted0lrLhJ41ONw7EdgRXsVtc2l/AbjSrsXVsXK+ZsKEkYypU8qw6EVtGXMiLWJZr0+UyoOD69PwqtFP0MpbHYDtTmhJY4JA6cnjNKttI5YgEEcAnkUwBpEkI2kY646UrPjG8kJjgD1qMwBASR06g9zSlcRKBgg9ee1FgH+ezKMZHqOn41HvGfvknoVP8AjRJuRRsYDpkdfypqE+aNoJwOTnrSAtQDMYLcgdqbI8eVL8kjgY6VEDlcjGc+tEikJ8uC5OM+tAxEkBKnPDHgnoKmZEVwehI6+9V0jO8BAGCnkE5xUkjsxKxgY+lACO4+ZWPT25qFdgI6ls8UrbygJUbs5DDsaYhBjxuyQcE0CIpSzPt5UnuooeJUiG5vbGODT2LLlvmbsppR5jP8+CGHrQMqguiEA+/JzQJVYDOQOnXpVlIJJAV6Keuf6VCsBQAhD97H/wBegDE8Qq5n0+DnyJpDvHr061s2ixWsapGCV6tjufWoL20aaeCRRloZN4DHGQRg/wCP4VOuUJ3Osajq56YrRy9yMUZqHvtsvRz8AbSO+KytVQwX8N1vYK5/JhVabVdrHYhwD8pY/nWjLJ9ssNuPmI3KG9RSg7MMTRk6fn0G37yN9nuVkG0LtYKOVIrUtL2C7hRjksMb1Fc/Y3kT77e42+S/yk9MH61b0RZrcyxzBRG/III5P9a0ltZnFQm5TU47Pf1IUjeTxJc3MqeUbNeEU5YjHykDuMUU6/lFt4gsJUYB3Uxuo7jsTRWlV3UW10OiCs5K/U5a5uJby4LyuFQe+AorP1CYX0MixZynK+9Omyums2OWbvUlk6xwptXLt+orkO6rGMotPbYzdPk3RlSclfukjkVDrSN9liRjtRpAHbHQVrwQIk0kiZXd94EcZ9aztZDyTQWyqdsjAlycA+1a0lzVYnnqLp0nGRFaJIL+6+UbyB0PG3sfxqTysuMLwe9SWquL29LqqSJhAueg7VZ27UDMM/WorL3l6L8jals/VlJE/hYHB6E1LHCDkkZI7EYqeMGRhlQB3wOlWIkjZgg3ZHUmsrGhXECltucHocVKtiACR8xHXtVpVKA7R1PORV22TzEIK8ZxxVJCMx7QKm5UOPSpLQgttwAR6nitOS1URgB889B0o+yHcAQAM4yKaQy9pxAZVByR3Het2F2xggbc/SsSGIQEA4x6itO1cmInnORjNUhFuaFXGQxDf3Sah8j5cnaVPAHpVqByHwxBYnripZAm5UGFPU+9AGW1uN3y7QB3xUSoynYVOc9TzV9o92SrA4/hx1qtMrs5CkfUDp/9agYycssZAwQD26inG5UgxjJbqTjpSMu7gHn69DSCNQWz8x9cdqAJ0uCyYPLD171etb4BwjLnPzehrMWL93nkEfwjrT4zJvVgMeppWuCOgW93JtQKFJxwev1qZLnIIOV5wMcViWsvlj/WDBOcY6VovKr8hRu6/KMmptYq5ou4VRHk8dRnmoZAXKkMgUdV7VUZsx5MnzHrjrUoYeRsyN59TSAsBtzbCRt7Ad/aqesoTasxYKq4I/2j6VJ5xhjTeygg4Bxnii7kS6hZGKbyOBmmVB8skzn8nAyBnrzWrZFltozFGrZyST0zmsp12uQ/yn0PWtXSZF3GIkD5SynpkdwKo78T70NDKvmzdzbgc7znNX7eVJrRF27iOGAqvrSx5MqZG5vnxziqNpOLd/n5Q8YB5o6GbSq0lbdGs5L5B4HbPXFHkEFSilWPOTyfyqIXlsqglyV6lCOc1e0yVLh2aJVVxyM5BIoON05JXaMzU7WabTZ47ZzFLjOe59R/SuJ0rTLW6mAeTbIDkIR972B9favUirPlpHVEU9MdTXnuowfZdduFiyMSZXbgdeRiu7B3nGdNaaHn4tcrjU3szivEmnHTtdaQu7JMMgt9en4Vj3sbyB0BAY8oR2YdP8K9I8d26yw2Z2hdzHK9T05wa4PWrV7K8KpkYwV9QK4q0fcjLrqvuOmnK05R9PxMRJSYw+3BHDL6H/CvSPhb4mRZV0a9ZRHK263kbj5+6H1z2zXEy2ontftEYB/hZRVGKNkcFWI7qehB/wAa5lLldza1z6XKRjqmR68gg03CLCSOWBztIrnPAXiV/EWmrDOy/wBo2igSZ/5aL0D/AF9ff610NxMIly+NucZxzXSndXJI8ybsuA/sR/WoTEwdnkGBjI9KnWbe4YyHjngcUvmjgHjHY0AU0CO7Bc7ccccjNNCLG+HzsHU9zVr5Yvcdm/pUIaOQc/K44CikBG6Ak7SdpHfrTHQCMnB4OMHrVgbSGMgw69s8UgQFizZx3GentQA6LttzkjPAppbZnIKknk0+BwxLZB9CPSm/K7kNk49T1oAYdrncwIPTrwai2KMMMKSasMuxs7cD+lRMpYnCZB6LQBCd3AXp+oqUhZMbX+c9ccUwCTO0IDgcAmpRAy4kUYLdeeKAH79qkg5GeQaaCrqdq4Izz6UyTeNyhRgHhqVE8xBGhIJ54oAilCiMEAgHgk1i6pKZHCKf3acZ9TXSXGEjc7QGCnn14rlpEDt8mPzoOjDxTd30GQWytE08wAiT/wAePoKjt7ic3aFCSmfu1rXcTf2UoYYACnHfOaqaagXc+cMTgH29KC3JNOTRm6zA8N0HiT91L82OwbvWto8z3FiocKGjbb71NfW6zxiBxtjPO4DofWmafaSQW4jBSQhucHHFW5XjY8qNFwrOS2Zk6rhNfglvSxt5F+UE4244x9M0VV1K9j1HWbZISzRxHZuAyc55orslFckOd2djNN88uRXVzIVlmg8licjkD1ptslxCfmhcp7DkfSnSWkkTM0RIUnIB64q9A11uBeEMOnWvPR6zaa93ZjrVTIn7yNkX0J5rN8Q7GktoI0YyBt3y84FdEm14v38HlnPrWDrL+XeWZgI+0CTIHfHvW+H/AIqOHE/AxdPYXGo3rKAeAob1xxVlo8j5mJGeg6VS04OusXqRhhCCSVHQVtNCpPqcdO1KutVbsvyCjs792VRCNwJXJHPFI6lcllwfbvUzRPGoYcCoNshKhhwenesTUlUhFD8/hVuCVsjaMqeuaqnKqQ2Qex61JbK+NyZBPHSmBqIquq7yFZjgDNSECFQiJk555yfrVKLdtycbh/FjvUolOTnjP8VMCeJAJwN+G/uk5rTgBLHOUA4yaz4UfILYLFeGPFSozlj5hYIPU8GhAakZxIoB384yOtaIg/dfM37zH1/OsuFnPIKsq9q0Y3IALH5T2zTETNEqw4ZuvAC1A0Jdxj5R0GB1qb5uqgbc8tmnRuyupwwCg9OaAKojEYJ2/TioRAWBYjG48CtF2BLCTluvPGKgJycKOe5oGUmty0gUtkjn6UoiO/5x09anYBUOePpyTUTSnZtbIQ+vekBHIhBbYcKPypRcYjAJAccexpiR9GjYYU/dJ4oZPNfncD1GBQMtQ4lwzOhX0NWspsIAUgc8ViuCMgNtPr61PEziJc49MKakZdDHcRyVAzk0sflSSng7h7/zqsrDJCEgjrTxKQAXdj2oAq6jCFcyBSEJxntmqqMBIm5igH3W64Na3mPM5RlDp3J71nXFky7vLzIByQTyKaOyjWTXLI0bYR3ce2QBWxgqDwfenxWNqm/fHv3Z79Kwo3lWVTH1zxzVv7dNHIHdAwPbFAp0ZL4GaY0yA7SMgdD6D3q7HaR26BIyRkZ3Z5P1rHj1M4CeWwx6kk1o2d8s1vKrpgjqB/SgxmqlveC+kNnYz3AUyLGNwAXn6kH0rg7Zri4v/PwXlkfOQB97054r0BryM8PGHTGMH9a46yn/ALL8RywOXW3Zigz0IP3TXfgpJRnZe9b+keZi43cbvS5R8TSre6x+7Q7bcBSV5G4ct+tZHjXT8Wkcwy0iAFiepz1roPEavY6wk8JKGb5mI4x2J96i1JDe6dvnQ72BRj1BI4z+PX8ayxMU6MHHYvDu1aalucPoHlfahC+BFMNv0bsai1yxNvO0ir+7PXHaq6B7a4eMcMpyp/lXb3NqmpaTBcqRtlXc3HQ9CPzrz3G6sdlzhdI1K40fUoL2zbE0TZ56MO4PsRXtWnalb6tYRX8CsyScbSclG7qfevEtQtDbyMgzgEge4rZ8D+Im0PUMTEmxnws69cejj3H8qmnJxfKwavqeusr+XiPDE8k9MU1FI+abjjnnNWVCvEjKAQRkOh4YHoR7UqKobB2nHHNdNiSKPccgAYxwp6GiOAyS5LELntVryhIoaMszeg5FKqvHIclfwFAENxAVJ8vJXv71BGQozJ83bPWr0qggB84ODgVD5bxnd8v0pANXC9AGz0APSo5kUON+Rg9f6VPuiIBOFPTPrUDfNJgYYetAD3uA4wU3Ae9NR2bC8g4z16VXcheMYAOATwCKfuyBzg+oH60ATTKBHuyTzyelNRgACzYzxg96heZlUqRvFJv+YDOB/L6UASINzEM5C/w4FKAmdxJGDzj1qJivOX46dajc7WBUjCnjd2oAstOjgqysQTj5ucVzjr8xBAzkj8q3Ypgzk55H8OKo6ogLCQcbvvHPemjehJJ2fUlkjN1aDy/vFQOvpWbaTfZ5xux5bHDA/wA6s2lyInbeQy91z19x71a+xwTgzKcq3ULwM0F6U7xlsxJLiInIZSnY7hihCSpkQ5XqAFzUH9lxkO4LcHp7VLGPK2xpny/THNIwko2905rVGfS9fW6tiB9oUMyDoecEfjRUd6l1da/5LBUeI4RexXrkZ6+tFei1Dkjz2vY8y8+eXs72uBT50LnLemKmQklUC4FRbP3gUja3XOe1SBSy5UdOhFecd4oLZKs4I6c/0rIvLeL+37VtoYspLYPTHQn0rUVgrAsOKH2CTeIvmA27sdR1xWlOfI7kThzqxnaO5jutQikG+TzctIOhz0rTXEh3YJHqeKfFbxxsXSNQ8hy59T705shSAuQT9KU5czv6fkOEeVWI5I1mUYLA45GelNKtnn5V7VME+X5QRgfjTmh+TKgsc/xVBRUwEwX5HYZxTt0mMKTwe3apSvCtt3c9KYHbeTzu6BSMigBOqjf2/SpLeRg6jJA9+cUpiJG5iAfQDk0mUPQc9TxigZfglIyDLlQeOOAKnSUgFcc9/pWcJlUhVVskdCKngldZQCB68Dr7UxGvGyrHg8HPPNWFnKsp/h7+1Ug/mglsAL1qZXym1Rvz0pgaSOWyqttBGTipY5RuyOQODxiqUfC7s8kYx1qaGYt977q9x6/SgRamQtmTqh4PFJxIu4jYSMDmmxsDjIHPUHvTyUk5VW59uBQMrSxt0UZ9yKqyoX3eZhm646VfRQ0oQDae/NOuIodrA43YwcDrQBlpJvXaBhfUCpRGNucnA5OOo+tAEaryDkHpUuVXJzjI4x/KkBRkYOSykZA79xUds8m7KjCjjHXIq2yI6kylVxkjb3pqoNvABBOSRQMYskqOSVA57dBTBMXdgRjA69qkkVf4uR9P0pjINhJwdvOMYxU2GW7Una2SuGHapA4ikVAgbHIPes+3YKRhgR14GeathkxliWb1FAE+1WYs8C56nI4Oe1K8cUiMiRrhjnB9e+PSqyzhWG6Rs9s8YpVl3vgruHcj1pj5n3J2ig27DGpbHQgjFIYlhCKiDfjBGTzRkyFQoyw4z7VKUDBV3kH0IoByb3ZEHaCNjK6RLGCxJNcf5zahrbSxxqBK2NrdAOnJro9ZtWudPuI4nPmYyuDwcdj7Vg+Etslz8jsrx4Yn2zggeh/Su/B8sYTqPdHBi+aU4U1sy5415NqIyB8pQg9eoqeytHGkQRyRhGAPAHr04/rVHX1W88RW1qxCx4ABY8Enk59K6uFUjQKx2kDbg+npUVXahCD66l0o3rzmumh5D4w0x7O6WZVKq3B/pW38PLxJ7W706YEsv7+LHcHhh+eD+NbHi2xivbGQL1wSCDkV51oeoHSNZtbztDJiQeq9GH5fyrgWjOtnWeJNJMi7jHtOePWuCuLd7aUhgVGenpXteowQ3ilt5cOMhugwehrhPEuiyBgUXPHf+KlOIJmh8NfEQjZNJvXOD/x6uT0PeP8Aw/Ku/P72RipKqMmvn9d0U23JVlOQQeQR/WvZPBmtnXNMIlYfbIQBOMdR2cD3/nVQlfRg0dLaygI3Kou0szs21VA6sT0AHc1xGv8AxKihkaLw7bwXbrw19dofLP8AuR8Fh7t9QKp/Fq/uLfVJPDFs6bYAjX3ltkNKRuERPogIJHQsfauPs9CnuACWx+FRKo5aQHy23N2H4jeIRIGM+kMc/wCrksF2/pg/rXRaX8SbW4Ag8QWf9nsxwLy2JmgJ/wBtfvL9QTj0rhpPDMgyFl/SqE+k3MAKhs9yKSnNbhoe5ko8CSW5imhlAZZEcOjj1BHUVACwkJWNhgYwOgrx3wn4guvDOoZCtJYuf39ueQR/eUdmFewx3KXMUE8EgeCUb0kB6rWqd0IflWXYwPr60zZhSV5PYY/WnD5XYh+Tzn2qJkZ2IaQhWwRjt+NMRIFYZV0GQe/emouxx+7+719KewQEgyexOOtVpWcFvKJ2nk85oAfIqlg65yxyAOlNYEgtgZzyeoNOUHYqghieuKc3yocsC/oTQBHChfkKAfepCVIaJgcn0FM34ySV3Dpzik3FgSCUYnGR6UAV59OBX9xt3cYB6VWhsbgMwD7B1GWxWrGNikFsE9M96QkyN6AcZxx9KZqq0krGeEv8bg/1GR+tSfvWjjSUbue3erS7R0JDZyeelRyRqAFPToSKCZT5uhyvimdYdUspYJj9pQYYdcc8ZoqGbT5f+EkZJJRLIW3xs5yGHb/9VFd0pwpwhFpPQ81RnUnJxdtSVVUvknIq04WTG0jGO9UkIZl3A4/2eM1MHYLhDnHGM81wncO8vkLx0PfoakKB1UM5xnIzUIJTO8EnHWp9zPjaVyB25oAVykfQAgetDSscKRsU8A460w4xl22sTn61YjaMpknIx92gBvyx45OD6HrTfnVWUuD7g8inDLHPTuTTMMxYKc47jigBjuY27gtwcd6QruHyhgfX0pY97HDoS2OMdqVnZQMru7bTSGCpEfk8zJplwrouflKZ429/rULmTKsUwg7HvSBSY2O1mPrQIsQyBXzIPmx2GasQSo2Qqk59ao7dkXyjDLwcmhJGO3ywQ3f3oA2Idu3APJ4wTTvtRhAEkgB6DjpVS2d3cgjI6Z6YrQiEHlneUYkcoy8/WmBNFI8sZMeCvHU1ailYA4wc9T6Gs6NwFLZ2qD0FTBwGXPQnHpzTAvxFgcCQ7hye9XYkeSNh0Gcg54rKhU5LRkNnIyTjB9KvxzOgCjjHUGgC2IWU/KQSecHrUM4dZIwx9/U1JHIJJMglXA+UAZpJzGY1OcP0zmgQJH82149rDgmo5VG0+XyAehPNSsDIoLMQwORt5/OolQiXDqcMP196BleSJ8fPjB7dqroxVAqqcDJJrUmh2gct9TVORVU42MB1+tIZAcsfmPB7YoVAEYhjz+NSALIu3GH+naq4zGwOc5OSCO1ACMPLwuCR069amUsYfmG3PUUxyGQ4BZu/0pkrnAVsnpz6UgFALKWYY6Y3d6nVjjggcYPFVFVmfJGV9Ke0SpGpXAI7HsaBlqOXZgjgHqRSl98gYnG04yW7VUd2BGQQrd80x/m+4xJHbtigReM0YB2nodxIHGPWuY8KzGTVbm5ihYQFmCnHBB/ka1Mbj5eGCnjg0+wtorKPyIlVIclto5P51rTqckZLuZ1KfPKL7FHxgVFvbXHlYZXKEnuvpW7A7GxhE8iuQgy2Bk9xwPSqF7bJdQotwrEK2VVTUyIUGSSMcADgU5VL040+1xRp2qOfcZdhriJwSNpGMAdBXk3iGzNtfycfKTn6166Wzyu4DGTkdq4XxxYll8xVHHPA7VzS7mx0HgDUxf8Ah9IJBvuLRvK9SV/hP5cfhV3VLQ3Eb46e/avPPAWpf2bryJIcQ3I8lvYn7p/P+deqNFncWBKenpV7oR5H4g0qSGeSRUwOpx/MU7wrIqahHM7FEh+dznHA5P4cV3Guad9oLKv3B1zXnGtWUlpLIIiyxvwQO49KyasyjZ0JTq91eajcje9xcO7n0zzXZWtsioNoCgDqOK5L4ZTRyy3tjIcMwEyD1xww/ka71bdi/DKIwfT9KqCstBNkS2wcbVKs2ep5rPlsVbKuoVskDpya244xlWXOO3tT57cNjC47ndzirsI851/SNvzxqDtPb+tavw3vnjlutIlYgIPOgz2H8Qrdv7MOrt94leDjiuUtkNh4t0uTGPMDIQe4/wAmotZ3GehFtshJJz0B7GlG4kbh0PfioEYtJ8g+TPT0qRuEJYFivbPNWIkjYFyCo29gadsIDKylQR1FRqQUyRjPc1OdphG1snHIoAi3Kjc8jGOeopkjvg7iVPVTjmpNqiRWbacdCTTZHDOSckdASaAGKjyq20DB657/AIUqZUlFHTrTHB2knJx93BxS+bIEXC4OeTntQA7azZ3gqBxgdDSlSCOpIPOehpnmEDhs5yPUmnpuKL5hCkfjmgBwOznbyfanQBXJ3LtPoORUQYA5kfdg9D0qRpIwf3YAz0NMDMntZLjXoZZYcQQR/K2OGPPFFabyZTB2qv8AeFFVOfNZPoTGPK2+5w6vztAJIqzCFzufceOmetQhSHboD7Ugd2Q54HqDUDLMsqtJhcgn0FNQ8KAvfOQMVGoIBKKAc8knrU+4FVDNk+me9MCVApY72P8Au9QKeCi7duM55qusjb8EAZ7VK7EjAOGOeTQBOVBz+8yD3FNOwhWQkkHHHekjDsinAGR371KUYxKy9B0HegCCdi2BET157ZoQBwS+8dsgcmpSrMOAF/vEjmpRHhAAApI+8e9AFQQx4xlsDnLVBuK/IC2O5Per8oHA27SMc1X8vec/KQPu+/1oAgERHz5GT7ZqMOEPB7/l71oSRK6nJBHTgYqs1uACeDzxgUDEhuJQ+1sEDvjGKvwljzgFT39aznTbGwAG4nO31qUStGEMQJ44WgRqrCqjPILdcUsZWN/LLhj33DJ/KqoMtyNpypI65waktcINr4Zu7daANAMm7upHGfWrETsqnIUn3qgZEyoU/OR0qWCVcsWJ3L2Xj9KYGgs5UMFUegOealjw6KAQfX2NVDKPKyFw/XJHWo/MOcjOM8D/ABoA042UEhiCB/dHOaczAggbC5xkdCBVMSDapAw5OPpU8gRdilSc9TQBO7l1Im54wPWmSQgOF4ORnJ7U0N82AoOee9KUJUtJj06/rQBAxTOxOp4FRyRY2s5BI6kdKmmgk2HaQG7GolRgMPkAjvSGV3OwjOCDz/n1oaby/lYDBP41YVCobcflP6VXaMzMSqHGOW6UAIm4qx454H+NMUswKth8HuOlKSeEKk54yDjFN2sjkqrAj360AK4Xrjcv8Oe9JF5nzAldvbFKoMYJA3jsDUgPzgBduRnBOcUgIkD/ADKQCT0//XSCJ0Y7wADzjkmpCBuBGQw547ili3E5d8884oAljiaQthsYGORVqCIy5VQQQOpHf1qJJAsqlAdp42gc1xnj7xncW9xJo/h9tlyuVubqP7ynvGh7Y7t1zwMYpSkooaVzu7xdK0tCNa1bT7DPzbbmb94fpGoLH8QK5m71vwNdSiC+168e27tbaXIc+wLEfnivKIdFvp2L7Czv8xLHJP1NNm0S+gUtsOP9k1m6j7DsdH4jtPDMMjS6DrslyM7kV7N4nB6jrxXo+gX8eq6BaXoPzyJmUZ6OOGz+P868GcTRMBMu3PQ9Pzrv/hZqZWe60uV2VZB50Y/2hww/Ln8KqDEztpWwjJtByeTjPNcx4g04XIb5QzduK65iIhl8n0U9KguFSSLhQAOo7VbVxHjge50DWYrqEZlhbdg9HXuD9RxXs+mXFvqmkW99YbpLeUHLZAKHure46VxfiDSVuI2cL7rxXL+G9evfCepsyRie0c/vrZz8r+49GHY/nURdnZjZ7KhEbABdy5ociRTglSeCaPD+uaN4jiD2N3F53VraZhHIp9MHr+Ga0X06RMGQDYpAO48fU1pYRh3cRMYQDrwOcZri9SAbxZZQx4ZrZC7D0J6A/gP1rqPFfinS9ISSK1ljvb8jCRRnKp7uRxj26muO8MRy3N1JeXLF7idy7SHjJP8AKok7uyGjurfKkNIzDI6Z4HvUgKIdsQLZ5JPemQKrFdwORxgHg1aSPAPlDKN6fw1QiENknK/Q9eakSUoSCcj3PeklVlBZQePyqBCSMxnuflPFAFhhuQsW6fxdKGRSpJbI9+tOG7aCScnsR09qjcgcIRkevWgBqqXccgA8dKds5fu49elSrG5G8KQpHfqDVZnPJQEYOB3zQAvl5GVAU+1MZni2lgHHrmnxP+6C4wc5yalj2sxJT265zQBVcGRQ56j070rttUNGOvp0qZ3I4Awo/wA9KUqF5T8jQBXDEuN65B54NFOZmDbfujvxRQBzBTleePWmFUWQKrZXuDzio3JbBViCOwp5BO3AyT+goJH4K42AKp7dqnQqygbVC9yOtQpv2/MAccYFCsAQoOD06fzpjLiIrBh1I6E03DKhORge9QyMezAEfeOaSORjBnPC0Ai/byfKN7dR909qGlyQFI568c1QQ+Y4DD73t1qTzHXIA6dAetAFlXTzcllAxnrzSmRRKrIu/PcmqZYFfNdh1+6BxmpbeTBCEEDPGDQBZly5O7aQTzjtS74+owQvGT0qCSNpo2XcMA96jkYDAA+Re7etAFiWbMY2NtYdBjOajZk2bW+ZieQtMfG4SHA5z+FOkQONxOG656igCFn3k4XbnrimhsbmbAYd+tODgjbtXPqtK23aC64B6YoGWYyxY7AenepQ43ICOc5x6VTaV1CqoGe1RvL0Vy2epwf5UCNvh+RjePToDSMMDeTuOccdqoxybFIUMy+maVJyF2sWHoC386ANS3JUkB92TmrELqN6ttIrKt5SjEsTnHarCtG2RgAgc59KANFbhUcgY3Yzk1ahmEZJdgf61kbwp3KQTx2qzGQxGVX3NMDRjl3ZKDAApYJTt3P8/GAM9DVTz3J4AX03Dg0DDgbjtY+/WgCyxLMBgtzn2FSIgcsnzE4xk9qgYr5QRFXcpxjNOS5MWVXJVeuP8aAEki2ITwR70wZKFh8owRjNPLtMxGBk/wB70pEYpKflwnqR1oAZbRBoyrjDEnnsfeho03ou0cDI9am8suzbBhBzuP8AhUEkh564Ufl6UANkVkAdCSp6j0pnlNjk4/TilWTcgyDnHSmlmZiFHOMD2pDEUbQVTkE/ep0LSOcqNmeDnvVcnYclmIHU1Ibnpx97gA0AVPEuqS6Vo9xPDgXJwkR6bWPAP4da4/RNFEQV5EJfqWPJNXPHU5NimWLBZkYk+gNbVpErMhGfLIG3BqLXdxsfa20YRlVPlbuafJZRLFtdefYVbhVQThQG6Uxw2WVh849D2q7COT1vR4HjZQgYjqcVx9t52kalBdYINvKMn+8v/wCrIr1Ge33A7lzxjg1x/iTTgyXTDp5TMOOeBn+lZyVtRnoQkLqhQfKRuBPoelR+S7swfaOc571meHblrjQbFz/rPJUZPTgYrSjkdj/tE9D/ABVoIq3dgq2+N27PPriuM8QaIJgHQHHbaK72RWyEZiv17VF5PnKRw3HU96mUUx3PFrzTJ7aX5oycdDjkfjUPnXDLs82dgP4WkY/pmvYbjToVTDoDwc96oR6Rbvmbyl2EfL8uDmsvZvuO5wmhaVJNIrSjagOQoGK9C0zTlt0UAgMOdvWrdvZwbTtUrzjPvVlY/mIIAPXPYe9XGKiJslUEABkxUiTMgwCMdwOOKglcK67R82MYPShpSQWCZz6D+tWIu7hIuXfKjjA/rTmhQurxgKxGSPX8KohSGO1iAxzwO9StKyDgfQUAWzGXXCkBT19c0wIYXyyhh6f1pPPBVFY4Y9fWiOcYYA7jnGDTAVphIxVFIX3PSkRQEUryO9QzYGCOGPfpmpQQRjdkNjGT1oAe6kqvQL3x3qPZswNgwxzkdqJJWAAZc49D0pJpmEeRhl9+lADmG9cKBJznIHSoZVw3XHfC0xZzsO7CkHrnpR5oCkFsjuT1FACEk/eLb/Ru9FJvWTLDkDgj/CigDjwqlmLDge9SRSFydpKhetMGFU9j155pY3AwTHnPHHakSSLl2xyo7jPNSiRYz8wA9v61EckqWOB6f/XpwXJ3YUHPJJpjHSYK5C5z19aTBQKynr0p0ceG5YAY609VY5UKCxoAbG7ByerdSaWQ5O8Dk9ialRNi8r9aa23aCuCD3oASILsODjP508OEOwnC/rSeYOPlJIHT1pysrqVcfKaAGeeWYALyOAT6U94SQCp34PT0pWQMRtHyjpj+tHmndgq2QM8HAoAlhTo7YwvZTkmkdYZCM/IB0GetMMxQkKA2RzmnFkMYDAkdc9fwoAiG0ZGSF9e+aXaSoORnuTQzjJYqSf0IpTKD0wQvPHSgCJsE5jzkdjTUyXbgnHJFKzYALoVGc/WlE5wQv3RQMtoitHjJHHHvSLhdoJVmXriqsTs7Ljccds9KnSfexUrhugxQBY3MXboeM/LVuNBKFJO3HY1nxyBZFD8Dt71cMqltpwR2296AHcpNwST6mrKSFRw5JPUnpVZpUSMHaGGecnBpwZSAxXBPOB0pgXkbdnexORjrxTknCOwYE7fT+GqYXYcFeD3BqVGRHxJj1GOo+tAi2JCASSCT7VNCyKoy5Hpg5/DFZ/n5ZjgkgfQ1Ijh2AkACjGF6EGgDRMi5O1efU9qhkaTBK4b1Uc1HGyu+NmFHtT0KLcM3CNjGe1AyaOc4yfu9Bg4/OoZVMiEL82euD/OnbSw3bx9AM1MVU4I6gc8Y/GgRUVdmNx7ce1RsXwMY6Zx3FWmjRl43eZ2x0qJ4lH3kPnHgY60hlRxv4kBYHHXrntSyRyAA9fw71ZRVzl/oRjmpJXbadsYwO/tQFzifFdt5tlMpXGV5P/16u+Br4aloyLuAu7UeVMO5H8J+lXtUtpJ7STK4PIx14rzmC7uvDOupf2ikqpxJGeA6d1P+PaovyvUe561GvJZmU46YqMKTJuGB2PFXNAvLDxHbC60eYT4GZYcYmh9mTr/wIZB9anltNjnOwDOAcitLEma8H7vIBfnp6Vg+KoBBoWp3L5wsBjX/AH3IVR/P8jXaw2/yzSPsFvECZZi4SKMDqzueAP19Aa8w8UeIYNf1K3s9Pz/ZlrIZPMZSpuZcY3kdlA4VTz1J5NRPRWKj3Nfw9H5emwRrkGNAp9zitqPaqqy8uOoHUH0Gay9NiIiH3gDg8jitMIEOSv3uRimIfISysI2C57kZPvSqWTnAPHUdqi3ggFi23ucdqkiK7GGBt7GmBHlpGG4EZHcUqxqAu9tvPH0p8iRvs3bt2cn3pSiupG7GOOR0oAijjZWOCAvUA1IquBlOSfvZqNvlKK4Yqc4bsKUF2AxyDxyeaQEjMXj+UYI65phjVhwpXHIPSlZfMfYxB29cGnybOFUgspzQBAW3sfLJDDt6/jTI2aMM0rKWHSiRVVwM7QTx7UyQhZCWYnjrQBJG2HJOCDz161M0hIyqj/CqqMwibcN3PYZ4qMu2z5C2M4IPegC40pYYzlieCR0pJPM2AElvpzVUI/mYOFYDg5/pTxEsW2Qbh2A7fWgCRJGdMEkOM8mmOTgBWHHb+9SSM3l7VIyP7oqNTtDZy5GMcUAPV8blZOSPypNjEZcHPfHanxrtYuDlsdCOKexRtrSMqn60AQbiJTg5yejdqKW5MfmBVIHHUc5ooA5ry1OCp7cc1ANyudpbgdPWptrFAQuMdTTDuRQARkdM0Ejxl1O9evQA4FKkhVxg5HTFLEhdPmfHHU06CBEBPmA47Z5oAmdyww6jafWpQyqq4wMjqBVdGUAgH5j60R+aVxnBHemMtPMXchsgCkMXyAjgnlh0zUCllGJFDEHNPjDtGwYggnOc0APHyD5QT6A9qjR1iBMzfOex7U1ldmIX8gadFDEWxcqrp/dagASVSpKbganH3A75JBwD60vkRs4EedvY5oeARMQ0hZT2IwaAImQFVcZ2k8qasQFMnOQOy5605Ckactkj1NROzSY8tRtz2/rQA933t8pOR2I6CmAovytl29QOlM2u7kIMEdSDUw3qyqwznjGMUANRTMGJz8vByf6UxlATAJB659Ks5AJVvlB7ioJoDlg2TnGMdqBlQyA8gbSO/eniTyiGDfU4prBUYncdw4AApVddmPLAzySaQFuC4ByxXe2PlJq9DdIyKHCqSOcCqJK7FbqB1xwAadExc8kADktTAvL+73ucFD+NJvDcZGAeMdRULyLsC7TyenapiypEODvblhmgRYiYl8gjj16UrFTLubj2qkssfLOQOOMd6a1yrLuPJHFAy/vWRV8tVU9gTVhCFVQxUnryOlYxuEVT5aliD696b9okbBBC85oA3xI33WJYY4NTeZGV2qmeeoNYUN25Zf3hyfvHHWrkcgCq5IyeRTEaGCEIGUz2PNTxbtigMWHPP9KoLOiruYtnsalhu2kHDYOe45IoAtQYVWDnIz09KV4y+XQgHHG49aqNNukAIIz97dxSC72ZyjYx9RQBdCAjdlV9QOmfWmAcnaWOB36VAkpclt5xjuKVHz8r5PvQMkPEJ3ABemPeuR1zSBdbyFAHr711UqhSEBJGD8wONtQOitKuQCvak1cDxm/srzTLkT2kksDqco8TFSPoRyK0bb4j+L7WPYNYmdRx++jjcj8WUmu/1XTo5X4G5D19vesM+HbKZ2bycY7Edax5ZLRMdzkb/Wdf8Syoupahc3ijkK7fIPoowoPvit7Q9KNuis6tnqRitu00SK2I8qNVJ53DsK144FVFwMEdW96qMOrC5JaArbhiuGUYxnirinzSFBwR2NVd7AFWJUA5JxwacJT5hAIHHbrWghZFMQIXOB1U06NmEY2YIIzkdqJMb1BzzxzT41VDvX5k6HaKAI2bnnlv5VGDwSfnU9jjIpHImOWQrg8YPWmLDHknft3dgDk0gHxT8FZScngYGQKlURkEtlSe4OM+9NeFUiXC4PakLchl4wO44B+lMCdNoUhVwT1PrUG9UZgdw29TURkkB+VtwPTNNXcNuWyw5pATEuy7gAx/vYpqgkk/dOeRikEm1QV6tyBioweCSSCOpPf60ASGRwx+UAAdcUwttbJXgjv2NNeT93s5YnnA4/DNJlSvKnI7NQA6MbyQMKeAD6U6QyhSQC6KcYAyRUZJH+rGG9v1oCEHch5HUHpQBLC2wk/xdDntTdhDBg+cjjI6/SlY42lyMk9R3qQLyC3LdB7UARqd5IO7GOfSqtxBk7R2PCmrbAINuTn1FQ7Jgyk7mx370AMto9rAt8wHQt2oqaUFY2YLgdx3NFAHMOwVcg8YpiAFdyk/RjmhHIUAgHjk9aax2vuRQc+lBI93Kplmyc9BTVbvuXHcUx8M2BxmnFUKou0DNAEiSD7wPPoDU8JIJzkHOeuapqsm4ZXGDwcVaiHylgud3f0+tMCWTaWVQxHfHUmrDyJ5WUPzqOf/ANVUFQh1IGScgVZZMKGIXcBzQMbE5YEfL8w6jijmRtu0HHAz2pG5bG7GeSRT8jCnkFenHWgCbcY48ZAIGPc1GszzpgMcfyokk8wbWUbR1IPJpY0JbhVUeuetACJ/rBs47EnnNSLEdz4djz1zilnA2Y7g8bTSpxuBIIPde1AFhd4zjYxzgc4FMMpZjuBz9aimlKKBtBz6dfrURuVdQpAB6gUAT52Pkg5WnSXBkXaRjb1qqkrAMCcHofep4+AzDkHtnrQMqqWLnf16ZPanFGzwykY646VPGwO7cvDHjaP0phdk+ZAAx4DdqAHBwkPynI9KWNS8fUr65HFRqmJFdssD29KsPwSz4bPZeKAH7BGuVOQO/wDLNMdnXLE5TOfemxDMgIwf9k9KfsPmfMWyeoFAFe73GRCGBB9OxpHMhAQ4B6YHQ1aZEysYVs9eKglEZkwCxZec5oAjiRwCqH/HFKUaPbzgNxjNIA5zy2AOaSKUj5dobvSAtSqUC/dy3pU1ox2vncpzj5qrLKVYHBA7d6tb0ZQyjGTz3pgXBukKg4Tb3apY9sLjbls9f8ay8r8ymQ7lGfwqxBOjxqQvIxzQBoLnIGC2e5pWc5CkHp36CoElcxtuB2juaj87fgsvK/d9CKALZPlxfMVyR9KdFJhcOQEHc81B8khUuOOwzUluVJfAHPBHegCRHO9hJyf7w5yKQuzEA7c9ge4pY3G4qcKRnGe9Dx8YY5JGcg80AVZSykcb0JxnHSgkI2BznrwM1ZdUkXPIdcHA600QYDZV/r3oAglVQWKnbwCV9PrUUaNJ/q5NuQcY71aY4REEYGTgMx61Ey4Ysoxz27e9ADVUujxlhx0BoQHYMHB6H2qQQZTzWbnGcdfxqTYoIZeQRkjbQBWbdhVyVxk7vU04SgKct0GBjihVBfGWdD1FIyo7sGT5eny9qQD7YFlJdR7ZHFMU4JEhzxxkcr+NNk+Zvlzhf1pHbYwBDNJnoaAJLj92qqrHpkE9qitCwMnmOMnpk9ae5QBCOi/iT7UhWP5iNzdwu2gB6O2NoUt/tEUhYDhhwetLCoBYdATkj3oZQu3YSxPJ74FAEKM27AKnHepAfMjbzQQfQcikMa+mWJ+Xtk0rKyc/MpJwQec+1AEYjK4BUkdKbIrMSCVxkEg/yqw7GRm4CgYwPU0xVUuwLHnqCKAGrEG+dBtAOCo5z71KLdgSWwAaYjCNdrFsZ/OnE7ycNyOmeKAIZWMb/K2OOvvT4mZm3ZAOM5FVnVgSCx3HoD60oLxpt3fMD0I60hlgSrM2Q+XxjIo/iLM7HAxg1WiV2zkKoznpUu0lht+XPtwaYiUoXH1HfoKKmUKqgY/CigDiXlCryAPpT4vnRmZ+fSqjNuxzntzT/M2cnnbzigkshDJhQQD6g1MVCKBxuzg5qpHMGXcqgE8UNM6uiE+/FAFhk3Lu5JXmp1bcuWOB2FUhdYOEYgE85FPkcnHGV9KYFr5VK7fmz2x29qlSLzcuTgDqM1DFMCmFGAeMU6KQxkgHK9DQBKwYNsXG32PNPW36BmIB96kjZSnmHGfao5WJ+YA59AaBjbhRER5ZJ9fr9KIxznd+A421IhKrwRjGeeaeiqzBnXAx0FAESkbmTIYnoCaRbWUMd3yqOvOc1KyKqCTvnBI71I5GNu5gR60AU5RhQVJfnrnj8KjVFRiUzn1q7w0fRR6Yp0doixsScs3SgCkI3YghgCOTzTpI2XkZ9sGrawMIhtAyKIkctgqOOvPWgCvG+yJhkseuM9KReV8yTgDr6VNPH87MVA6cCmSlGK7V2tjkds0DJofKVi3DKemeopZGAAKtn2qjISCcE5x90U8EnbsG3jpmgC7DOI1JK8noSQcn2qQziZC2Fz3XNUNx6jrjGD0oklwFVcDP3hjqKAL4Kqm0HDe3NVpRmRdpz6+tMgkjMZU7s9abu2vh492RnI4oAkjnYO2RlehAxUTq/mE7SikdBSuiJJiPhSOaeZTFEV+8g45PNAELhkiBVwFHYcmnxSHJbcCMcnFRnDRltoB6nvS258uMkqCf0pAKzucBwdvrirUE8HTP7wDlexqq0gdsLg49fWg7CWAXDYyDQBeS4eZyFyFX+VWNwUMR1P8ADjnjvWeGYIob159hVmKRZpeOhGBnmmBYAkKgZHPQ9cVYRWVlwdrd+KzpZTbhuTjP50sErRsXc5ZgPpQBqF5gcugIz1FPVm+z4dgTnhQOaqQyb1BcHdjpnilk3sgDAEDmgC9CCxyDt7gY/SrEr4RAMKfQis2CdFVsGTd7nIFOSU43OCcZIGeKALCKN7GQ5buB2qQoG4yD2xVNLgSnaqkZP4ipwVUhgWIA2g0ATH7wKBR2bA6VHIoLAg9Bxio2l2N8ilmzyaYqK20ozPIxOAeBQA+Itks4VR04/pSSlgQGIAxkHFO+YRhC3XrgUjhWTDMw569aAGhljA2gY7ZGDUTIFBaM5Z+S3+FSMq7V2Zxg8H1qpyw2rwM/lQA8Exgj73fIFNWWRMA4z/Dz+mKlUfJtyRz0qpIQG+YnCd+9ICZZJSTtG0dTgDn608t8o9D6d6qShlaNw5Td3AqxCJNx3kFeRQA9CUjA2jIORk5/KngsyjPJ61DjzcBQAP5VOYljXGSN3U0ANAA5bDD37UglCk7dnPtio5iS2zpg849KEVJ9wXPHagBrjcS2zczcY6GlySxEmOOcE07CqpypEjdwelIqnJMrnPbH9aAEnnDYHCjrzUckgKY+XA6n1pDDkHGCo7HnilmTanpnpSAV422A8HHJxRAWPKnIHaoUlZBjdnaec+lTrcgZVeSehpgChSWIOCTjmiq8anzS7c+4P9KKQH//2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Pictured are a head lamp and from top to bottom: a Schuknecht foreign body remover, right-angle Day hook, and alligator forceps.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Glenn C Isaacson, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_30_19940=[""].join("\n");
var outline_f19_30_19940=null;
var title_f19_30_19941="Necrotizing pneumonia";
var content_f19_30_19941=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F86362&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F86362&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Computed tomography: Left-sided Streptococcus pneumoniae necrotizing pneumonia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 371px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy William J Barson, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_30_19941=[""].join("\n");
var outline_f19_30_19941=null;
var title_f19_30_19942="Condyloma acuminatum3";
var content_f19_30_19942=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F51759&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F51759&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Condyloma acuminatum involving vulva, vagina, and perianal region",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 400px; height: 491px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_30_19942=[""].join("\n");
var outline_f19_30_19942=null;
var title_f19_30_19943="The pediatric physical examination: General principles and standard measurements";
var content_f19_30_19943=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   The pediatric physical examination: General principles and standard measurements",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/30/19943/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/30/19943/contributors\">",
"     Jan E Drutz, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/30/19943/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/30/19943/contributors\">",
"     Teresa K Duryea, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/30/19943/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/30/19943/contributors\">",
"     Mary M Torchia, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?19/30/19943/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 20, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sophisticated technological advances in medicine have proved to be remarkably beneficial in the diagnostic process, yet the well-performed history and the physical examination remain the clinician's most important tools. They are venerated elements of the art of medicine, the best series of diagnostic tests we have [",
"    <a class=\"abstract\" href=\"UTD.htm?19/30/19943/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A relatively complete physical examination should be performed on each patient, regardless of the reason for the visit. Numerous medical anecdotes relate instances in which the examination revealed findings unrelated to and unexpected from the patient's chief complaint and major concerns. On occasion, a limited or inadequate examination may miss a significant condition, mass lesion, or potentially life-threatening condition.",
"   </p>",
"   <p>",
"    The general principles, standard measurements, and overall approach to the pediatric patient are discussed here. Examination of specific organ systems is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/59/11194?source=see_link\">",
"     \"The pediatric physical examination: HEENT\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/36/38471?source=see_link\">",
"     \"The pediatric physical examination: Chest and abdomen\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/30/34280?source=see_link\">",
"     \"The pediatric physical examination: Back, extremities, nervous system, skin, and lymph nodes\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/3/10295?source=see_link\">",
"     \"The pediatric physical examination: The perineum\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GENERAL PRINCIPLES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     The approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;After years of experience, seasoned examiners become aware of potential avoidable pitfalls often encountered upon entering a patient's room. Before entering the room, the clinician should review the patient's chart and confirm the identity of the patient and others in the room. Most clinicians have experienced the discomfort of walking into a room and greeting the patient, parent, or caregiver by the wrong name or of having the correct name but the wrong chart in hand.",
"   </p>",
"   <p>",
"    To avoid a potentially embarrassing situation, the examiner should always knock on the door and await a response before entering. Small children standing on the other side can be injured easily by the door handle or by the door's impact as it is being opened.",
"   </p>",
"   <p>",
"    Regardless of whether the clinician and caregiver have met previously, it is appropriate to greet everyone in a cordial manner, maintaining a professional yet friendly demeanor. Infants older than six months and anxious toddlers who are leery of strangers often are more comfortable when held by their caregiver. To gain the child's confidence and to avoid an early adversarial relationship, the clinician should try using a calm approach, a reassuring smile, and a toy or bright object as a diversion. An appropriate distance should be maintained during the history-taking portion. The clinician's approach should be cautious and nonthreatening once the physical examination is about to begin.",
"   </p>",
"   <p>",
"    Infants younger than six months who have no stranger anxiety and children older than 30 to 36 months who are familiar with the examining clinician",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    who possess a trusting demeanor generally cooperate during the examination without being held. Physical examination of 5- to 12-year-old children usually is easy to perform because these children are not typically apprehensive and tend to be cooperative.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     General appearance",
"    </span>",
"    &nbsp;&mdash;&nbsp;The examiner may gain significant insight into important social and family dynamics by observation alone when entering the patient's room. Terms used to describe a patient's general appearance include degree of comfort (calm, nervous, shy), state of well-being (normal, ill appearing, distressed), activity level (sedate, alert, active, fidgety), physical appearance (neat, disheveled, unkempt), behavior and attitude (happy, sad, irritable, combative), body habitus (overweight, underweight, short, tall), and nutritional status (malnourished, normal, corpulent). The possibility of neglect should be considered if the child and caregiver make no eye contact or the patient lacks animation and has no social smile. Psychosocial intervention may be warranted in these circumstances. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/62/18408?source=see_link\">",
"     \"Child neglect and emotional abuse\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If a child appears ill, particular attention should be paid to the way the patient has positioned himself or herself. A child who lies completely still on the examination table, is verbally responsive, but noticeably winces when an attempt is made to change position may have an acute abdomen. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/61/22490?source=see_link\">",
"     \"Emergent evaluation of the child with acute abdominal pain\"",
"    </a>",
"    .) A dyspneic patient who is sitting upright and slightly forward with the arms extended and hands resting on the knees might be experiencing an exacerbation of asthma.",
"   </p>",
"   <p>",
"    If an infant who is about to be examined is crying when the clinician enters the examination room, the pitch and intensity of the cry should be noted. A boisterous hardy cry is somewhat reassuring, whereas a weak and listless cry may indicate a seriously ill infant. A high-pitched, screeching cry could indicate increased intracranial pressure, reaction to a painful injury, toxic reaction, strangulated inguinal hernia, or other serious disorders.",
"   </p>",
"   <p>",
"    Note the patient's breathing pattern and skin color. If the patient has rapid, shallow respiration yet appears to be in no acute distress, the underlying cause could be primary pulmonary disease or respiratory compensation for metabolic acidosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/11/6330?source=see_link\">",
"     \"Approach to the child with metabolic acidosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The examiner should evaluate the developmental status before touching the child. The patient's motor function, interaction with surrounding objects and people, response to sounds, and speech pattern give clues about whether the patient is normal or is in need of extensive developmental assessment. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/49/26394?source=see_link&amp;anchor=H307347#H307347\">",
"     \"Developmental-behavioral surveillance and screening in primary care\", section on 'Monitoring milestones'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;Historical information depends almost completely upon the caregiver for patients in the neonatal age range through early childhood. To obtain pertinent information regarding a 5- to 12-year-old child, the clinician must still rely primarily on the caregiver, although attention should be given to the relevant, and often honest, comments made by the patient. Interview the adolescent patient in the absence of caregivers when appropriate so that pertinent historical information, anticipatory guidance, and preventive health care issues can be more openly discussed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/35/19000?source=see_link\">",
"     \"Guidelines for adolescent preventive services\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Key elements in the history-taking process include establishing a warm, caring atmosphere and asking questions in a nonconfrontational, unhurried manner. The terminology and language used by the examiner should be appropriate for the educational level of the caregiver and the patient. Good eye contact and a sense of undivided attention should be maintained. The clinician should sit opposite the caregiver",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    patient at a comfortable distance, unencumbered by large objects, such as desks or tables. Outside interruption by the medical staff and by telephone calls should be kept to a minimum. An effort should be made to maintain an uninterrupted dialogue, to write few notes, and to refer to written data as little as possible.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;The examiner should wash his or her hands thoroughly before beginning and after completing the examination. Protective gloves should be worn when appropriate. Patients and caregivers are well aware when the examiner fails to carry out this seemingly routine practice.",
"   </p>",
"   <p>",
"    Skilled clinicians employ different techniques to gain pediatric patient cooperation. The use of toys, distracting objects, and pictures helps in the examination of young children, infants, and toddlers. Engaging the two- to four-year-old in stories or a discussion of imaginary animals frequently creates an effective diversion. Food, in the form of chewable snacks or liquid refreshments, can be used as a means of pacification, depending upon the stage of the examination.",
"   </p>",
"   <p>",
"    When an otherwise normal-acting child older than four years fails to cooperate for an examination, even in the presence of a familiar caregiver, it may be an indication of either an earlier traumatic encounter between the patient and another examiner or a failure on the part of the current examining clinician to use the correct approach. An underlying psychosocial problem or personality defect should be suspected when a child who is older than four years is totally combative or extremely uncooperative.",
"   </p>",
"   <p>",
"    For patients old enough to understand but who appear apprehensive, the examiner should explain what is going to be done during the examination and allow them to look at and touch any of the instruments to be used. Older patients should be warned in advance of potential pain or discomfort.",
"   </p>",
"   <p>",
"    The examination of an infant, toddler, or child should be performed in the presence of a parent or guardian; if the parent&rsquo;s presence may interfere with the examination (eg, suspected child abuse), a chaperone should be present [",
"    <a class=\"abstract\" href=\"UTD.htm?19/30/19943/abstract/2\">",
"     2",
"    </a>",
"    ]. The use of a chaperone for the examination of the anorectal and genital areas",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    breasts of female adolescent patients should be a shared decision between the patient and the clinician after the clinician has explained the reason for the examination and described how the examination will proceed. The sex of the chaperone should be determined by the patient&rsquo;s wishes and comfort (if possible). If a patient is offered the use of a chaperone and declines, this should be documented in the chart.",
"   </p>",
"   <p>",
"    If the patient has a complaint, sign, or symptom that appears to involve a particular part of the anatomy, that part of the examination should be performed last. As an example, consider a patient complaining of right-lower-quadrant abdominal pain thought to be attributable to appendicitis; by not examining that part of the body first, the clinician may be able to divert the patient's attention away from the involved area and rule out other possible causes for the pain.",
"   </p>",
"   <p>",
"    Patient privacy should be respected. If a patient objects to being unclothed or to wearing an examination gown, allow him or her to remain clothed until a specific part of the anatomy must be checked. When an area needs to be examined, the patient should be asked to remove or pull free the garments that are hindering visualization, palpation, or auscultation.",
"   </p>",
"   <p>",
"    The order in which the physical examination is conducted often is age-specific and depends upon examiner preference. For an infant and younger child, the clinician may prefer to begin by examining the eyes, noting the red-light reflex, extraocular eye muscle movements, and visual tracking and then move to other parts of the body or organ systems before finally examining the ears, which are sensitive. For the older, more cooperative child, the examination might begin at the head and progress down the body, with the neurologic examination last. In general, the portions of the pediatric examination that require the most patient cooperation, such as blood pressure measurement, lung and heart auscultation, and eye and neurologic examinations, are performed initially. These examinations are followed by the more bothersome portions, including abdominal and ear examinations and measurement of head circumference.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     STANDARD MEASUREMENTS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Weight, height, head, and chest circumference",
"    </span>",
"    &nbsp;&mdash;&nbsp;Measurement of the standard growth parameters throughout childhood and adolescence is essential for assessing normal development [",
"    <a class=\"abstract\" href=\"UTD.htm?19/30/19943/abstract/3\">",
"     3",
"    </a>",
"    ]. Data obtained should be plotted on standard growth curves to determine progress.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Weight is measured at each periodic well-child visit (",
"      <a class=\"graphic graphic_figure graphicRef50006 graphicRef71721 \" href=\"UTD.htm?10/19/10552\">",
"       figure 1A-B",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef63877 graphicRef53325 \" href=\"UTD.htm?2/56/2952\">",
"       figure 2A-B",
"      </a>",
"      ) (",
"      <a class=\"calc calc_professional\" href=\"UTD.htm?11/46/12003?source=see_link\">",
"       calculator 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Height (length) is measured at each periodic well-child visit. In the child younger than two years, measuring body length when the child is in the supine position is preferable to trying to obtain an accurate measurement while the child is standing (",
"      <a class=\"graphic graphic_figure graphicRef67950 graphicRef80511 \" href=\"UTD.htm?38/48/39687\">",
"       figure 3A-B",
"      </a>",
"      ) (",
"      <a class=\"calc calc_professional\" href=\"UTD.htm?9/51/10035?source=see_link\">",
"       calculator 2",
"      </a>",
"      ). In older children, the height measurement should always be done with the patient standing (",
"      <a class=\"graphic graphic_figure graphicRef56127 \" href=\"UTD.htm?27/45/28371\">",
"       figure 4",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef63399 graphicRef77249 \" href=\"UTD.htm?43/30/44519\">",
"       figure 5A-B",
"      </a>",
"      ) (",
"      <a class=\"calc calc_professional\" href=\"UTD.htm?21/47/22262?source=see_link\">",
"       calculator 3",
"      </a>",
"      and",
"      <a class=\"calc calc_professional\" href=\"UTD.htm?22/7/22646?source=see_link\">",
"       calculator 4",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Frontal-occipital head circumference is recorded routinely until the patient is two or three years old. Measurement should be attempted only at the conclusion of the physical examination, as infants generally dislike this portion of the examination. The measuring tape should encircle the head and include an area 1 to 2 cm above the glabella anteriorly and the most prominent portion of the occiput posteriorly (",
"      <a class=\"graphic graphic_picture graphicRef70799 \" href=\"UTD.htm?35/54/36707\">",
"       picture 1",
"      </a>",
"      ). Frontal-occipital head circumference should be plotted on a standardized head circumference chart. A number head circumference charts are available. They are discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/51/36665?source=see_link&amp;anchor=H18523310#H18523310\">",
"       \"Etiology and evaluation of microcephaly in infants and children\", section on 'Head circumference charts'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      A disproportionately large head may be indicative of hydrocephalus or macrocephaly. A head circumference that is smaller than normal may constitute microcephaly and suggest potential underlying neurologic deficits. In some children, however, small head size may be normal. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/51/36665?source=see_link&amp;anchor=H5#H5\">",
"       \"Etiology and evaluation of microcephaly in infants and children\", section on 'Definitions'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/54/3946?source=see_link&amp;anchor=H6#H6\">",
"       \"Etiology and evaluation of macrocephaly in infants and children\", section on 'Etiology'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Chest circumference is measured at the time of the newborn examination, but it is not a part of the routine examination for well-child visits. The chest circumference is measured at the nipple line. Head circumference is 1 to 2 cm larger than chest circumference in most newborns and in children 12 to 18 months old; an exception is the normal rapidly growing head of the premature infant.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H610209046\">",
"    <span class=\"h2\">",
"     Vital signs",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Temperature",
"    </span>",
"    &nbsp;&mdash;&nbsp;Routine measurement of the patient's temperature is not always necessary. When a temperature measurement is needed, the technique and appropriate site for measurement are age dependent. Rectal temperature recordings in infants and young children are preferred, although axillary recordings are acceptable; axillary measurements are consistently lower than rectal measurements, but the absolute difference varies too widely for a standard conversion [",
"    <a class=\"abstract\" href=\"UTD.htm?19/30/19943/abstract/4\">",
"     4",
"    </a>",
"    ]. Oral temperature readings (about 1&ordm;F [0.6&ordm;C] below rectal temperatures) should not be obtained until the child is old enough to understand how to hold and retain an oral thermometer under the tongue. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/8/18570?source=see_link&amp;anchor=H703490142#H703490142\">",
"     \"Pathophysiology and management of fever in infants and children\", section on 'Temperature measurement'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Rectal temperature measurements should be taken with the patient in the prone position with the legs slightly flexed at the hips and knees; the thermometer is directed anteriorly at an angle of approximately 20&ordm; to the surface of the examination table [",
"    <a class=\"abstract\" href=\"UTD.htm?19/30/19943/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. Battery-operated and electronic thermometers for recording oral or rectal temperatures generally are reliable and fast. The use of infrared tympanic membrane and temporal artery thermometers is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/8/18570?source=see_link&amp;anchor=H703490142#H703490142\">",
"     \"Pathophysiology and management of fever in infants and children\", section on 'Temperature measurement'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Respiratory rate",
"    </span>",
"    &nbsp;&mdash;&nbsp;Accurate determination of the respiratory rate should be attempted only when the patient is asleep or at rest. It can be obtained by auscultation, palpation, or direct observation.",
"   </p>",
"   <p>",
"    The normal range for the respiratory rate depends upon the age of the child. A systematic review of 20 studies provided respiratory rate percentiles for healthy children who were typically awake and at rest (",
"    <a class=\"graphic graphic_table graphicRef78097 \" href=\"UTD.htm?27/37/28252\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/30/19943/abstract/7\">",
"     7",
"    </a>",
"    ]. A sustained breathing rate in excess of the upper limit of normal generally indicates primary respiratory tract disease; it may also occur secondary to a metabolic disorder, infectious disease, high fever, or underlying heart disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Heart rate",
"    </span>",
"    &nbsp;&mdash;&nbsp;According to one author, \"those who wish to know the inner body feel the pulse and thus have the fundamentals for diagnosis\" [",
"    <a class=\"abstract\" href=\"UTD.htm?19/30/19943/abstract/8\">",
"     8",
"    </a>",
"    ]. The heart rate can be measured by direct auscultation or palpation of the heart or by palpation of peripheral arteries (carotids, femorals, brachials, or radials).",
"   </p>",
"   <p>",
"    Like the respiratory rate, the normal heart rate varies with age. A systematic review of 59 studies provided heart rate percentiles for healthy children who were typically awake and at rest (",
"    <a class=\"graphic graphic_table graphicRef78097 \" href=\"UTD.htm?27/37/28252\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/30/19943/abstract/7\">",
"     7",
"    </a>",
"    ]. A heart rate above the upper limit of normal may indicate primary cardiac disease; it also can occur secondary to an underlying systemic or metabolic disorder, infectious disease, or high fever.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Blood pressure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Yearly blood pressure measurements are measured in children ages three years and older. Obtaining an accurate blood pressure reading in children under the age of three often is difficult. In most circumstances, routine blood pressure measurements should not be attempted in these children unless they have evidence of underlying renal disease, such as a tumor, nephrotic syndrome, glomerulonephritis, pyelonephritis, or renal artery stenosis. Another reason for measuring the blood pressure in children under the age of three is the finding or suspicion of underlying cardiovascular disease, such as coarctation of the aorta or patent ductus arteriosus (PDA).",
"   </p>",
"   <p>",
"    Blood pressure devices include the standard extremity cuff and mercury bulb sphygmomanometer, the hand-held aneroid manometer, and the Doppler and oscillometric devices. Patients old enough to understand should be shown the blood pressure device before the examiner attempts to take a measurement. The patient should be allowed to play with the device or feel the cuff inflate to gain his or her cooperation. The proper technique for blood pressure measurement is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/45/17113?source=see_link&amp;anchor=H11#H11\">",
"     \"Definition and diagnosis of hypertension in children and adolescents\", section on 'Measurement of blood pressure'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As with pulse and respiratory rates in children, blood pressure varies with age. Standard reference charts that give the ranges of normality should be consulted (",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?9/15/9463?source=see_link\">",
"     calculator 5",
"    </a>",
"    and",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?9/33/9751?source=see_link\">",
"     calculator 6",
"    </a>",
"    ) (",
"    <a class=\"graphic graphic_table graphicRef78097 \" href=\"UTD.htm?27/37/28252\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef63856 \" href=\"UTD.htm?7/45/7894\">",
"     table 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef52646 \" href=\"UTD.htm?7/46/7910\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/30/19943/abstract/9\">",
"     9",
"    </a>",
"    ]. The systolic pressure measured in the lower extremity generally is about 20 mmHg higher than that measured in the upper extremity. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/45/17113?source=see_link\">",
"     \"Definition and diagnosis of hypertension in children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      High blood pressure &ndash; In addition to the disorders mentioned above, elevated blood pressures are associated with neuroblastomas, pheochromocytomas, thyroid disease, neurofibromatosis, Cushing disease, intoxication from or ingestion of various substances, increased intracranial pressure, and myriad other disorders. It is wise to keep in mind that elevated systolic pressures alone frequently are noted in patients after vigorous exercise, excessive agitation, or during febrile illnesses. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/7/42105?source=see_link&amp;anchor=H15#H15\">",
"       \"Epidemiology, risk factors, and etiology of hypertension in children and adolescents\", section on 'Secondary hypertension'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Low blood pressure &ndash; Abnormally low blood pressure recordings are noted in patients with heart failure from numerous causes and in patients in shock from causes such as sepsis or hypovolemia. A rapid change in the patient's position from supine to standing or sitting may result in orthostatic hypotension. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/49/14104?source=see_link\">",
"       \"Initial evaluation of shock in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Wide pulse pressure &ndash; Widened pulse pressures can occur in patients with aortic regurgitation, arteriovenous fistulas, patent ductus arteriosus, or hyperthyroidism. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/33/1559?source=see_link\">",
"       \"Aortic regurgitation in children\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/52/35656?source=see_link\">",
"       \"Clinical manifestations and diagnosis of patent ductus arteriosus\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/29/7641?source=see_link\">",
"       \"Clinical manifestations and diagnosis of hyperthyroidism in children and adolescents\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Narrow pulse pressure &ndash; Narrowed pulse pressures are found in patients with subaortic or aortic valve stenosis and occasionally in those with hypothyroidism. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/27/33207?source=see_link\">",
"       \"Subvalvar aortic stenosis (subaortic stenosis)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/28/38345?source=see_link\">",
"       \"Valvar aortic stenosis in children\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/22/21865?source=see_link\">",
"       \"Acquired hypothyroidism in childhood and adolescence\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Assessment of the general appearance should include the child's state of well-being, activity level, physical appearance, behavior and attitude, body habitus, nutritional status, preferred position (particularly for ill-appearing children), pitch and intensity of the cry (in crying infants), breathing pattern, skin color, and developmental status. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'General appearance'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The history is generally obtained from the caregiver for infants and preschool children. Children aged 5 through 12 may contribute to the history if they are willing and able. Adolescent patients should be interviewed in the absence of caregivers when appropriate. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'History'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The order in which the physical examination is conducted often is age specific and depends upon examiner preference. The portions of the examination that require the most cooperation usually are performed first, and the more bothersome portions are performed last. If the patient has a localized complaint, sign, or symptom, that part of the examination should be performed last. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Physical examination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Measurement of the weight,",
"      <span class=\"nowrap\">",
"       length/height,",
"      </span>",
"      and head circumference is essential for assessing normal development. Data obtained should be plotted on standard growth curves to determine progress. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Weight, height, head, and chest circumference'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Routine measurement of the patient's temperature is not always necessary at health supervision visits. When a temperature measurement is needed, the technique and appropriate site for measurement are age dependent. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Temperature'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The respiratory rate can be obtained by auscultation, palpation, or direct observation. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Respiratory rate'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The heart rate can be measured by direct auscultation or palpation of the heart or peripheral arteries (carotids, femorals, brachials, or radials). (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Heart rate'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Yearly blood pressure measurements are routinely obtained in children ages three years and older. Blood pressure measurements also should be obtained in children younger than three years if there is evidence or suspicion of underlying renal or cardiovascular disease. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Blood pressure'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/30/19943/abstract/1\">",
"      Sackett DL, Rennie D. The science of the art of the clinical examination. JAMA 1992; 267:2650.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/30/19943/abstract/2\">",
"      Committee on Practice and Ambulatory Medicine. Use of chaperones during the physical examination of the pediatric patient. Pediatrics 2011; 127:991.",
"     </a>",
"    </li>",
"    <li>",
"     Committee on Psychosocial Aspects of Child and Family Health 1995-1996. Guidelines for health supervision III, American Academy of Pediatrics, Elk Grove Village, IL 1997.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/30/19943/abstract/4\">",
"      Anagnostakis D, Matsaniotis N, Grafakos S, Sarafidou E. Rectal-axillary temperature difference in febrile and afebrile infants and children. Clin Pediatr (Phila) 1993; 32:268.",
"     </a>",
"    </li>",
"    <li>",
"     Bates B. A Guide to Physical Examination and History Taking, 6th ed, Lippincott, Philadelphia 1995.",
"    </li>",
"    <li>",
"     Rowe PC. Pediatric procedures. In: Principles and Practice of Pediatrics, Oski FA, DeAngelis CD, Feigin RD, Warshaw JB (Eds), Lippincott, Philadelphia 1990. p.2010.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/30/19943/abstract/7\">",
"      Fleming S, Thompson M, Stevens R, et al. Normal ranges of heart rate and respiratory rate in children from birth to 18 years of age: a systematic review of observational studies. Lancet 2011; 377:1011.",
"     </a>",
"    </li>",
"    <li>",
"     Veith I (translator). The Yellow Emperor's Classic of Internal Medicine, University of California Press, Berkeley, CA 2002.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/30/19943/abstract/9\">",
"      Update on the 1987 Task Force Report on High Blood Pressure in Children and Adolescents: a working group report from the National High Blood Pressure Education Program. National High Blood Pressure Education Program Working Group on Hypertension Control in Children and Adolescents. Pediatrics 1996; 98:649.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2865 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-218.189.88.190-7920B88E07-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_30_19943=[""].join("\n");
var outline_f19_30_19943=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H13\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GENERAL PRINCIPLES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      The approach",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      General appearance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      STANDARD MEASUREMENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Weight, height, head, and chest circumference",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H610209046\">",
"      Vital signs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Temperature",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Respiratory rate",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Heart rate",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Blood pressure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/2865\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/2865|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?39/52/40770\" title=\"figure 1A\">",
"      WHO weight for age boys 0 to 24 months",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?13/61/14291\" title=\"figure 1B\">",
"      CDC weight for age boys 2 to 20 years",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?38/6/39010\" title=\"figure 2A\">",
"      WHO weight for age girls 0 to 24 months",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?41/7/42098\" title=\"figure 2B\">",
"      CDC weight for age girls 2 to 20 years",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?30/44/31426\" title=\"figure 3A\">",
"      WHO length for age boys 0 to 24 months",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?29/51/30514\" title=\"figure 3B\">",
"      WHO length for age girls 0 to 24 months",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?27/45/28371\" title=\"figure 4\">",
"      Height measurement technique",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?43/1/44050\" title=\"figure 5A\">",
"      CDC stature for age boys 2 to 20 years",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?29/10/29858\" title=\"figure 5B\">",
"      CDC stature for age girls 2 to 20 years",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/2865|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?35/54/36707\" title=\"picture 1\">",
"      Head circumference measure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/2865|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?27/37/28252\" title=\"table 1\">",
"      Normal respiratory rate and heart rate in children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?7/45/7894\" title=\"table 2\">",
"      Normal BP boys",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?7/46/7910\" title=\"table 3\">",
"      Normal BP girls",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?11/46/12003?source=related_link\" title=\"calculator 1\">",
"      Calculator: WHO Infant Weight for Age Percentiles (&lt; 24 months)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?9/51/10035?source=related_link\" title=\"calculator 2\">",
"      Calculator: WHO Infant Length for Age Percentiles (&lt; 24 months)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?21/47/22262?source=related_link\" title=\"calculator 3\">",
"      Calculator: CDC height for age percentiles for boys (2 to 20 years)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?22/7/22646?source=related_link\" title=\"calculator 4\">",
"      Calculator: CDC height for age percentiles for girls (2 to 20 years)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?9/15/9463?source=related_link\" title=\"calculator 5\">",
"      Calculator: Blood pressure percentiles for boys (2 to 17 years)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?9/33/9751?source=related_link\" title=\"calculator 6\">",
"      Calculator: Blood pressure percentiles for girls (2 to 17 years)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/22/21865?source=related_link\">",
"      Acquired hypothyroidism in childhood and adolescence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/33/1559?source=related_link\">",
"      Aortic regurgitation in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/11/6330?source=related_link\">",
"      Approach to the child with metabolic acidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/62/18408?source=related_link\">",
"      Child neglect and emotional abuse",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/29/7641?source=related_link\">",
"      Clinical manifestations and diagnosis of hyperthyroidism in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/52/35656?source=related_link\">",
"      Clinical manifestations and diagnosis of patent ductus arteriosus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/45/17113?source=related_link\">",
"      Definition and diagnosis of hypertension in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/49/26394?source=related_link\">",
"      Developmental-behavioral surveillance and screening in primary care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/61/22490?source=related_link\">",
"      Emergent evaluation of the child with acute abdominal pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/7/42105?source=related_link\">",
"      Epidemiology, risk factors, and etiology of hypertension in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/54/3946?source=related_link\">",
"      Etiology and evaluation of macrocephaly in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/51/36665?source=related_link\">",
"      Etiology and evaluation of microcephaly in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/35/19000?source=related_link\">",
"      Guidelines for adolescent preventive services",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/49/14104?source=related_link\">",
"      Initial evaluation of shock in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/8/18570?source=related_link\">",
"      Pathophysiology and management of fever in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/27/33207?source=related_link\">",
"      Subvalvar aortic stenosis (subaortic stenosis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/30/34280?source=related_link\">",
"      The pediatric physical examination: Back, extremities, nervous system, skin, and lymph nodes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/36/38471?source=related_link\">",
"      The pediatric physical examination: Chest and abdomen",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/59/11194?source=related_link\">",
"      The pediatric physical examination: HEENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/3/10295?source=related_link\">",
"      The pediatric physical examination: The perineum",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/28/38345?source=related_link\">",
"      Valvar aortic stenosis in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_30_19944="Molecularly targeted therapy for metastatic melanoma";
var content_f19_30_19944=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Molecularly targeted therapy for metastatic melanoma",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/30/19944/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/30/19944/contributors\">",
"     Jeffrey A Sosman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/30/19944/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/30/19944/contributors\">",
"     Michael B Atkins, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/30/19944/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/30/19944/contributors\">",
"     Michael E Ross, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?19/30/19944/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 19, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H186311728\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the incidence of malignant melanoma is increasing, most cases are diagnosed at an early stage. In that setting, surgical excision is curative in most cases, and patients at high-risk of developing metastatic disease may benefit from adjuvant therapy with interferon alpha [",
"    <a class=\"abstract\" href=\"UTD.htm?19/30/19944/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/61/26585?source=see_link\">",
"     \"Initial surgical management of melanoma of the skin and unusual sites\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/42/44711?source=see_link\">",
"     \"Adjuvant immunotherapy for melanoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The management of patients with disseminated disease is a difficult problem. Approaches that have been shown to provide clinically important benefit for appropriately selected patients with disseminated melanoma include immunotherapy with high-dose interleukin-2 (IL-2), immunotherapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/52/19270?source=see_link\">",
"     ipilimumab",
"    </a>",
"    (a monoclonal antibody targeting CTLA-4), and inhibition of the MAP kinase pathway with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/48/17159?source=see_link\">",
"     vemurafenib",
"    </a>",
"    in patients whose tumors contain a V600 mutation in the BRAF gene. There are no randomized trials that compare targeted therapy with immunotherapy and there are no prospective data on the appropriate sequencing of these therapies for patients with a V600 BRAF mutation.",
"   </p>",
"   <p>",
"    The use of targeted therapies in the treatment of advanced melanoma will be reviewed here. An overview of the management of advanced melanoma is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/12/15558?source=see_link\">",
"     \"Overview of the management of advanced melanoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H615776956\">",
"    <span class=\"h1\">",
"     MOLECULAR PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;An understanding of the role of activation of the MAPK pathway has led to the identification of several drug targets. This is resulting in the development of important therapeutic approaches for the treatment of advanced melanoma in various patient subsets (",
"    <a class=\"graphic graphic_figure graphicRef53134 \" href=\"UTD.htm?41/46/42724\">",
"     figure 1",
"    </a>",
"    ). These include inhibition of BRAF, MEK, NRAS, and Kit.",
"   </p>",
"   <p>",
"    The molecular pathogenesis of melanoma is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/34/1576?source=see_link\">",
"     \"The molecular biology of melanoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H100472985\">",
"    <span class=\"h1\">",
"     BRAF INHIBITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Activating mutations in BRAF are present in approximately 40 to 60 percent of advanced melanomas [",
"    <a class=\"abstract\" href=\"UTD.htm?19/30/19944/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]. In 80 to 90 percent of cases, this activating mutation consists of the substitution of glutamic acid for valine at amino acid 600 (V600E mutation) with most of the remainder consisting of an alternate substitution (lysine for valine) at the V600 locus (V to K).",
"   </p>",
"   <p>",
"    In one study, advanced melanomas with a mutation in BRAF appear to have some clinical differences that are associated with a more aggressive clinical course [",
"    <a class=\"abstract\" href=\"UTD.htm?19/30/19944/abstract/4\">",
"     4",
"    </a>",
"    ]. In a consecutive series of 197 patients at a single institution, the presence of mutant BRAF was significantly more frequent in patients with a truncal primary, an earlier age of onset, and lack of chronic skin damage. Furthermore, for patients not treated with a BRAF inhibitor, survival was shorter overall. &nbsp;",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/48/17159?source=see_link\">",
"     Vemurafenib",
"    </a>",
"    and dabrafenib, inhibitors of BRAF, have demonstrated dramatic antitumor activity in phase III trials in patients with advanced disease whose tumors have characteristic mutations in BRAF. However, virtually every patient treated with an inhibitor of BRAF eventually has disease progression [",
"    <a class=\"abstract\" href=\"UTD.htm?19/30/19944/abstract/5\">",
"     5",
"    </a>",
"    ]. Additional data will be required to determine whether different agents have a differential effect depending upon the specific mutation present.",
"   </p>",
"   <p>",
"    In an analysis from the large phase II BRIM-2 single arm trial of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/48/17159?source=see_link\">",
"     vemurafenib",
"    </a>",
"    , tumor samples were centrally collected and analyzed for mechanisms of resistance through use of sequenom mutation analysis, Sanger DNA sequencing of MEK1 exons 2,3 and 6,and immunohistochemistry for activation of MAP kinase pathway [",
"    <a class=\"abstract\" href=\"UTD.htm?19/30/19944/abstract/6\">",
"     6",
"    </a>",
"    ]. Nearly all tumors demonstrated re-activation of the MAP kinase pathway with elevation of pERK at the time of resistance. In some patients progression was associated with an additional",
"    <em>",
"     NRAS",
"    </em>",
"    <em>",
"     <sup>",
"      Q61",
"     </sup>",
"    </em>",
"    <sup>",
"    </sup>",
"    mutation. In a small subset of patients, several MEK1 mutations were found in association with resistance, which was the first time these mutations were found in patient tumor samples. These included MEK1 Q56 and E203 mutations. On the other hand",
"    <em>",
"     MEK1",
"    </em>",
"    <em>",
"     <sup>",
"      P124L",
"     </sup>",
"    </em>",
"    <em>",
"    </em>",
"    was not associated with resistance and was seen de novo. All relapse tumor specimens continued to demonstrate the",
"    <em>",
"     BRAF",
"    </em>",
"    <em>",
"     <sup>",
"      V600",
"     </sup>",
"    </em>",
"    <em>",
"    </em>",
"    mutation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H100472992\">",
"    <span class=\"h2\">",
"     Vemurafenib",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/48/17159?source=see_link\">",
"     Vemurafenib",
"    </a>",
"    is a potent inhibitor of the kinase domain in mutant BRAF. Phase I and II studies showed that vemurafenib had a high level of activity against advanced melanomas containing characteristic mutations of the BRAF gene [",
"    <a class=\"abstract\" href=\"UTD.htm?19/30/19944/abstract/7,8\">",
"     7,8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These findings were confirmed in a phase III trial that compared",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/48/17159?source=see_link\">",
"     vemurafenib",
"    </a>",
"    with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/49/4887?source=see_link\">",
"     dacarbazine",
"    </a>",
"    in previously untreated patients whose tumors contained the V600 mutation in BRAF [",
"    <a class=\"abstract\" href=\"UTD.htm?19/30/19944/abstract/5\">",
"     5",
"    </a>",
"    ]. In the BRIM-3 trial, 675 patients were randomly assigned to either vemurafenib (960 mg twice a day) or dacarbazine (1000",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    intravenously every three weeks). Treatment was to be continued until disease progression. All patients had either metastatic disease or unresectable stage IIIC disease (95 and 5 percent, respectively).",
"   </p>",
"   <p>",
"    The co-primary endpoints of the trial were overall survival and progression-free survival. Following a planned interim analysis based upon predetermined criteria, patients assigned to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/49/4887?source=see_link\">",
"     dacarbazine",
"    </a>",
"    were allowed to crossover to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/48/17159?source=see_link\">",
"     vemurafenib",
"    </a>",
"    . Median follow-ups at the interim analysis for the vemurafenib and dacarbazine treatment arms were 3.8 and 2.3 months, respectively. Results of the trial, based upon that interim analysis, include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Overall survival was significantly increased in patients assigned to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/48/17159?source=see_link\">",
"       vemurafenib",
"      </a>",
"      compared with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/49/4887?source=see_link\">",
"       dacarbazine",
"      </a>",
"      (estimated six-month survival rates 84 versus 64 percent, hazard ratio [HR] for death 0.37, 95% CI 0.26-0.55).",
"     </li>",
"     <li>",
"      Progression-free survival was significantly longer in those initially treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/48/17159?source=see_link\">",
"       vemurafenib",
"      </a>",
"      (median 5.3 versus 1.6 months, HR 0.26, 95% CI 0.20-0.33).",
"     </li>",
"     <li>",
"      The objective response rate was significantly higher with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/48/17159?source=see_link\">",
"       vemurafenib",
"      </a>",
"      (48 versus 4 percent). The trial included 10 patients with V600K mutations who were treated with vemurafenib: four of these (40 percent) had a partial response to treatment.",
"     </li>",
"     <li>",
"      Planned subset analyses found that the improvement in overall survival and progression-free survival with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/48/17159?source=see_link\">",
"       vemurafenib",
"      </a>",
"      therapy appeared to be independent of age, sex, disease stage (IIIC, M1a, M1b, or M1c (",
"      <a class=\"graphic graphic_table graphicRef50225 \" href=\"UTD.htm?7/61/8157\">",
"       table 1",
"      </a>",
"      )), or lactate dehydrogenase level (normal or elevated).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Additional follow-up data from the BRIM-3 trial were presented at the American Society of Clinical Oncology (ASCO) meeting in 2012 [",
"    <a class=\"abstract\" href=\"UTD.htm?19/30/19944/abstract/9\">",
"     9",
"    </a>",
"    ]. Following the interim analysis, 25 percent of patients assigned to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/49/4887?source=see_link\">",
"     dacarbazine",
"    </a>",
"    were crossed over to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/48/17159?source=see_link\">",
"     vemurafenib",
"    </a>",
"    . Approximately 20 percent of patients on each treatment arm received treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/52/19270?source=see_link\">",
"     ipilimumab",
"    </a>",
"    . Patients assigned to dacarbazine were censored at the time of crossover to vemurafenib. With a median follow-up of 12.5 months for patients treated with vemurafenib and 9.5 months for those initially receiving dacarbazine, the following results were observed:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Progression-free survival was significantly prolonged with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/48/17159?source=see_link\">",
"       vemurafenib",
"      </a>",
"      compared with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/49/4887?source=see_link\">",
"       dacarbazine",
"      </a>",
"      (6.9 versus 1.6 months, HR 0.70)",
"     </li>",
"     <li>",
"      Overall survival was significantly prolonged with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/48/17159?source=see_link\">",
"       vemurafenib",
"      </a>",
"      (13.6 versus 9.7 months)",
"     </li>",
"     <li>",
"      Objective response rate was significantly higher with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/48/17159?source=see_link\">",
"       vemurafenib",
"      </a>",
"      (57.0 versus 8.6 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The toxicity observed with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/48/17159?source=see_link\">",
"     vemurafenib",
"    </a>",
"    is discussed below. (See",
"    <a class=\"local\" href=\"#H13700824\">",
"     'Toxicity from BRAF inhibition'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H100472999\">",
"    <span class=\"h2\">",
"     Dabrafenib",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dabrafenib is another BRAF kinase inhibitor that has demonstrated significant activity in patients with advanced melanoma compared with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/49/4887?source=see_link\">",
"     dacarbazine",
"    </a>",
"    chemotherapy, although it has not yet received regulatory approval.",
"   </p>",
"   <p>",
"    Based upon phase",
"    <span class=\"nowrap\">",
"     I/II",
"    </span>",
"    results [",
"    <a class=\"abstract\" href=\"UTD.htm?19/30/19944/abstract/10,11\">",
"     10,11",
"    </a>",
"    ], a phase III trial was conducted in which 250 patients with advanced melanoma (unresectable stage III or stage IV disease) were randomly assigned in a 3:1 ratio to either dabrafenib (150 mg orally twice a day) or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/49/4887?source=see_link\">",
"     dacarbazine",
"    </a>",
"    (1000",
"    <span class=\"nowrap\">",
"     mg/m2",
"    </span>",
"    IV every three weeks) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/30/19944/abstract/12\">",
"     12",
"    </a>",
"    ]. All patients were required to have the V600E mutation in BRAF.",
"   </p>",
"   <p>",
"    The primary endpoint of the trial was progression-free survival (PFS) as ascertained by the investigators; the PFS was independently reviewed as a secondary trial endpoint. Patients were allowed to cross over to the alternative treatment upon the development of progressive disease.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Dabrafenib significantly increased PFS compared with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/49/4887?source=see_link\">",
"       dacarbazine",
"      </a>",
"      (median 5.1 versus 2.7 months, HR 0.30, 95% CI 0.18-0.51). Based upon independent review of the data, the PFS was similarly increased (6.7 versus 2.9 months, HR 0.35, 95% CI 0.20-0.61).",
"     </li>",
"     <li>",
"      Objective responses, as assessed by the independent review committee, were seen in 93 of 187 patients treated with dabrafenib (50 percent), including six cases with a complete response. Among those treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/49/4887?source=see_link\">",
"       dacarbazine",
"      </a>",
"      there were four partial responses in 63 cases, for an overall response rate of 6 percent.",
"     </li>",
"     <li>",
"      Overall survival favored patients treated with dabrafenib (HR 0.61, 95% CI 0.25-1.48), but was not statistically significant. However, there were too few deaths, and patients treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/49/4887?source=see_link\">",
"       dacarbazine",
"      </a>",
"      were allowed to cross over to dabrafenib.",
"     </li>",
"     <li>",
"      Treatment with dabrafenib was generally well tolerated. Like",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/48/17159?source=see_link\">",
"       vemurafenib",
"      </a>",
"      , the most frequent grade 2 or greater toxicities were dermatologic. &nbsp;Other grade 2 or greater toxicities observed in between 5 and 15 percent of cases included arthralgia, fatigue, headache, and fever. (See",
"      <a class=\"local\" href=\"#H13700824\">",
"       'Toxicity from BRAF inhibition'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4490321\">",
"    <span class=\"h2\">",
"     Brain metastases",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/48/17159?source=see_link\">",
"     vemurafenib",
"    </a>",
"    and dabrafenib have activity in patients with brain metastases. The results of clinical studies in this setting and the role of these agents in the management of brain metastases in patients with melanoma are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/63/39927?source=see_link&amp;anchor=H13565198#H13565198\">",
"     \"Management of brain metastases in melanoma\", section on 'Targeted therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H122779234\">",
"    <span class=\"h2\">",
"     Sorafenib",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/45/9944?source=see_link\">",
"     Sorafenib",
"    </a>",
"    blocks BRAF, as well as tyrosine kinases associated with vascular endothelial growth factor and platelet derived growth factor. However, sorafenib does not block the V600E mutated oncogenic BRAF.",
"   </p>",
"   <p>",
"    Although",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/45/9944?source=see_link\">",
"     sorafenib",
"    </a>",
"    appeared to have antitumor activity when combined with chemotherapy in phase II studies [",
"    <a class=\"abstract\" href=\"UTD.htm?19/30/19944/abstract/13-15\">",
"     13-15",
"    </a>",
"    ], two randomized phase III trials failed to confirm any benefit from combining sorafenib with cytotoxic chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?19/30/19944/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. There is no rationale at present for the clinical use of sorafenib either as a single agent or in combination with chemotherapy in patients with advanced melanoma, regardless of their V600 mutation status.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13700824\">",
"    <span class=\"h2\">",
"     Toxicity from BRAF inhibition",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H96780640\">",
"    <span class=\"h3\">",
"     Cutaneous toxicity and secondary tumors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinically significant cutaneous side effects are common with both",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/48/17159?source=see_link\">",
"     vemurafenib",
"    </a>",
"    and dabrafenib [",
"    <a class=\"abstract\" href=\"UTD.htm?19/30/19944/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. These include squamous cell carcinomas and keratoacanthomas in 6 to 12 percent of cases. These skin tumors occur within weeks of initiation of treatment with these BRAF inhibitors and are generally treated with excision. The development of such lesions did not require discontinuation of therapy. In addition, in the BRIM-3 trial comparing vemurafenib with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/49/4887?source=see_link\">",
"     dacarbazine",
"    </a>",
"    , 8 of 337 patients assigned to vemurafenib developed a second primary melanoma [",
"    <a class=\"abstract\" href=\"UTD.htm?19/30/19944/abstract/5,9\">",
"     5,9",
"    </a>",
"    ]. Various other cutaneous toxicities have also been observed, including photosensitivity and rashes.",
"   </p>",
"   <p>",
"    Molecular studies indicate that these squamous cell carcinomas and keratoacanthomas are due to a paradoxical activation of the mitogen activated protein kinase MAPK pathway that bypasses the inhibition of BRAF [",
"    <a class=\"abstract\" href=\"UTD.htm?19/30/19944/abstract/20\">",
"     20",
"    </a>",
"    ]. Furthermore, the short latency period until the development of these skin lesions is consistent with the presence of preexisting RAS mutations in the skin that enhance their activation of downstream proteins in the MAPK pathway when subjected to BRAF inhibition.",
"   </p>",
"   <p>",
"    Data from studies of the combination of a BRAF inhibitor and a MEK inhibitor indicate that there is a reduced incidence of skin toxicity including the development of skin cancers, presumably by the MEK inhibitor blocking this paradoxical activation of the MAPK pathway. (See",
"    <a class=\"local\" href=\"#H175767803\">",
"     'Trametinib plus BRAF inhibition'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    At least one case report has observed rapid progression of a chronic myelomonocytic leukemia that was associated with a RAS mutation concurrent with the initiation of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/48/17159?source=see_link\">",
"     vemurafenib",
"    </a>",
"    therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?19/30/19944/abstract/21\">",
"     21",
"    </a>",
"    ]. As experience with BRAF inhibitors increases, it is possible that progression of other malignancies associated with RAS may also be observed. It is hypothesized that the combination of a BRAF inhibitor and a MEK inhibitor could reduce the incidence of such cancers similar to that seen with skin cancers, although this remains to be determined.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H96780647\">",
"    <span class=\"h3\">",
"     Other noncutaneous toxicities",
"    </span>",
"    &nbsp;&mdash;&nbsp;A range of other toxicities have been observed during the phase III trials with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/48/17159?source=see_link\">",
"     vemurafenib",
"    </a>",
"    and dabrafenib [",
"    <a class=\"abstract\" href=\"UTD.htm?19/30/19944/abstract/5,12\">",
"     5,12",
"    </a>",
"    ]. In addition to the cutaneous toxicities, moderate or severe adverse events reported with both agents in approximately 5 percent or more of patients include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Arthralgias",
"     </li>",
"     <li>",
"      Weakness or fatigue",
"     </li>",
"     <li>",
"      Headache",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, moderate or severe pyrexia was reported in 11 percent of patients treated with dabrafenib.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/48/17159?source=see_link\">",
"     Vemurafenib",
"    </a>",
"    has been associated with prolongation of the QT interval. The FDA-approved manufacturers&rsquo; labeling recommends that ECG and electrolytes be monitored before treatment and after dose modification. Vemurafenib is a CYP3A4 substrate, and it should be used with caution in patients with congenital long QT syndrome and those who are receiving other drugs that prolong the QT interval (",
"    <a class=\"graphic graphic_table graphicRef57431 \" href=\"UTD.htm?2/48/2830\">",
"     table 2",
"    </a>",
"    ) or inhibit CYP3A4 (",
"    <a class=\"graphic graphic_table graphicRef76992 \" href=\"UTD.htm?9/45/9950\">",
"     table 3",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/12/40138?source=see_link&amp;anchor=H950925#H950925\">",
"     \"Cardiotoxicity of nonanthracycline cancer chemotherapy agents\", section on 'Vemurafenib'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other rare toxicities may also be seen with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/48/17159?source=see_link\">",
"     vemurafenib",
"    </a>",
"    . As an example, peripheral facial palsy has been reported and may be bilateral [",
"    <a class=\"abstract\" href=\"UTD.htm?19/30/19944/abstract/22\">",
"     22",
"    </a>",
"    ]. Understanding the frequency and mechanism of such rare toxicities will require additional clinical experience.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H100473006\">",
"    <span class=\"h1\">",
"     MEK INHIBITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several MEK inhibitors are under development for treating metastatic melanoma and other malignancies. Initial clinical studies suggested that these agents had only limited activity in patients with melanoma, but more recent trials indicate that these agents have clinically useful activity in patients selected based upon their molecular abnormalities.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H175767667\">",
"    <span class=\"h2\">",
"     Trametinib",
"    </span>",
"    &nbsp;&mdash;&nbsp;Trametinib is a potent, highly specific inhibitor of",
"    <span class=\"nowrap\">",
"     MEK1/MEK2.",
"    </span>",
"    Trametinib demonstrated significant activity in phase",
"    <span class=\"nowrap\">",
"     I/II",
"    </span>",
"    studies in patients with advanced melanoma and a V600 mutation [",
"    <a class=\"abstract\" href=\"UTD.htm?19/30/19944/abstract/23-25\">",
"     23-25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H175767796\">",
"    <span class=\"h3\">",
"     Trametinib versus chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Trametinib was more extensively evaluated in the phase III METRIC trial, in which 322 patients with advanced melanoma were randomly assigned in a 2:1 ratio to either trametinib (2",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    orally) or chemotherapy (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/49/4887?source=see_link\">",
"     dacarbazine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/30/19944/abstract/26\">",
"     26",
"    </a>",
"    ]. All patients had either the V600E or V600K mutation in their melanoma (87 and 13 percent, respectively). One third of patients had received prior chemotherapy and 30 percent had received prior immunotherapy. Crossover to trametinib was permitted in patients who progressed on chemotherapy.",
"   </p>",
"   <p>",
"    Key results included the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Progression-free survival, the primary endpoint of the trial, was significantly increased with trametinib compared with chemotherapy (median 4.8 versus 1.5 months, HR 0.45, 95% CI 0.33-0.63).",
"     </li>",
"     <li>",
"      Overall survival was significantly improved with trametinib (6 month survival rate 81 versus 67 percent, HR for death 0.54, 95% CI 0.32-0.92), even though 47 percent of patients who progressed on chemotherapy received secondary treatment with trametinib.",
"     </li>",
"     <li>",
"      The improvements in PFS and overall survival were present in all patient subsets, including those with brain metastases or other visceral metastases (M1c).",
"     </li>",
"     <li>",
"      Treatment was generally well tolerated, and severe toxicity was rare. The most common side effects were rash, diarrhea, and edema, in 57, 43, and 26 percent of cases, respectively. A decreased cardiac ejection fraction was seen in 7 percent of patients treated with trametinib, and this led to discontinuation of trametinib in two cases. Blurred vision was reported in 9 percent of cases, but was generally grade 1 or grade 2.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H175767803\">",
"    <span class=\"h3\">",
"     Trametinib plus BRAF inhibition",
"    </span>",
"    &nbsp;&mdash;&nbsp;Trametinib has been combined with dabrafenib, a BRAF inhibitor, in an effort to delay the development of resistance to treatment and to minimize the toxicity associated with BRAF inhibition.",
"   </p>",
"   <p>",
"    A phase",
"    <span class=\"nowrap\">",
"     I/II",
"    </span>",
"    study demonstrated the feasibility of combining full doses of dabrafenib (150 mg twice daily) and trametinib (2 mg daily) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/30/19944/abstract/27\">",
"     27",
"    </a>",
"    ]. In the phase II component of that trial, 162 patients whose tumor contained a V600 mutation were randomly assigned to one of three regimens: dabrafenib (150 mg twice daily) as monotherapy, dabrafenib plus trametinib (150 mg twice daily and 1 mg once daily, respectively), or dabrafenib plus trametinib (150 mg twice daily and 2 mg once daily, respectively).",
"   </p>",
"   <p>",
"    In the analysis of the randomized component of the trial, treatment with the combination regimen using full doses of both dabrafenib and trametinib (2mg once daily) significantly prolonged progression-free survival compared with dabrafenib alone (median 9.4 versus 5.8 months, HR 0.39, 95% CI 0.25-0.62), and significantly increased the proportion of patients alive and progression-free at one year (41 versus 9 percent). Dermatologic toxicity, manifested by squamous cell carcinoma (including keratoacanthoma) was decreased in both combination dose levels (5 versus 19 percent), although the incidence of pyrexia was increased (71 versus 26 percent).",
"   </p>",
"   <p>",
"    Two phase III trials have been initiated, in which patients with advanced melanoma and a V600E or V600K mutation will be randomly assigned to the combination of dabrafenib plus trametinib or to either dabrafenib plus placebo (",
"    <a class=\"external\" href=\"file://www.clinicaltrials.gov/ct2/show/NCT01584648?term=01584648&amp;rank=1\">",
"     NCT01584648",
"    </a>",
"    ) or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/48/17159?source=see_link\">",
"     vemurafenib",
"    </a>",
"    plus placebo (",
"    <a class=\"external\" href=\"file://www.clinicaltrials.gov/ct2/show/NCT01597908?term=01597908&amp;rank=1\">",
"     NCT01597908",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H175767869\">",
"    <span class=\"h2\">",
"     MEK162",
"    </span>",
"    &nbsp;&mdash;&nbsp;MEK162 is a specific inhibitor of MEK that has demonstrated activity in patients with advanced melanoma and a mutation of NRAS.",
"   </p>",
"   <p>",
"    MEK162 was studied in a phase II study in 71 patients with advanced melanoma and either a V600 BRAF mutation or an NRAS mutation (41 and 30 cases, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/30/19944/abstract/28\">",
"     28",
"    </a>",
"    ]. At a median follow-up of three months, partial responses were observed in 8 of 41 cases with BRAF mutation (20 percent) and 6 of 30 patients with NRAS mutation (20 percent). The rates of objective response plus stable disease were 52 and 63 percent, respectively, for those with BRAF and NRAS mutations [",
"    <a class=\"abstract\" href=\"UTD.htm?19/30/19944/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A phase III trial comparing MEK162 versus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/49/4887?source=see_link\">",
"     dacarbazine",
"    </a>",
"    in patients with advanced NRAS mutation positive melanoma is planned (",
"    <a class=\"external\" href=\"file://www.clinicaltrials.gov/ct2/show/NCT01763164?term=NCT01763164&amp;rank=1\">",
"     NCT01763164",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H175767695\">",
"    <span class=\"h2\">",
"     Selumetinib",
"    </span>",
"    &nbsp;&mdash;&nbsp;Selumetinib is another MEK inhibitor that was compared with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/47/11000?source=see_link\">",
"     temozolomide",
"    </a>",
"    in a randomized, phase II trial that included 200 patients with previously untreated, unresectable stage III or IV melanoma [",
"    <a class=\"abstract\" href=\"UTD.htm?19/30/19944/abstract/30\">",
"     30",
"    </a>",
"    ]. Patients were not selected based upon their BRAF mutation status. There was no significant difference in progression-free survival, the primary endpoint of the trial. In a retrospective analysis, 5 of 45 (11 percent) patients with a BRAF mutation had an objective tumor response.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H100473013\">",
"    <span class=\"h1\">",
"     KIT INHIBITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mutations in c-kit are seen in approximately 15 to 20 percent of patients with acral or mucosal melanomas and in a smaller percentage of melanomas arising in areas of chronic skin damage. Phase II studies using",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    in unselected groups of patients with advanced melanoma demonstrated only minimal evidence of activity [",
"    <a class=\"abstract\" href=\"UTD.htm?19/30/19944/abstract/31-33\">",
"     31-33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, kit inhibitors may have useful clinically activity in patients with activating mutations of the c-kit gene. The efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    was analyzed in two phase II studies in patients whose tumors contained either c-kit mutation or amplification [",
"    <a class=\"abstract\" href=\"UTD.htm?19/30/19944/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. Together these studies included 68 evaluable patients, and the objective partial response rate for these studies was 21 percent with some of the responses long-term and on-going.",
"   </p>",
"   <p>",
"    Additional studies using other kit inhibitors are in progress in selected patient populations with mutations of c-kit, including an international randomized trial comparing",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/1/29720?source=see_link\">",
"     nilotinib",
"    </a>",
"    to DTIC (NCT01028222) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/30/19944/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1656046957\">",
"    <span class=\"h1\">",
"     ANGIOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Numerous angiogenesis-promoting molecules are overexpressed in melanoma, including VEGF, PDGF, fibroblast growth factor, and interleukin-8. The expression of these factors has been associated with a poorer prognosis in patients with melanoma. Inhibition of small molecule tyrosine kinases and the monoclonal antibody",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    , which binds to VEGF, have been most extensively studied.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1656046964\">",
"    <span class=\"h2\">",
"     Axitinib",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/13/43222?source=see_link\">",
"     Axitinib",
"    </a>",
"    , a potent inhibitor of multiple vascular endothelial growth factor receptors, was evaluated in a phase II study that included 32 patients with metastatic melanoma, 25 of whom had received one prior systemic treatment modality [",
"    <a class=\"abstract\" href=\"UTD.htm?19/30/19944/abstract/37\">",
"     37",
"    </a>",
"    ]. The objective response rate was 19 percent, and the median progression-free and overall survival durations were 2.9 and 6.6 months. Additional clinical trials will be required to determine whether axitinib has a role in patients with metastatic melanoma, either alone or in a combination regimen.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1656047233\">",
"    <span class=\"h2\">",
"     Bevacizumab",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several small phase II studies evaluating",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    , either alone or in combination with interferon-alfa or chemotherapy (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    ), showed evidence of activity in patients with advanced melanoma [",
"    <a class=\"abstract\" href=\"UTD.htm?19/30/19944/abstract/38-40\">",
"     38-40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Based upon these results, the randomized",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/20/2377?source=see_link\">",
"     Bevacizumab",
"    </a>",
"    in Advanced Melanoma (BEAM) phase II trial was conducted, in which 214 patients were treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    , with or without bevacizumab [",
"    <a class=\"abstract\" href=\"UTD.htm?19/30/19944/abstract/41\">",
"     41",
"    </a>",
"    ]. In the planned analysis with a median follow-up of 13 months, progression-free survival and overall survival were better with bevacizumab (5.6 versus 4.2 months, p = 0.14 and 12.3 versus 8.6 months, p = 0.04). The combination with bevacizumab resulted in a higher response rate (25.5 versus 16.4 percent, p = 0.16). Although the overall data only showed a trend toward benefit, in the subset of patients with M1c disease, particularly those with high LDH, there was significant overall survival benefit. A randomized phase III trial is being considered in this subset of patients to prospectively validate this observation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1656046751\">",
"    <span class=\"h1\">",
"     APOPTOSIS PATHWAY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H100473034\">",
"    <span class=\"h2\">",
"     Oblimersen",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oblimersen is an antisense oligonucleotide that suppresses expression of Bcl-2, a key anti-apoptotic protein in malignant cells. Although results from an initial phase III trial suggested that the agent had promising results in one subset [",
"    <a class=\"abstract\" href=\"UTD.htm?19/30/19944/abstract/42\">",
"     42",
"    </a>",
"    ], these findings were not confirmed in a second trial [",
"    <a class=\"abstract\" href=\"UTD.htm?19/30/19944/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H100473062\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The mitogen-activated protein (MAP) kinase pathway is made up of several important targets for therapy of melanoma. Specific mutations in BRAF, which are present in approximately 40 to 60 percent of advanced cutaneous melanomas, can stimulate this pathway. Patients with metastatic melanoma should have tissue assessed for the presence or absence of the V600 mutation in the BRAF gene. The presence of a V600E or K mutation predicts responsiveness to BRAF inhibition with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/48/17159?source=see_link\">",
"       vemurafenib",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H615776956\">",
"       'Molecular pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/48/17159?source=see_link\">",
"       Vemurafenib",
"      </a>",
"      is a specific inhibitor of activated BRAF, and thus provides a means for individualized therapy in selected patients with advanced disease. Vemurafenib significantly prolonged overall survival compared with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/49/4887?source=see_link\">",
"       dacarbazine",
"      </a>",
"      in patients with metastatic melanoma that contain the V600 mutation. Vemurafenib has not been compared with immunotherapy in randomized clinical trials. (See",
"      <a class=\"local\" href=\"#H100472985\">",
"       'BRAF inhibition'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with a V600 BRAF mutation and a good performance status, we suggest immunotherapy rather than targeted therapy as the initial systemic therapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/12/15558?source=see_link&amp;anchor=H863137387#H863137387\">",
"       \"Overview of the management of advanced melanoma\", section on 'Choice and sequence of therapy'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For patients with a V600 BRAF mutation who were initially treated with immunotherapy and whose disease can no longer be controlled with immunotherapy using either high dose IL-2 or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/52/19270?source=see_link\">",
"       ipilimumab",
"      </a>",
"      , we recommend targeted therapy (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/48/17159?source=see_link\">",
"       vemurafenib",
"      </a>",
"      ) rather than chemotherapy (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with a V600 BRAF mutation and a poor performance status, we suggest targeted therapy rather than immunotherapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Targeted therapy with BRAF inhibitors is not indicated in patients without a characteristic V600 BRAF mutation. (See",
"      <a class=\"local\" href=\"#H100472985\">",
"       'BRAF inhibition'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/30/19944/abstract/1\">",
"      Cole BF, Gelber RD, Kirkwood JM, et al. Quality-of-life-adjusted survival analysis of interferon alfa-2b adjuvant treatment of high-risk resected cutaneous melanoma: an Eastern Cooperative Oncology Group study. J Clin Oncol 1996; 14:2666.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/30/19944/abstract/2\">",
"      Wellbrock C, Hurlstone A. BRAF as therapeutic target in melanoma. Biochem Pharmacol 2010; 80:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/30/19944/abstract/3\">",
"      Smalley KS, Sondak VK. Melanoma--an unlikely poster child for personalized cancer therapy. N Engl J Med 2010; 363:876.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/30/19944/abstract/4\">",
"      Long GV, Menzies AM, Nagrial AM, et al. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. J Clin Oncol 2011; 29:1239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/30/19944/abstract/5\">",
"      Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011; 364:2507.",
"     </a>",
"    </li>",
"    <li>",
"     Sosman JA, Pavlick AC, Schuchter LM, et al. Analysis of molecular mechanisms of response and resistance to vemurafenib (vem) in BRAFV600E melanoma (abstract #8503). J Clin Oncol 2012. 30s.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/30/19944/abstract/7\">",
"      Flaherty KT, Puzanov I, Kim KB, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010; 363:809.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/30/19944/abstract/8\">",
"      Sosman JA, Kim KB, Schuchter L, et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 2012; 366:707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/30/19944/abstract/9\">",
"      Chapman PB, et al. Updated overall survival (OS) results for BRIM-3, a phase III randomized, open-label, multicenter trial comparing BRAF inhibitor vemurafenib (vem) with dacarbazine (DTIC) in previously untreated patients with BRAFV600E-mutated melanoma. J Clin Oncol 2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/30/19944/abstract/10\">",
"      Kefford R, Arkenau H, Brown MP. Phase I/II study of GSK2118436, a selective inhibitor of oncogenic mutant BRAF kinase, in patients with metastatic melanoma and other solid tumors. J Clin Oncol 2010; 28:611s.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/30/19944/abstract/11\">",
"      Falchook GS, Long GV, Kurzrock R, et al. Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. Lancet 2012; 379:1893.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/30/19944/abstract/12\">",
"      Hauschild A, Grob JJ, Demidov LV, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 2012; 380:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/30/19944/abstract/13\">",
"      Flaherty KT, Brose M, Schuchter L. Phase I/II trial of BAY 43-9006, carboplatin and paclitaxel demonstrates preliminary amtotumor activity in the expansion cohort of patients with metastatic melanoma. Proc Am Soc Clin Oncol 2004; 23:708a.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/30/19944/abstract/14\">",
"      Amaravadi RK, Schuchter LM, McDermott DF, et al. Phase II Trial of Temozolomide and Sorafenib in Advanced Melanoma Patients with or without Brain Metastases. Clin Cancer Res 2009; 15:7711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/30/19944/abstract/15\">",
"      Eisen T, Marais R, Affolter A, et al. Sorafenib and dacarbazine as first-line therapy for advanced melanoma: phase I and open-label phase II studies. Br J Cancer 2011; 105:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/30/19944/abstract/16\">",
"      Hauschild A, Agarwala SS, Trefzer U, et al. Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. J Clin Oncol 2009; 27:2823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/30/19944/abstract/17\">",
"      Flaherty KT, Lee SJ, Zhao F, et al.. Phase III Trial of Carboplatin and Paclitaxel With or Without Sorafenib in Metastatic Melanoma. J Clin Oncol 2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/30/19944/abstract/18\">",
"      Anforth R, Fernandez-Pe&ntilde;as P, Long GV. Cutaneous toxicities of RAF inhibitors. Lancet Oncol 2013; 14:e11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/30/19944/abstract/19\">",
"      Boyd KP, Vincent B, Andea A, et al. Nonmalignant cutaneous findings associated with vemurafenib use in patients with metastatic melanoma. J Am Acad Dermatol 2012; 67:1375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/30/19944/abstract/20\">",
"      Su F, Viros A, Milagre C, et al. RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med 2012; 366:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/30/19944/abstract/21\">",
"      Callahan MK, Rampal R, Harding JJ, et al. Progression of RAS-mutant leukemia during RAF inhibitor treatment. N Engl J Med 2012; 367:2316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/30/19944/abstract/22\">",
"      Klein O, Ribas A, Chmielowski B, et al. Facial Palsy As a Side Effect of Vemurafenib Treatment in Patients With Malignant Melanoma. J Clin Oncol 2013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/30/19944/abstract/23\">",
"      Falchook GS, Lewis KD, Infante JR, et al. Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial. Lancet Oncol 2012; 13:782.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/30/19944/abstract/24\">",
"      Infante JR, Fecher LA, Falchook GS, et al. Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial. Lancet Oncol 2012; 13:773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/30/19944/abstract/25\">",
"      Kim KB, Kefford R, Pavlick AC, et al. Phase II Study of the MEK1/MEK2 Inhibitor Trametinib in Patients With Metastatic BRAF-Mutant Cutaneous Melanoma Previously Treated With or Without a BRAF Inhibitor. J Clin Oncol 2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/30/19944/abstract/26\">",
"      Flaherty KT, Robert C, Hersey P, et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med 2012; 367:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/30/19944/abstract/27\">",
"      Flaherty KT, Infante JR, Daud A, et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 2012; 367:1694.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/30/19944/abstract/28\">",
"      Ascierto PA, Schadendorf C, Berking C, et al. MEK162 for patients with advanced melanoma harbouring or Val600 mutations: a non-randomised, open-label phase 2 study. Lancet Oncol 2013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/30/19944/abstract/29\">",
"      Ascierto PA, et al. Efficacy and safety of oral MEK162 in patients with locally advanced and unresectable or metastatic cutaneous melanoma harboring BRAFV600 or NRAS mutations (abstract #8511). J Clin Oncol 2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/30/19944/abstract/30\">",
"      Kirkwood JM, Bastholt L, Robert C, et al. Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma. Clin Cancer Res 2012; 18:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/30/19944/abstract/31\">",
"      Penel N, Delcambre C, Durando X, et al. O-Mel-Inib: a Canc&eacute;ro-p&ocirc;le Nord-Ouest multicenter phase II trial of high-dose imatinib mesylate in metastatic uveal melanoma. Invest New Drugs 2008; 26:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/30/19944/abstract/32\">",
"      Wyman K, Atkins MB, Prieto V, et al. Multicenter Phase II trial of high-dose imatinib mesylate in metastatic melanoma: significant toxicity with no clinical efficacy. Cancer 2006; 106:2005.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/30/19944/abstract/33\">",
"      Ugurel S, Hildenbrand R, Zimpfer A, et al. Lack of clinical efficacy of imatinib in metastatic melanoma. Br J Cancer 2005; 92:1398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/30/19944/abstract/34\">",
"      Carvajal RD, Antonescu CR, Wolchok JD, et al. KIT as a therapeutic target in metastatic melanoma. JAMA 2011; 305:2327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/30/19944/abstract/35\">",
"      Guo J, Si L, Kong Y, et al. Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification. J Clin Oncol 2011; 29:2904.",
"     </a>",
"    </li>",
"    <li>",
"     ClinicalTrials.gov file://www.clinicaltrials.gov/.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/30/19944/abstract/37\">",
"      Fruehauf J, Lutzky J, McDermott D, et al. Multicenter, phase II study of axitinib, a selective second-generation inhibitor of vascular endothelial growth factor receptors 1, 2, and 3, in patients with metastatic melanoma. Clin Cancer Res 2011; 17:7462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/30/19944/abstract/38\">",
"      Varker KA, Biber JE, Kefauver C, et al. A randomized phase 2 trial of bevacizumab with or without daily low-dose interferon alfa-2b in metastatic malignant melanoma. Ann Surg Oncol 2007; 14:2367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/30/19944/abstract/39\">",
"      Gonz&aacute;lez-Cao M, Viteri S, D&iacute;az-Lagares A, et al. Preliminary results of the combination of bevacizumab and weekly Paclitaxel in advanced melanoma. Oncology 2008; 74:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/30/19944/abstract/40\">",
"      Perez DG, Suman VJ, Fitch TR, et al. Phase 2 trial of carboplatin, weekly paclitaxel, and biweekly bevacizumab in patients with unresectable stage IV melanoma: a North Central Cancer Treatment Group study, N047A. Cancer 2009; 115:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/30/19944/abstract/41\">",
"      Kim KB, Sosman JA, Fruehauf JP, et al. BEAM: a randomized phase II study evaluating the activity of bevacizumab in combination with carboplatin plus paclitaxel in patients with previously untreated advanced melanoma. J Clin Oncol 2012; 30:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/30/19944/abstract/42\">",
"      Bedikian AY, Millward M, Pehamberger H, et al. Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group. J Clin Oncol 2006; 24:4738.",
"     </a>",
"    </li>",
"    <li>",
"     Bedikian AY, Lebbe C, Robert C, et al. Survival in a phase III, randomized, double-blind study of dacarbazine with or without oblimersen (Bcl-2 antisense) in patients with advanced melanoma and low-normal serum lactate dehydrogenase (LDH; AGENDA) (abstract #8531). J Clin Oncol 2011.",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15408 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-122.72.76.133-F9B63D4400-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_30_19944=[""].join("\n");
var outline_f19_30_19944=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H100473062\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H186311728\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H615776956\">",
"      MOLECULAR PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H100472985\">",
"      BRAF INHIBITION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H100472992\">",
"      Vemurafenib",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H100472999\">",
"      Dabrafenib",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4490321\">",
"      Brain metastases",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H122779234\">",
"      Sorafenib",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13700824\">",
"      Toxicity from BRAF inhibition",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H96780640\">",
"      - Cutaneous toxicity and secondary tumors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H96780647\">",
"      - Other noncutaneous toxicities",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H100473006\">",
"      MEK INHIBITION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H175767667\">",
"      Trametinib",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H175767796\">",
"      - Trametinib versus chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H175767803\">",
"      - Trametinib plus BRAF inhibition",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H175767869\">",
"      MEK162",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H175767695\">",
"      Selumetinib",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H100473013\">",
"      KIT INHIBITION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1656046957\">",
"      ANGIOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1656046964\">",
"      Axitinib",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1656047233\">",
"      Bevacizumab",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1656046751\">",
"      APOPTOSIS PATHWAY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H100473034\">",
"      Oblimersen",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H100473062\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/15408\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/15408|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?41/46/42724\" title=\"figure 1\">",
"      MAP kinase pathway",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/15408|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?7/61/8157\" title=\"table 1\">",
"      Melanoma 7th TNM staging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/48/2830\" title=\"table 2\">",
"      Causes of long QT syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?9/45/9950\" title=\"table 3\">",
"      Inhibitors and inducers of cytochrome P450 3A4",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/42/44711?source=related_link\">",
"      Adjuvant immunotherapy for melanoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/12/40138?source=related_link\">",
"      Cardiotoxicity of nonanthracycline cancer chemotherapy agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/61/26585?source=related_link\">",
"      Initial surgical management of melanoma of the skin and unusual sites",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/63/39927?source=related_link\">",
"      Management of brain metastases in melanoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/12/15558?source=related_link\">",
"      Overview of the management of advanced melanoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/34/1576?source=related_link\">",
"      The molecular biology of melanoma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_30_19945="Evaluation of the patient with suspected heart failure";
var content_f19_30_19945=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Evaluation of the patient with suspected heart failure",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/30/19945/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/30/19945/contributors\">",
"     Wilson S Colucci, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/30/19945/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/30/19945/contributors\">",
"     Stephen S Gottlieb, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/30/19945/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/30/19945/contributors\">",
"     Susan B Yeon, MD, JD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?19/30/19945/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 21, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Heart failure (HF) is a common clinical syndrome caused by a variety of cardiac diseases [",
"    <a class=\"abstract\" href=\"UTD.htm?19/30/19945/abstract/1\">",
"     1",
"    </a>",
"    ]. The initial evaluation of the patient with suspected HF due to systolic or diastolic dysfunction will be reviewed here. Evaluation of the etiology and management of HF and evaluation and treatment of acute decompensated HF are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/28/39369?source=see_link\">",
"     \"Evaluation of the patient with heart failure or cardiomyopathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/63/38906?source=see_link\">",
"     \"Overview of the therapy of heart failure due to systolic dysfunction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/22/43368?source=see_link\">",
"     \"Clinical manifestations and diagnosis of diastolic heart failure\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/23/7544?source=see_link\">",
"     \"Evaluation of acute decompensated heart failure\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/7/41079?source=see_link\">",
"     \"Treatment of acute decompensated heart failure: General considerations\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Heart failure (HF) is a complex clinical syndrome that can result from any structural or functional cardiac disorder that impairs the ability of the ventricle to fill with or eject blood. It is characterized by specific symptoms, such as dyspnea and fatigue, and signs, such as those related to fluid retention. There are many ways to assess cardiac function. However, there is no diagnostic test for HF, since it is largely a clinical diagnosis that is based upon a careful history and physical examination (",
"    <a class=\"graphic graphic_table graphicRef55866 \" href=\"UTD.htm?37/44/38603\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The approach to the patient with suspected HF includes the history and physical examination, and diagnostic tests to help establish the diagnosis, assess acuity and severity and initiate assessment of etiology. Recommendations for the evaluation of patients with HF were included in the 2005 American College of Cardiology",
"    <span class=\"nowrap\">",
"     (ACC/AHA)",
"    </span>",
"    guidelines with 2009 focused update (",
"    <a class=\"graphic graphic_table graphicRef51433 \" href=\"UTD.htm?21/9/21661\">",
"     table 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_algorithm graphicRef73507 \" href=\"UTD.htm?17/14/17647\">",
"     algorithm 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?19/30/19945/abstract/2\">",
"     2",
"    </a>",
"    ], the 2010 Heart Failure Society of America (HFSA) guidelines [",
"    <a class=\"abstract\" href=\"UTD.htm?19/30/19945/abstract/3\">",
"     3",
"    </a>",
"    ], the 2008 European Society of Cardiology (ESC) guidelines [",
"    <a class=\"abstract\" href=\"UTD.htm?19/30/19945/abstract/4\">",
"     4",
"    </a>",
"    ], and the 2006 Canadian Cardiovascular Society (CCS) consensus conference [",
"    <a class=\"abstract\" href=\"UTD.htm?19/30/19945/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The discussion below focuses on diagnosis of heart failure. The history and physical examination of the patient with suspected heart failure should also include assessment of risk factors and potential etiologies of heart failure as discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/28/39369?source=see_link\">",
"     \"Evaluation of the patient with heart failure or cardiomyopathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/23/7544?source=see_link\">",
"     \"Evaluation of acute decompensated heart failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;Symptoms of HF include those due to excess fluid accumulation (dyspnea, orthopnea, edema, pain from hepatic congestion, and abdominal distention from ascites) and those due to a reduction in cardiac output (fatigue, weakness) that is most pronounced with exertion. Fluid retention in HF is initiated by the fall in cardiac output, leading to alterations in renal function, due in part to activation of the sodium-retaining renin-angiotensin-aldosterone and sympathetic nervous systems. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/44/32455?source=see_link\">",
"     \"Pathophysiology of heart failure: Neurohumoral adaptations\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Important information concerning the acuity of HF is suggested by the presenting symptoms:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Acute and subacute presentations (days to weeks) are characterized primarily by shortness of breath, at rest",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      with exertion. Also common are orthopnea, paroxysmal nocturnal dyspnea, and, with right HF, right upper quadrant discomfort due to acute hepatic congestion, which can be confused with acute cholecystitis. Patients with atrial",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      ventricular tachyarrhythmias may complain of palpitations with or without lightheadedness.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients with acute decompensated heart failure require prompt diagnosis and management. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/23/7544?source=see_link\">",
"     \"Evaluation of acute decompensated heart failure\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/7/41079?source=see_link\">",
"     \"Treatment of acute decompensated heart failure: General considerations\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Chronic presentations (months) differ in that fatigue, anorexia, abdominal distension, and peripheral edema may be more pronounced than dyspnea. The anorexia is secondary to several factors including poor perfusion of the splanchnic circulation, bowel edema, and nausea induced by hepatic congestion. Over time, pulmonary venous capacitance accommodates to the chronic state of volume overload, leading to less or no fluid accumulation in the alveoli, despite the increase in total lung water. These patients present with excessive fatigue and low-output symptoms.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other clinical features such as older age, history of coronary artery disease or myocardial infarction, and use of a loop diuretic are associated with increased likelihood of heart failure [",
"    <a class=\"abstract\" href=\"UTD.htm?19/30/19945/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. As discussed below, the history alone is insufficient to make the diagnosis of HF. (See",
"    <a class=\"local\" href=\"#H12260556\">",
"     'Diagnostic accuracy of clinical features'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Nevertheless, a detailed history remains the single best discriminator to determine the acuity, etiology, and rate of progression of HF and the history often provides important clues to the cause of HF. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/28/39369?source=see_link\">",
"     \"Evaluation of the patient with heart failure or cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;The physical examination can provide evidence of the presence and extent of cardiac filling pressure elevation, volume overload, ventricular enlargement, pulmonary hypertension, and reduction in cardiac output.",
"   </p>",
"   <p>",
"    In the study of primary care patients cited above, the physical finding of a displaced apical impulse had the best combination of sensitivity, specificity, and positive and negative predictive value of any physical sign of systolic HF [",
"    <a class=\"abstract\" href=\"UTD.htm?19/30/19945/abstract/8\">",
"     8",
"    </a>",
"    ]. Other strong predictors of HF included a gallop rhythm and elevated jugular venous pressure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Vital signs and appearance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with advanced HF may show evidence of a major decline in cardiac output and therefore a decrease in tissue perfusion. Four major findings suggest severity of the cardiac dysfunction: resting sinus tachycardia, narrow pulse pressure, diaphoresis, and peripheral vasoconstriction. The last abnormality is manifested as cool, pale, and sometimes cyanotic extremities (due to the combination of decreased perfusion and increased oxygen extraction). A decrease in cardiac output should be suspected when the pulse pressure is reduced below 25 mmHg.",
"   </p>",
"   <p>",
"    Both the cardiac disease itself and the secondary neurohumoral adaptation contribute to the low output state. Patients compensate for a fall in cardiac output by increasing sympathetic outflow with resultant shunting of the cardiac output to vital organs.",
"   </p>",
"   <p>",
"    An irregularly irregular pulse is suggestive of atrial fibrillation which frequently accompanies HF. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/30/24042?source=see_link\">",
"     \"Atrial fibrillation in patients with heart failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Volume assessment",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are three major manifestations of volume overload in patients with HF: pulmonary congestion, peripheral edema, and elevated jugular venous pressure.",
"   </p>",
"   <p>",
"    Pulmonary congestion that may manifest as rales is more prominent in acute or subacute disease. As noted above, chronic HF is associated with increases in venous capacitance and lymphatic drainage of the lungs; as a result, rales are often absent even though the pulmonary capillary pressure is elevated. Continued sodium retention in this setting preferentially accumulates in the periphery although a chronic elevation in pulmonary venous pressure can lead to pleural effusions.",
"   </p>",
"   <p>",
"    Peripheral edema is manifested by swelling of the legs (which is more prominent when the patient is upright), and may also cause ascites, scrotal edema, hepatomegaly, and splenomegaly [",
"    <a class=\"abstract\" href=\"UTD.htm?19/30/19945/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/34/34346?source=see_link\">",
"     \"Approach to the adult patient with splenomegaly and other splenic disorders\"",
"    </a>",
"    .) In this setting, manual compression of the right upper quadrant to increase venous return may elevate jugular venous pressure above the transient 1 to 3 cm elevations seen in normal individuals. This sign is known as the hepatojugular reflux. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/59/33719?source=see_link&amp;anchor=H13#H13\">",
"     \"Examination of the jugular venous pulse\", section on 'Hepatojugular reflux'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Elevated jugular venous pressure is usually present if peripheral edema is due to HF, since it is the high intracapillary pressure that is responsible for fluid movement into the interstitium. With the patient sitting at 45&ordm; jugular venous pressure can be estimated from the height above the left atrium of venous pulsations in the internal jugular vein. The height of external jugular vein pulsations may also be helpful but care must be taken to avoid spurious interpretation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/59/33719?source=see_link\">",
"     \"Examination of the jugular venous pulse\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The accuracy of clinical volume assessment is discussed below. (See",
"    <a class=\"local\" href=\"#H12260556\">",
"     'Diagnostic accuracy of clinical features'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Pulsus alternans",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pulsus alternans, if present, is virtually pathognomonic of severe left ventricular failure. This phenomenon is characterized by evenly spaced alternating strong and weak peripheral pulses. It is best appreciated by applying light pressure on the peripheral arterial pulse, and can be confirmed by measuring the blood pressure. When the cuff pressure is slowly released, phase I Korotkoff sounds are initially heard only during the alternate strong beats; with further release of cuff pressure, the softer sounds of the weak beat also appear. The degree of pulsus alternans can be quantitated by measuring the difference in systolic pressure between the strong and the weak beat. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/15/33013?source=see_link&amp;anchor=H3#H3\">",
"     \"Examination of the arterial pulse\", section on 'Pulsus alternans'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The pathophysiology of pulsus alternans is not well understood. The severe ventricular dysfunction may be associated with variations in contractility secondary to shifts in afterload, preload, and electrical excitability [",
"    <a class=\"abstract\" href=\"UTD.htm?19/30/19945/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Precordial palpation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ventricular chamber size can be estimated by precordial palpation. An apical impulse that is laterally displaced past the midclavicular line is usually indicative of left ventricular enlargement. Left ventricular dysfunction can also lead to sustained apical impulse, which may be accompanied by a parasternal lift in the setting of right ventricular hypertrophy or enlargement. The S3 may be palpable in severe ventricular failure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/43/9909?source=see_link\">",
"     \"Examination of the precordial pulsation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Heart sounds",
"    </span>",
"    &nbsp;&mdash;&nbsp;An S3 gallop is associated with left atrial pressures exceeding 20 mmHg, increased left ventricular end-diastolic pressures (&gt;15 mmHg), and elevated serum brain natriuretic peptide concentrations. However, there is appreciable interobserver variability in the ability to detect an S3 that cannot be solely explained by the experience of the observer [",
"    <a class=\"abstract\" href=\"UTD.htm?19/30/19945/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. In addition, in a phonocardiographic study of patients who were undergoing cardiac catheterization, an S3 was not very sensitive (40 to 50 percent) for the detection of an elevated left ventricular end-diastolic pressure or a reduced left ventricular ejection fraction; however, the S3 was highly specific (90 percent) for these parameters and for an elevated serum brain natriuretic peptide concentration [",
"    <a class=\"abstract\" href=\"UTD.htm?19/30/19945/abstract/13\">",
"     13",
"    </a>",
"    ]. Similarly, an S3 (or &ldquo;extra heart sound&rdquo;) has a low sensitivity (eg, 4 to 11 percent) but high specificity (eg, 99 percent) for clinical diagnosis of HF [",
"    <a class=\"abstract\" href=\"UTD.htm?19/30/19945/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/56/22410?source=see_link&amp;anchor=H30#H30\">",
"     \"Auscultation of heart sounds\", section on 'Left ventricular gallops'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Pulmonary hypertension",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with chronic HF often develop secondary pulmonary hypertension, which can contribute to dyspnea as pulmonary pressures rise with exertion. These patients may also complain of substernal chest pressure, typical of angina. In this setting, elevated right ventricular end-diastolic pressure leads to secondary right ventricular subendocardial ischemia. Physical signs of pulmonary hypertension can include increased intensity of P2, a murmur of pulmonary insufficiency, a parasternal lift, and a palpable pulmonic tap (felt in the left second intercostal space). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/37/26202?source=see_link\">",
"     \"Auscultation of cardiac murmurs\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/56/22410?source=see_link\">",
"     \"Auscultation of heart sounds\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/43/9909?source=see_link\">",
"     \"Examination of the precordial pulsation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12260556\">",
"    <span class=\"h2\">",
"     Diagnostic accuracy of clinical features",
"    </span>",
"    &nbsp;&mdash;&nbsp;The accuracy of symptoms and signs for the clinical diagnosis of heart failure was evaluated by a systematic review that included data from 15 studies of patients with suspected heart failure [",
"    <a class=\"abstract\" href=\"UTD.htm?19/30/19945/abstract/6\">",
"     6",
"    </a>",
"    ]: &nbsp;",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Dyspnea was the only symptom or sign with high sensitivity (87 percent) but its specificity was low (51 percent).",
"     </li>",
"     <li>",
"      Other clinical features had relatively high specificity but low sensitivity:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Symptoms - Orthopnea (specificity and sensitivity of 89 and 44 percent) and history of myocardial infarction (89 and 26 percent).",
"     </li>",
"     <li>",
"      Signs - Extra heart sounds were highly specific (99 percent) but had low sensitivity (11 percent). In this population, hepatomegaly was also highly specific (97 percent) but had low sensitivity (17 percent). Greater specificity than sensitivity was also seen for cardiomegaly (85 and 27 percent), lung crepitation (81 and 51 percent), edema (72 and 53 percent), and elevated jugular venous pressure (70 and 52 percent). &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The accuracy of clinical evaluation of cardiac filling pressures varies among observers as illustrated by a study of 116 patients undergoing cardiac catheterization [",
"    <a class=\"abstract\" href=\"UTD.htm?19/30/19945/abstract/14\">",
"     14",
"    </a>",
"    ]. Signs of elevated right heart filling pressure included increased jugular venous pressure, peripheral edema, and ascites. Signs of elevated left heart filling pressure included findings of elevated right heart filling pressure as well as gallops or rales.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Right and left heart filling pressures were accurately estimated by physical examination in 71 and 60 percent of 215 observations. Examination by staff cardiologists was more accurate than by trainees for right heart pressures (82 versus 67 percent) and left heart pressures (71 versus 55 percent).",
"     </li>",
"     <li>",
"      Exposure to echocardiographic and NT-pro-BNP results did not improve the accuracy of clinical evaluations. The accuracy of estimation of right filling pressure by echocardiographic examination of the IVC (75 percent) was similar to the accuracy of physical examination. The accuracy of estimates of left heart filling pressures by NT-pro-BNP (67 percent) and by echocardiography",
"      <span class=\"nowrap\">",
"       E/e&rsquo;",
"      </span>",
"      ratio (60 percent) was also similar to physical examination. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'NT-proBNP'",
"      </a>",
"      below and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/22/19818?source=see_link\">",
"       \"Natriuretic peptide measurement in heart failure\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/60/33735?source=see_link&amp;anchor=H8#H8\">",
"       \"Echocardiographic evaluation of left ventricular diastolic function\", section on 'Algorithms for estimating LV filling pressure'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The diagnosis of HF is based upon a constellation of symptoms, signs, and test results. Diagnostic rules based upon combinations of clinical features are discussed below (See",
"    <a class=\"local\" href=\"#H1559215\">",
"     'Diagnostic rules'",
"    </a>",
"    below.).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many of the symptoms and signs of HF are non-specific so other potential causes should be considered. Patients with HF may present with a syndrome of decreased exercise tolerance, fluid retention, or both [",
"    <a class=\"abstract\" href=\"UTD.htm?19/30/19945/abstract/2\">",
"     2",
"    </a>",
"    ]. Various other causes for such symptoms and signs should also be considered.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with decreased exercise tolerance have symptoms of dyspnea or fatigue with exertion and may also have symptoms at rest. Heart failure should be distinguished from other causes of dyspnea including myocardial ischemia, pulmonary disease, and other disorders [",
"      <a class=\"abstract\" href=\"UTD.htm?19/30/19945/abstract/15\">",
"       15",
"      </a>",
"      ]. Causes of fatigue include deconditioning, sleep apnea and depression. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/10/16553?source=see_link\">",
"       \"Approach to the patient with dyspnea\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/36/23111?source=see_link\">",
"       \"Approach to the adult patient with fatigue\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      For example, chronic obstructive pulmonary disease (COPD) and HF may be difficult to distinguish in some patients. Because of the high prevalence of these disorders, their similar presentations, and their frequent coexistence, it is reasonable to consider both diagnoses, not only in patients presenting with dyspnea for the first time, but also in any patient with one of these diagnoses who presents with a deterioration in respiratory status [",
"      <a class=\"abstract\" href=\"UTD.htm?19/30/19945/abstract/16\">",
"       16",
"      </a>",
"      ]. This issue is discussed in detail separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/14/30954?source=see_link&amp;anchor=H13#H13\">",
"       \"Chronic obstructive pulmonary disease: Definition, clinical manifestations, diagnosis, and staging\", section on 'Diagnosis'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/14/30954?source=see_link\">",
"       \"Chronic obstructive pulmonary disease: Definition, clinical manifestations, diagnosis, and staging\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients presenting with fluid retention may complain of leg or abdominal swelling. Heart failure should be distinguished from other causes of edema including venous thrombosis or insufficiency, renal sodium retention, drug side effect (eg, calcium channel blocker) and cirrhosis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/36/34375?source=see_link\">",
"       \"Clinical manifestations and diagnosis of edema in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/34/36393?source=see_link\">",
"       \"Pathophysiology and etiology of edema in adults\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12260616\">",
"    <span class=\"h1\">",
"     INITIAL TESTING",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Electrocardiogram",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients with HF due to systolic dysfunction have a significant abnormality on an electrocardiogram (ECG). A normal ECG makes systolic dysfunction unlikely (98 percent negative predictive value) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/30/19945/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although the ECG may be less predictive of HF than the BNP (or NT-proBNP) level [",
"    <a class=\"abstract\" href=\"UTD.htm?19/30/19945/abstract/6\">",
"     6",
"    </a>",
"    ], the ECG may show findings that favor the presence of a specific cause of HF and can also detect arrhythmias (eg, atrial fibrillation) that suggest heart disease and may cause or exacerbate HF. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/29/27097?source=see_link\">",
"     \"Tachycardia-mediated cardiomyopathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/28/39369?source=see_link\">",
"     \"Evaluation of the patient with heart failure or cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The ECG is particularly important for identifying evidence of acute or prior myocardial infarction or acute ischemia. Ischemia may cause symptoms of dyspnea similar to HF and may also cause or exacerbate HF. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/24/11658?source=see_link\">",
"     \"Electrocardiogram in the diagnosis of myocardial ischemia and infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Initial blood tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recommended initial blood tests for patients with symptoms and signs of HF include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A complete blood count which may suggest concurrent or alternate conditions. Anemia or infection can exacerbate pre-existing HF. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/42/1705?source=see_link\">",
"       \"Impact of anemia in patients with heart failure\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Serum electrolytes, blood urea nitrogen, and creatinine may indicate associated conditions. Hyponatremia generally indicates severe HF, though it may occasionally result from excessive diuresis [",
"      <a class=\"abstract\" href=\"UTD.htm?19/30/19945/abstract/2\">",
"       2",
"      </a>",
"      ]. Renal impairment may be caused by",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      contribute to HF exacerbation. Baseline evaluation of electrolytes and creatine is also necessary when initiating therapy with diuretics",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      angiotensin converting enzyme inhibitors.",
"     </li>",
"     <li>",
"      Liver function tests, which may be affected by hepatic congestion. In one study, gamma-glutamyltransferase level (GGT) &gt;2 times the upper limit of normal was the only standard initial blood test that added diagnostic value to the history and physical examination [",
"      <a class=\"abstract\" href=\"UTD.htm?19/30/19945/abstract/7\">",
"       7",
"      </a>",
"      ]. However, NT-proBNP was the most powerful supplementary test.",
"     </li>",
"     <li>",
"      Fasting blood glucose to detect underlying diabetes mellitus. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/57/28569?source=see_link\">",
"       \"Heart failure in diabetes mellitus\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     BNP and NT-proBNP",
"    </span>",
"    &nbsp;&mdash;&nbsp;Brain natriuretic peptide (BNP) is a natriuretic hormone released primarily from the heart, particularly the ventricles. The active BNP hormone is cleaved from the C-terminal end of its prohormone, pro-BNP. The N-terminal fragment (NT-proBNP) is also released into the circulation. The plasma concentrations of BNP and NT-proBNP are increased in patients with left ventricular dysfunction, particularly those with heart failure.",
"   </p>",
"   <p>",
"    BNP or NT-proBNP levels are useful in distinguishing HF due to systolic",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    diastolic dysfunction from other causes of dyspnea. As noted below, studies developing and validating diagnostic rules for HF have found that the BNP or NT-proBNP levels add greater diagnostic value to the history and physical examination than other initial tests (ECG, chest x-ray, and initial blood tests) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/30/19945/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. Evidence of efficacy and limitations of BNP and NT-proBNP levels in the diagnosis of HF is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/22/19818?source=see_link\">",
"     \"Natriuretic peptide measurement in heart failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Measurement of plasma BNP or NT-proBNP is suggested in the evaluation of patients with suspected HF when the diagnosis is uncertain, as recommended in the 2005",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines with 2009 update as well as the 2006 HFSA, 2008 ESC, and 2006 CCS guidelines [",
"    <a class=\"abstract\" href=\"UTD.htm?19/30/19945/abstract/2,4,5,15\">",
"     2,4,5,15",
"    </a>",
"    ]. Elevated natriuretic peptide levels should be interpreted in the context of other clinical information; they may lend weight to the diagnosis of HF or trigger consideration of HF but should NOT be used in isolation to diagnose HF [",
"    <a class=\"abstract\" href=\"UTD.htm?19/30/19945/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     BNP",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most dyspneic patients with HF have values above 400",
"    <span class=\"nowrap\">",
"     pg/mL,",
"    </span>",
"    while values below 100",
"    <span class=\"nowrap\">",
"     pg/mL",
"    </span>",
"    have a very high negative predictive value for HF as a cause of dyspnea [",
"    <a class=\"abstract\" href=\"UTD.htm?19/30/19945/abstract/18\">",
"     18",
"    </a>",
"    ]. In the range between 100 and 400",
"    <span class=\"nowrap\">",
"     pg/mL,",
"    </span>",
"    plasma BNP concentrations are not very sensitive or specific for detecting or excluding HF. Other diagnoses, such as pulmonary embolism, LV dysfunction without exacerbation, and cor pulmonale should also be considered in patients with plasma BNP concentrations in this range.",
"   </p>",
"   <p>",
"    Atrial fibrillation (AF) is associated with higher levels of BNP in the absence of HF. In one analysis, a BNP cutoff of &ge;100",
"    <span class=\"nowrap\">",
"     pg/mL",
"    </span>",
"    was associated with a specificity of only 40 percent compared to 79 percent in patients without AF [",
"    <a class=\"abstract\" href=\"UTD.htm?19/30/19945/abstract/19\">",
"     19",
"    </a>",
"    ]. Using a cutoff of &ge;200",
"    <span class=\"nowrap\">",
"     pg/mL",
"    </span>",
"    in patients with AF increased specificity from 40 to 73 percent with a smaller reduction in sensitivity from 95 to 85 percent.",
"   </p>",
"   <p>",
"    Normal plasma BNP values increase with age and are higher in women than men [",
"    <a class=\"abstract\" href=\"UTD.htm?19/30/19945/abstract/20\">",
"     20",
"    </a>",
"    ]. Thus, somewhat higher cutoff values may be needed in these settings, although the optimal discriminatory values that should be used have not been determined.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     NT-proBNP",
"    </span>",
"    &nbsp;&mdash;&nbsp;In normal subjects, the plasma concentrations of BNP and NT-proBNP are similar (approximately 10",
"    <span class=\"nowrap\">",
"     pmol/L).",
"    </span>",
"    However, in patients with LV dysfunction, plasma NT-proBNP concentrations are approximately fourfold higher than BNP concentrations [",
"    <a class=\"abstract\" href=\"UTD.htm?19/30/19945/abstract/21\">",
"     21",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/22/19818?source=see_link&amp;anchor=H5#H5\">",
"     \"Natriuretic peptide measurement in heart failure\", section on 'Plasma N-terminal pro-BNP'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The optimal values for distinguishing HF from other causes of dyspnea vary with patient age. In a large multicenter study, for patients &lt;50, 50 to 75, and &gt;75 years of age, the optimal plasma NT-proBNP cutoffs for diagnosing HF were 450",
"    <span class=\"nowrap\">",
"     pg/mL,",
"    </span>",
"    900",
"    <span class=\"nowrap\">",
"     pg/mL,",
"    </span>",
"    and 1800",
"    <span class=\"nowrap\">",
"     pg/mL",
"    </span>",
"    respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?19/30/19945/abstract/22\">",
"     22",
"    </a>",
"    ]. Overall, these cutoffs yielded a sensitivity and specificity of 90 and 84 percent, respectively. Across the entire population, NT-proBNP levels below 300",
"    <span class=\"nowrap\">",
"     pg/mL",
"    </span>",
"    were optimal for excluding a diagnosis of HF, with a negative predictive value of 98 percent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Limitations of BNP and NT-proBNP",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are several important limitations to the use of plasma BNP and NT-proBNP for diagnosis of HF [",
"    <a class=\"abstract\" href=\"UTD.htm?19/30/19945/abstract/23\">",
"     23",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients may present with more than one cause of dyspnea (such as pneumonia and an exacerbation of HF). Thus, a high plasma BNP or NT-proBNP concentration does not exclude the presence of other diseases.",
"     </li>",
"     <li>",
"      In some patients with acute decompensated HF, plasma BNP or NT-proBNP levels are not diagnostic.",
"     </li>",
"     <li>",
"      Some patients with severe chronic HF may have persistently elevated plasma BNP or NT-proBNP concentrations regardless of treatment, and such levels may not be useful in guiding management.",
"     </li>",
"     <li>",
"      Right heart failure and pulmonary hypertension are associated with elevations in plasma BNP and NT-proBNP. However, when right heart failure is due solely to lung disease and not due to secondary pulmonary hypertension from left sided heart disease or as part of a global cardiomyopathy, elevated plasma BNP may be misinterpreted since dyspnea in these patients is due to lung disease not left heart failure.",
"     </li>",
"     <li>",
"      Plasma BNP and NT-proBNP levels tend to be lower in obese patients and are elevated in patients with renal failure, and some acute noncardiac illnesses such as sepsis. Greater increases in NT-proBNP than BNP levels are observed in renal failure.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Measurement and interpretation of BNP and NT-proBNP levels is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/22/19818?source=see_link\">",
"     \"Natriuretic peptide measurement in heart failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Chest x-ray",
"    </span>",
"    &nbsp;&mdash;&nbsp;The chest x-ray is a useful first diagnostic test, particularly in the evaluation of patients who present with dyspnea, to differentiate HF from primary pulmonary disease [",
"    <a class=\"abstract\" href=\"UTD.htm?19/30/19945/abstract/24-26\">",
"     24-26",
"    </a>",
"    ]. Findings suggestive of HF include cardiomegaly (cardiac-to-thoracic width ratio above 50 percent), cephalization of the pulmonary vessels, Kerley B-lines, and pleural effusions (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef59773 graphicRef61783 graphicRef53728 graphicRef72562 graphicRef58394 \" href=\"UTD.htm?42/45/43738\">",
"     image 1A-E",
"    </a>",
"    ). The cardiac size and silhouette may also reveal signs of congenital anomalies (ventricular or atrial septal defect) or valvular disease (mitral stenosis or aortic stenosis).",
"   </p>",
"   <p>",
"    A systematic review of the utility of the chest x-ray to diagnose LV dysfunction concluded that redistribution and cardiomegaly were the best predictors of increased preload and reduced ejection fraction, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?19/30/19945/abstract/25\">",
"     25",
"    </a>",
"    ]. Neither finding, however, was sufficient to make a definitive diagnosis of HF. In a multicenter study of 880 patients, alveolar edema, interstitial edema, and cephalization all had a specificity of &gt;90 percent for HF, but only cardiomegaly had a sensitivity &gt;50 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?19/30/19945/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12260638\">",
"    <span class=\"h2\">",
"     Diagnostic accuracy of initial testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;The accuracy of initial testing for the clinical diagnosis of heart failure was evaluated by a systematic review that included data from 15 studies of patients with suspected heart failure [",
"    <a class=\"abstract\" href=\"UTD.htm?19/30/19945/abstract/6\">",
"     6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      BNP or NT-proBNP levels have relatively high sensitivity (both 93 percent) and more limited specificity for clinical diagnosis of HF (74 and 65 percent). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/22/19818?source=see_link\">",
"       \"Natriuretic peptide measurement in heart failure\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      As noted above, an ECG has relatively high sensitivity (89 percent) but more limited specificity (56 percent). (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Electrocardiogram'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Chest x-ray evidence of HF is helpful in confirming the diagnosis since it has relatively high specificity (83 percent) though more limited sensitivity (68 percent). &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Diagnostic rules for HF that include initial testing are discussed below. (See",
"    <a class=\"local\" href=\"#H1559215\">",
"     'Diagnostic rules'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     ECHOCARDIOGRAPHY",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with symptoms and signs of HF, echocardiography is helpful for determining whether ventricular function and hemodynamics are consistent with HF and in identifying a cause. The 2007",
"    <span class=\"nowrap\">",
"     ACCF/ASE/ACEP/ANC/SCAI/SCCT/SCMR",
"    </span>",
"    appropriateness criteria rate echocardiography as appropriate in patients with symptoms (including dyspnea, shortness of breath and others) due to a suspected cardiac etiology [",
"    <a class=\"abstract\" href=\"UTD.htm?19/30/19945/abstract/27\">",
"     27",
"    </a>",
"    ]. They also rate echocardiography appropriate when other studies (such as chest x-ray or elevation of serum BNP) are concerning for cardiac disease.",
"   </p>",
"   <p>",
"    Important echocardiographic findings include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Atrial and ventricular sizes, which may be helpful in identifying the cause and chronicity of disease. For example, patients with idiopathic dilated cardiomyopathy typically have both left and right atrial and ventricular enlargement (four chamber dilatation) with decreased left systolic ventricular function (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef73155 \" href=\"UTD.htm?1/36/1605\">",
"       image 2",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef70128 \" href=\"UTD.htm?31/37/32339\">",
"       figure 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_movie graphicRef78668 \" href=\"UTD.htm?40/35/41521\">",
"       movie 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_movie graphicRef75021 \" href=\"UTD.htm?43/0/44035\">",
"       movie 2",
"      </a>",
"      and",
"      <a class=\"graphic graphic_movie graphicRef68493 \" href=\"UTD.htm?38/61/39902\">",
"       movie 3",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/12/15562?source=see_link\">",
"       \"Echocardiographic recognition of cardiomyopathies\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Global left and right ventricular systolic function (left and right ventricular ejection fraction, LVEF and RVEF). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/21/11610?source=see_link&amp;anchor=H12#H12\">",
"       \"Noninvasive methods for measurement of left ventricular systolic function\", section on 'Echocardiography'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Diastolic left ventricular function. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/60/33735?source=see_link\">",
"       \"Echocardiographic evaluation of left ventricular diastolic function\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Regional wall motion abnormalities in a coronary distribution are suggestive of coronary heart disease but segmental abnormalities also occur commonly in patients with dilated cardiomyopathy",
"     </li>",
"     <li>",
"      Pericardial disease includes thickening suggestive of constrictive pericarditis or effusion which may or may not be associated with tamponade. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/12/12490?source=see_link\">",
"       \"Constrictive pericarditis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/52/19273?source=see_link\">",
"       \"Cardiac tamponade\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Valvular heart disease",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Echocardiography also provides a noninvasive assessment of hemodynamic status:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The pulmonary capillary wedge pressure (PCWP) can be estimated via the ratio",
"      <span class=\"nowrap\">",
"       (E/Ea",
"      </span>",
"      or",
"      <span class=\"nowrap\">",
"       E/E')",
"      </span>",
"      of tissue Doppler of early mitral inflow velocity (E) to early diastolic velocity of the mitral annulus (Ea or e'). An",
"      <span class=\"nowrap\">",
"       E/e'",
"      </span>",
"      ratio &gt;15 suggests a PCWP &gt;15 mm Hg when e' is the mean of medial and lateral mitral annulus early diastolic velocities. Use and limitations of this method are discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/60/33735?source=see_link&amp;anchor=H5#H5\">",
"       \"Echocardiographic evaluation of left ventricular diastolic function\", section on 'Tissue Doppler imaging'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Right ventricular and pulmonary artery pressures can be estimated by the peak velocity of tricuspid regurgitation on Doppler echocardiography. Right atrial pressure may be estimated from evaluating the size of the inferior vena cava and its respiratory variation.",
"     </li>",
"     <li>",
"      The cardiac output can be estimated by pulsed-wave Doppler from the left ventricular outflow tract [",
"      <a class=\"abstract\" href=\"UTD.htm?19/30/19945/abstract/28\">",
"       28",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1559215\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC RULES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diagnostic rules have been developed in an attempt to increase the accuracy and efficiency of HF diagnosis as illustrated by the following two examples.",
"   </p>",
"   <p>",
"    An individual patient data analysis tested various diagnostic models in one dataset [",
"    <a class=\"abstract\" href=\"UTD.htm?19/30/19945/abstract/6\">",
"     6",
"    </a>",
"    ]. The model with the best fit was simplified into the following clinical prediction rule:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Echocardiography is recommended for a patient with suspected HF presenting with symptoms such as breathlessness if any one of the following is present: history of myocardial infarction, or basal crepitations (rales), or male with ankle edema.",
"     </li>",
"     <li>",
"      A patient with suspected HF without one of the above features is referred for BNP or NT-proBNP level testing. Echocardiography is recommended in the following settings :",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Female without ankle edema if BNP &gt;210 to 360",
"      <span class=\"nowrap\">",
"       pg/mL",
"      </span>",
"      (or NT-proBNP &gt;620 to 1060",
"      <span class=\"nowrap\">",
"       pg/mL)",
"      </span>",
"      depending upon local availability of echocardiography.",
"     </li>",
"     <li>",
"      Male without ankle edema if BNP &gt;130 to 220",
"      <span class=\"nowrap\">",
"       pg/mL",
"      </span>",
"      (or NT-proBNP &gt;390 to 660",
"      <span class=\"nowrap\">",
"       pg/mL).",
"      </span>",
"     </li>",
"     <li>",
"      Female with ankle edema if BNP &gt;100 to 180",
"      <span class=\"nowrap\">",
"       pg/mL",
"      </span>",
"      (or NTproBNP &gt;190 to 520",
"      <span class=\"nowrap\">",
"       pg/mL).",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The above model was applied to other datasets with an area under the ROC curve (AUC) of 0.84 to 0.96. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/52/10054?source=see_link&amp;anchor=H14#H14\">",
"     \"Evaluating diagnostic tests\", section on 'Receiver operating characteristic curves'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A multicenter prospective study of 721 patients with suspected HF evaluated various models including elements from history, physical examination, and initial testing [",
"    <a class=\"abstract\" href=\"UTD.htm?19/30/19945/abstract/7\">",
"     7",
"    </a>",
"    ]. A diagnostic rule was developed with the following elements:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Age &lt;60 years (no points), 60 to 70 (4 points), 70 to 80 (7 points), &gt;80 (10 points)",
"     </li>",
"     <li>",
"      History of myocardial infarction, coronary artery bypass graft surgery, or percutaneous coronary intervention (15 points if present)",
"     </li>",
"     <li>",
"      Loop diuretic (10 points if present)",
"     </li>",
"     <li>",
"      Displaced apical impulse (20 points if present)",
"     </li>",
"     <li>",
"      Rales (14 points if present)",
"     </li>",
"     <li>",
"      Irregularly irregular pulse (11 points if present)",
"     </li>",
"     <li>",
"      Heart murmur (10 points if present)",
"     </li>",
"     <li>",
"      Pulse rate",
"      <span class=\"nowrap\">",
"       [(bpm-60)/3",
"      </span>",
"      points}",
"     </li>",
"     <li>",
"      Elevated jugular venous pressure (12 points if present)",
"     </li>",
"     <li>",
"      NT-proBNP",
"      <span class=\"nowrap\">",
"       (pg/mL)",
"      </span>",
"      &lt;100 (no points), 100 to 200 (8 points), 200 to 400 (16 points), 400 to 800 (24 points), 800 to 1600 (32 points), 1600 to 3200 (40 points), &gt;3200 (48 points)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    With a summed score &lt;13 points, the estimated probability of HF is &lt;10 percent. With a summed score &gt;54 points, the estimated probability of HF is &gt;70 percent. The rule was applied to two external validation datasets with AUC of 0.88 to 0.95. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/52/10054?source=see_link&amp;anchor=H14#H14\">",
"     \"Evaluating diagnostic tests\", section on 'Receiver operating characteristic curves'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although both of the above rules performed well when applied to validation datasets, their generalizability to various clinical settings is uncertain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?17/12/17601?source=see_link\">",
"       \"Patient information: Heart failure (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?33/5/33877?source=see_link\">",
"       \"Patient information: Heart failure (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Initial evaluation of patients with symptoms or signs suggestive of heart failure (HF) includes clinical assessment (history and physical exam), electrocardiogram, blood tests, and chest x-ray.",
"     </li>",
"     <li>",
"      Early measurement of plasma BNP or NT pro-BNP levels is suggested in patients with suspected HF in whom the diagnosis is uncertain.",
"     </li>",
"     <li>",
"      In patients with symptoms and signs of HF, echocardiography is useful for evaluating hemodynamics and identifying potential causes of HF.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Further evaluation and management of patients diagnosed with heart failure is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/28/39369?source=see_link\">",
"     \"Evaluation of the patient with heart failure or cardiomyopathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/63/38906?source=see_link\">",
"     \"Overview of the therapy of heart failure due to systolic dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/30/19945/abstract/1\">",
"      Ho KK, Pinsky JL, Kannel WB, Levy D. The epidemiology of heart failure: the Framingham Study. J Am Coll Cardiol 1993; 22:6A.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/30/19945/abstract/2\">",
"      Hunt SA, Abraham WT, Chin MH, et al. 2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 2009; 119:e391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/30/19945/abstract/3\">",
"      Heart Failure Society of America, Lindenfeld J, Albert NM, et al. HFSA 2010 Comprehensive Heart Failure Practice Guideline. J Card Fail 2010; 16:e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/30/19945/abstract/4\">",
"      Dickstein K, Cohen-Solal A, Filippatos G, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J 2008; 29:2388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/30/19945/abstract/5\">",
"      Arnold JM, Liu P, Demers C, et al. Canadian Cardiovascular Society consensus conference recommendations on heart failure 2006: diagnosis and management. Can J Cardiol 2006; 22:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/30/19945/abstract/6\">",
"      Mant J, Doust J, Roalfe A, et al. Systematic review and individual patient data meta-analysis of diagnosis of heart failure, with modelling of implications of different diagnostic strategies in primary care. Health Technol Assess 2009; 13:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/30/19945/abstract/7\">",
"      Kelder JC, Cramer MJ, van Wijngaarden J, et al. The diagnostic value of physical examination and additional testing in primary care patients with suspected heart failure. Circulation 2011; 124:2865.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/30/19945/abstract/8\">",
"      Davie AP, Francis CM, Caruana L, et al. Assessing diagnosis in heart failure: which features are any use? QJM 1997; 90:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/30/19945/abstract/9\">",
"      O'Reilly RA. Splenomegaly in 2,505 patients at a large university medical center from 1913 to 1995. 1963 to 1995: 449 patients. West J Med 1998; 169:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/30/19945/abstract/10\">",
"      GLEASON WL, BRAUNWALD E. Studies on Starling's law of the heart. VI. Relationships between left ventricular enddiatolic volume and stroke volume in man with observations on the mechanism of pulsus alternans. Circulation 1962; 25:841.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/30/19945/abstract/11\">",
"      Ishmail AA, Wing S, Ferguson J, et al. Interobserver agreement by auscultation in the presence of a third heart sound in patients with congestive heart failure. Chest 1987; 91:870.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/30/19945/abstract/12\">",
"      Lok CE, Morgan CD, Ranganathan N. The accuracy and interobserver agreement in detecting the 'gallop sounds' by cardiac auscultation. Chest 1998; 114:1283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/30/19945/abstract/13\">",
"      Marcus GM, Gerber IL, McKeown BH, et al. Association between phonocardiographic third and fourth heart sounds and objective measures of left ventricular function. JAMA 2005; 293:2238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/30/19945/abstract/14\">",
"      From AM, Lam CS, Pitta SR, et al. Bedside assessment of cardiac hemodynamics: the impact of noninvasive testing and examiner experience. Am J Med 2011; 124:1051.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/30/19945/abstract/15\">",
"      . Evaluation of patients for ventricular dysfunction and heart failure. J Card Fail 2006; 12:e16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/30/19945/abstract/16\">",
"      Le Jemtel TH, Padeletti M, Jelic S. Diagnostic and therapeutic challenges in patients with coexistent chronic obstructive pulmonary disease and chronic heart failure. J Am Coll Cardiol 2007; 49:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/30/19945/abstract/17\">",
"      Davie AP, Francis CM, Love MP, et al. Value of the electrocardiogram in identifying heart failure due to left ventricular systolic dysfunction. BMJ 1996; 312:222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/30/19945/abstract/18\">",
"      Maisel A. B-type natriuretic peptide levels: diagnostic and prognostic in congestive heart failure: what's next? Circulation 2002; 105:2328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/30/19945/abstract/19\">",
"      Mehra MR, Uber PA, Park MH, et al. Obesity and suppressed B-type natriuretic peptide levels in heart failure. J Am Coll Cardiol 2004; 43:1590.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/30/19945/abstract/20\">",
"      Redfield MM, Rodeheffer RJ, Jacobsen SJ, et al. Plasma brain natriuretic peptide concentration: impact of age and gender. J Am Coll Cardiol 2002; 40:976.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/30/19945/abstract/21\">",
"      Hunt PJ, Richards AM, Nicholls MG, et al. Immunoreactive amino-terminal pro-brain natriuretic peptide (NT-PROBNP): a new marker of cardiac impairment. Clin Endocrinol (Oxf) 1997; 47:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/30/19945/abstract/22\">",
"      Januzzi JL, van Kimmenade R, Lainchbury J, et al. NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients: the International Collaborative of NT-proBNP Study. Eur Heart J 2006; 27:330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/30/19945/abstract/23\">",
"      de Lemos JA, McGuire DK, Drazner MH. B-type natriuretic peptide in cardiovascular disease. Lancet 2003; 362:316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/30/19945/abstract/24\">",
"      Gillespie ND, McNeill G, Pringle T, et al. Cross sectional study of contribution of clinical assessment and simple cardiac investigations to diagnosis of left ventricular systolic dysfunction in patients admitted with acute dyspnoea. BMJ 1997; 314:936.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/30/19945/abstract/25\">",
"      Badgett RG, Mulrow CD, Otto PM, Ram&iacute;rez G. How well can the chest radiograph diagnose left ventricular dysfunction? J Gen Intern Med 1996; 11:625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/30/19945/abstract/26\">",
"      Knudsen CW, Omland T, Clopton P, et al. Diagnostic value of B-Type natriuretic peptide and chest radiographic findings in patients with acute dyspnea. Am J Med 2004; 116:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/30/19945/abstract/27\">",
"      Douglas PS, Khandheria B, Stainback RF, et al. ACCF/ASE/ACEP/ASNC/SCAI/SCCT/SCMR 2007 appropriateness criteria for transthoracic and transesophageal echocardiography: a report of the American College of Cardiology Foundation Quality Strategic Directions Committee Appropriateness Criteria Working Group, American Society of Echocardiography, American College of Emergency Physicians, American Society of Nuclear Cardiology, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography, and the Society for Cardiovascular Magnetic Resonance endorsed by the American College of Chest Physicians and the Society of Critical Care Medicine. J Am Coll Cardiol 2007; 50:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/30/19945/abstract/28\">",
"      Gola A, Pozzoli M, Capomolla S, et al. Comparison of Doppler echocardiography with thermodilution for assessing cardiac output in advanced congestive heart failure. Am J Cardiol 1996; 78:708.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3510 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.248-655E7897C0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_30_19945=[""].join("\n");
var outline_f19_30_19945=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H22\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Vital signs and appearance",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Volume assessment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Pulsus alternans",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Precordial palpation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Heart sounds",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Pulmonary hypertension",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12260556\">",
"      Diagnostic accuracy of clinical features",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12260616\">",
"      INITIAL TESTING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Electrocardiogram",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Initial blood tests",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      BNP and NT-proBNP",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - BNP",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - NT-proBNP",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Limitations of BNP and NT-proBNP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Chest x-ray",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12260638\">",
"      Diagnostic accuracy of initial testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      ECHOCARDIOGRAPHY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1559215\">",
"      DIAGNOSTIC RULES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/3510\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/3510|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?17/14/17647\" title=\"algorithm 1\">",
"      Evaluation patients DCM",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/3510|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?37/29/38357\" title=\"diagnostic image 1A\">",
"      Dilated cardiomyopathy CXR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?12/32/12805\" title=\"diagnostic image 1B\">",
"      Heart failure PA I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?3/54/3941\" title=\"diagnostic image 1C\">",
"      Interstitial pulmonary edema PA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?28/37/29267\" title=\"diagnostic image 1D\">",
"      Heart failure PA II",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?5/36/5701\" title=\"diagnostic image 1E\">",
"      Pulmonary edema PA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?1/36/1605\" title=\"diagnostic image 2\">",
"      M mode dilated cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/3510|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?31/37/32339\" title=\"figure 1\">",
"      M mode MV dilated CM",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/3510|MOV\">",
"      <a href=\"#\" title=\"MOVIES\">",
"       MOVIES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?40/35/41521\" title=\"movie 1\">",
"      Dilated cardiomyopathy four chamber echocardiogram",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?43/0/44035\" title=\"movie 2\">",
"      Dilated cardiomyopathy long axis echocardiogram",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?38/61/39902\" title=\"movie 3\">",
"      Dilated cardiomyopathy short axis echocardiogram",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/3510|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?37/44/38603\" title=\"table 1\">",
"      Framingham criteria Dx HF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?21/9/21661\" title=\"table 2\">",
"      ACC AHA evaluation HF",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/36/23111?source=related_link\">",
"      Approach to the adult patient with fatigue",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/34/34346?source=related_link\">",
"      Approach to the adult patient with splenomegaly and other splenic disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/10/16553?source=related_link\">",
"      Approach to the patient with dyspnea",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/30/24042?source=related_link\">",
"      Atrial fibrillation in patients with heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/37/26202?source=related_link\">",
"      Auscultation of cardiac murmurs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/56/22410?source=related_link\">",
"      Auscultation of heart sounds",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/52/19273?source=related_link\">",
"      Cardiac tamponade",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/14/30954?source=related_link\">",
"      Chronic obstructive pulmonary disease: Definition, clinical manifestations, diagnosis, and staging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/22/43368?source=related_link\">",
"      Clinical manifestations and diagnosis of diastolic heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/36/34375?source=related_link\">",
"      Clinical manifestations and diagnosis of edema in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/12/12490?source=related_link\">",
"      Constrictive pericarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/60/33735?source=related_link\">",
"      Echocardiographic evaluation of left ventricular diastolic function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/12/15562?source=related_link\">",
"      Echocardiographic recognition of cardiomyopathies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/24/11658?source=related_link\">",
"      Electrocardiogram in the diagnosis of myocardial ischemia and infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/52/10054?source=related_link\">",
"      Evaluating diagnostic tests",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/23/7544?source=related_link\">",
"      Evaluation of acute decompensated heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/28/39369?source=related_link\">",
"      Evaluation of the patient with heart failure or cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/15/33013?source=related_link\">",
"      Examination of the arterial pulse",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/59/33719?source=related_link\">",
"      Examination of the jugular venous pulse",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/43/9909?source=related_link\">",
"      Examination of the precordial pulsation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/57/28569?source=related_link\">",
"      Heart failure in diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/42/1705?source=related_link\">",
"      Impact of anemia in patients with heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/22/19818?source=related_link\">",
"      Natriuretic peptide measurement in heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/21/11610?source=related_link\">",
"      Noninvasive methods for measurement of left ventricular systolic function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/63/38906?source=related_link\">",
"      Overview of the therapy of heart failure due to systolic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/34/36393?source=related_link\">",
"      Pathophysiology and etiology of edema in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/44/32455?source=related_link\">",
"      Pathophysiology of heart failure: Neurohumoral adaptations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?33/5/33877?source=related_link\">",
"      Patient information: Heart failure (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?17/12/17601?source=related_link\">",
"      Patient information: Heart failure (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/29/27097?source=related_link\">",
"      Tachycardia-mediated cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/7/41079?source=related_link\">",
"      Treatment of acute decompensated heart failure: General considerations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_30_19946="Impact of medications and methylxanthines on stress testing";
var content_f19_30_19946=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Impact of medications and methylxanthines on stress testing",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/30/19946/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/30/19946/contributors\">",
"     Sarkis Baghdasarian, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/30/19946/contributors\">",
"     Gary V Heller, MD, PhD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/30/19946/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/30/19946/contributors\">",
"     Patricia A Pellikka, MD, FACC, FAHA, FASE",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/30/19946/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/30/19946/contributors\">",
"     Brian C Downey, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?19/30/19946/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 25, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H6560911\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Medications and patient diet may alter hemodynamics, electrolyte levels, or endothelial function, and potentially limit the accuracy of any stress testing modality for determining the presence of significant coronary heart disease (CHD). Certain medications may lead to &ldquo;false negative&rdquo; results while others may yield &ldquo;false positive&rdquo; results. Thus the decision to discontinue medications or dietary components is an integral part of ordering these tests, with the decision to withdraw medication based on the clinical circumstances, the indications for stress testing, and the type of stress testing performed.",
"   </p>",
"   <p>",
"    The interaction between major cardiovascular medications and stress testing will be discussed here. Indications and procedures for stress testing are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/30/44520?source=see_link\">",
"     \"Selecting the optimal cardiac stress test\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/57/26521?source=see_link\">",
"     \"Stress testing for the diagnosis of coronary heart disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/58/2986?source=see_link\">",
"     \"Stress testing to determine prognosis and management of patients with known or suspected coronary heart disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/6/35945?source=see_link\">",
"     \"Performance of exercise ECG testing\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/24/24970?source=see_link\">",
"     \"Exercise radionuclide myocardial perfusion imaging in the diagnosis and prognosis of coronary heart disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/5/10330?source=see_link\">",
"     \"Vasodilator stress radionuclide myocardial perfusion imaging: Testing methodologies and safety\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/9/42134?source=see_link\">",
"     \"Dobutamine stress radionuclide myocardial perfusion imaging\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/52/27466?source=see_link\">",
"     \"Stress echocardiography in the diagnosis and prognosis of coronary heart disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/5/41048?source=see_link\">",
"     \"Stress echocardiography: Indications, imaging techniques and safety\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/31/35319?source=see_link\">",
"     \"Protocols for stress echocardiography\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6561092\">",
"    <span class=\"h1\">",
"     FALSE STRESS TEST RESULTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A false negative stress test result occurs when a stress test fails to detect clinically significant coronary heart disease (CHD). In contrast, a false positive stress test result suggests underlying clinically significant CHD when no such disease exists. Medications and patient diet may result in false negative or false positive stress test results. Patients with false negative results may not receive appropriate medical therapy, potentially leading to worse clinical outcomes. In contrast, patients with false positive results may be subjected to further noninvasive or invasive testing with possible adverse outcomes. False positive results may also lead to treatment with unnecessary medical therapy and its associated risks and costs. Therefore, understanding the mechanisms by which medications and dietary ingestions can alter stress test results is critical to optimizing the information obtained from stress testing.",
"   </p>",
"   <p>",
"    Stress testing is performed using exercise or medications to increase coronary artery blood flow",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    myocardial oxygen requirements. Coronary blood flow increases to various degrees depending on the type of stress testing and the degree of stenosis. Exercise induces vasodilation and a two- to threefold increase in blood flow in normal coronary arteries [",
"    <a class=\"abstract\" href=\"UTD.htm?19/30/19946/abstract/1\">",
"     1",
"    </a>",
"    ]. Exercise also induces paradoxical vasoconstriction in stenotic segments, (secondary to endothelial dysfunction), which results in a myocardial oxygen",
"    <span class=\"nowrap\">",
"     demand/supply",
"    </span>",
"    mismatch in stenotic segments and heterogeneity in the perfusion of normal and stenotic segments [",
"    <a class=\"abstract\" href=\"UTD.htm?19/30/19946/abstract/2-10\">",
"     2-10",
"    </a>",
"    ]. Vasodilators used in stress testing increase flow in normal coronary arteries three- to fivefold, while arteries with a significant stenosis are not able to increase flow to the same extent, thus creating a heterogeneity in flow and tracer uptake [",
"    <a class=\"abstract\" href=\"UTD.htm?19/30/19946/abstract/11,12\">",
"     11,12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A stress test is interpreted as positive or negative based upon patterns seen on the electrocardiogram (ECG) and, when performed, an accompanying imaging study (eg, myocardial perfusion imaging, echocardiographic imaging). False results can be seen on either of these studies. Medications and dietary ingestions can yield",
"    <strong>",
"     false negative",
"    </strong>",
"    results on the ECG, the imaging study, or both, and",
"    <strong>",
"     false positive",
"    </strong>",
"    results on the ECG. While false positive imaging results may occur (ie, due to soft tissue attenuation or adjacent bowel activity), medications and dietary ingestions have not been shown to yield false positive results on the imaging portion of a stress test.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H653040\">",
"    <span class=\"h2\">",
"     Mechanisms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some of the mechanisms by which medications affect stress testing can be explained by the concept of the ischemic cascade that underlies the theoretical mechanism by which various stress test modalities detect coronary heart disease (CHD) (",
"    <a class=\"graphic graphic_figure graphicRef79335 \" href=\"UTD.htm?32/60/33741\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/30/19946/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. In this model, the manifestations of myocardial ischemia differ depending upon the product of the heart rate and systolic blood pressure. As the rate-pressure product increases, the manifestations of ischemia progress from flow heterogeneity to regional myocardial dysfunction in the area of abnormal flow and reduced perfusion relative to metabolic demand. At a higher rate-pressure product, the electrocardiogram (ECG) demonstrates ischemic ST segment changes and anginal symptoms develop.",
"   </p>",
"   <p>",
"    Different stress-test modalities are based upon the detection of one or more events in this cascade. However, the basic prerequisite is an imbalance between myocardial oxygen demand and oxygen supply. Therefore, medications or dietary components can yield false negative results by:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Decreasing myocardial oxygen demand with stress (ie, heart rate or blood pressure lowering drugs)",
"     </li>",
"     <li>",
"      Increasing myocardial oxygen supply at rest (ie, vasodilating drugs)",
"     </li>",
"     <li>",
"      Reducing the heterogeneity in coronary blood flow (ie, methylxanthine derivatives)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Furthermore, some medications affect the ECG obtained during the stress test resulting in false positive results.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     Digoxin",
"    </a>",
"    , estrogen replacement therapy, and diuretics, through varying mechanisms, may result in ST segment changes that mimic those seen with ischemia in the absence of obstructive CHD. (See",
"    <a class=\"local\" href=\"#H6561181\">",
"     'Medications associated with false positive stress test results'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The main mechanisms responsible for false negative stress testing rely on either the restoration of balance between demand and supply or preventing heterogeneity in perfusion. Exercise is the preferred stress modality, as in addition to an objective evaluation of symptoms, exercise capacity provides independent and incremental prognostic information to imaging data [",
"    <a class=\"abstract\" href=\"UTD.htm?19/30/19946/abstract/15-19\">",
"     15-19",
"    </a>",
"    ]. Adequate exercise endpoints including heart rate response are essential for the accuracy of stress testing [",
"    <a class=\"abstract\" href=\"UTD.htm?19/30/19946/abstract/20-23\">",
"     20-23",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/28/29129?source=see_link\">",
"     \"Exercise ECG testing to determine prognosis of coronary heart disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/57/26521?source=see_link&amp;anchor=H13#H13\">",
"     \"Stress testing for the diagnosis of coronary heart disease\", section on 'Exercise ECG test'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    During exercise or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/57/25494?source=see_link\">",
"     dobutamine",
"    </a>",
"    stress testing, the rate of myocardial oxygen consumption is determined by heart rate, left ventricular contractility, and blood pressure in the case of exercise. As such, adequate level of stress is defined as the achievement of 85 percent or more of the age-predicted maximal heart rate for exercise or dobutamine stress",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    a rate-pressure product of 20,000 or more for exercise testing. Achieving an adequate exercise endpoint, defined as positive exercise ECG or greater than or equal to 85 percent of maximal predicted heart rate (MPHR), resulted in a higher sensitivity of thallium-201 MPI for the detection of one, two, or three vessel CHD [",
"    <a class=\"abstract\" href=\"UTD.htm?19/30/19946/abstract/20\">",
"     20",
"    </a>",
"    ]. Conversely, the size and degree of ischemia with thallium-201 imaging were significantly reduced by both qualitative and quantitative criteria in patients with submaximal exercise [",
"    <a class=\"abstract\" href=\"UTD.htm?19/30/19946/abstract/21\">",
"     21",
"    </a>",
"    ]. Similar results were obtained in patients who did not achieve 85 percent MPHR with dobutamine stress testing (",
"    <a class=\"graphic graphic_figure graphicRef53454 \" href=\"UTD.htm?16/29/16862\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/30/19946/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. Thus, inadequate heart rate response results in lower diagnostic yield.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H653047\">",
"    <span class=\"h2\">",
"     Effect of medications on prognosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The effect of medications and dietary ingestions on the diagnostic value of stress testing has been clearly established. However, the effect of medical therapy on the prognostic value of stress testing, if any, continues to be debated. One of the largest prognostic studies included 7333 patients who underwent either high-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/25/41366?source=see_link\">",
"     dipyridamole",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/57/25494?source=see_link\">",
"     dobutamine",
"    </a>",
"    stress echocardiography [",
"    <a class=\"abstract\" href=\"UTD.htm?19/30/19946/abstract/26\">",
"     26",
"    </a>",
"    ]. Seventy-six percent of patients were evaluated after discontinuation of antianginal drugs (ie, long-lasting nitrates, beta blockers and calcium channel blockers) while 24 percent were evaluated on antianginal therapy. Mortality in patients with negative tests on therapy was similar to patients with positive tests off antianginal therapy. On the other hand, a smaller study of 261 patients demonstrated a low risk of cardiac events in patients with a normal exercise myocardial perfusion imaging regardless of concurrent antiischemic treatment or degree of stress achieved [",
"    <a class=\"abstract\" href=\"UTD.htm?19/30/19946/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Based on the conflicting information above, further data are required to better assess the effects of antiischemic medications on the prognostic value of stress testing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H653329\">",
"    <span class=\"h1\">",
"     MEDICATIONS ASSOCIATED WITH FALSE NEGATIVE STRESS TEST RESULTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Frequently, patients who undergo stress testing are on a variety of medications for treatment of acute or chronic medical disorders. When used appropriately, these medications effectively treat risk factors for coronary heart disease (CHD) or other conditions. However, these same medications may interfere with the diagnostic capability of stress testing, often by the same mechanism which beneficially treats the condition for which the medication was prescribed. Similarly, certain dietary ingestions may interfere with the optimal performance of, or yield suboptimal results from, stress testing.",
"   </p>",
"   <p>",
"    <br/>",
"    The decision to continue or discontinue any medication or to make certain dietary modifications prior to stress testing should be made on an individual basis. Factors involved in this decision include the indication for stress testing, indication for any medication(s) the patient is taking which may need to be stopped, and the potential harm to the patient from temporarily discontinuing the medication(s). If a patient is receiving multiple medical therapies for hypertension and withholding therapies is considered, it may be reasonable to continue diuretics (assuming serum potassium levels are normal), angiotensin converting enzyme inhibitors, and angiotensin receptor blockers, and to temporarily discontinue nitrates, beta blockers, and calcium channel blockers.",
"   </p>",
"   <p>",
"    To obtain the maximal benefit of stopping any medication(s), the medication(s) should be withheld for four to five half-lives",
"    <strong>",
"     prior to",
"    </strong>",
"    the stress test being performed. Discontinuation of therapies for four to five half-lives will reverse the hemodynamic impact of antianginal treatment with nitrates, beta blockers, and calcium channel blockers. This can be accomplished, when practical and safe for the patient, by withholding antianginal medications such as beta blockers, calcium channel blockers, and nitrates for at least 48 hours prior to a diagnostic stress test [",
"    <a class=\"abstract\" href=\"UTD.htm?19/30/19946/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Various medications and dietary ingestions which can cause false negative stress test results are discussed here. Our general approach to the decision to continue or discontinue any medications prior to stress testing is discussed in more detail below. (See",
"    <a class=\"local\" href=\"#H6561212\">",
"     'Summary'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6561099\">",
"    <span class=\"h2\">",
"     Medications with antihypertensive and anti-ischemic properties",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6561108\">",
"    <span class=\"h3\">",
"     Beta blockers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Beta blockers reduce the extent and severity of ischemia during exercise or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/57/25494?source=see_link\">",
"     dobutamine",
"    </a>",
"    stress testing and decrease the heterogeneity of perfusion (and as such the ability to detect ischemia) on perfusion imaging during vasodilator stress testing. Beta blockers should be withheld for 48 hours prior to stress testing performed for the diagnosis of coronary heart disease (CHD). However, if exercise testing is performed to evaluate the effectiveness of therapy in patients with known CHD, treatment should be continued.",
"   </p>",
"   <p>",
"    Beta blockers decrease myocardial oxygen demand through a combination of the following mechanisms:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Reduced myocardial contractility",
"     </li>",
"     <li>",
"      Reduced heart rate",
"     </li>",
"     <li>",
"      Reduced blood pressure",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The decrease in heart rate may also improve myocardial oxygen supply by increasing the duration of diastole and improving subendocardial collateral flow to ischemic areas [",
"    <a class=\"abstract\" href=\"UTD.htm?19/30/19946/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, beta blockers may also improve myocardial metabolism independent of their effect on heart rate and blood pressure in patients with angina [",
"    <a class=\"abstract\" href=\"UTD.htm?19/30/19946/abstract/30\">",
"     30",
"    </a>",
"    ]. Additionally, selective beta blockers without vasodilating properties may cause vasoconstriction and decreased flow in normal coronaries, while nonselective beta blockers share some of the same pathways as the A2 receptors of adenosine through their interaction with beta-2 receptors and may interfere with the adenosine induced vasodilation [",
"    <a class=\"abstract\" href=\"UTD.htm?19/30/19946/abstract/7,31-34\">",
"     7,31-34",
"    </a>",
"    ]. This is probably the same mechanism that interferes with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/57/25494?source=see_link\">",
"     dobutamine",
"    </a>",
"    induced vasodilation [",
"    <a class=\"abstract\" href=\"UTD.htm?19/30/19946/abstract/35-37\">",
"     35-37",
"    </a>",
"    ]. Beta blockers will also prevent the paradoxical vasoconstriction in abnormal coronary arteries [",
"    <a class=\"abstract\" href=\"UTD.htm?19/30/19946/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. The favorable effect on vasomotor tone may have the added benefit of preventing coronary steal and improving endocardial perfusion [",
"    <a class=\"abstract\" href=\"UTD.htm?19/30/19946/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with severe ischemia receiving beta blockers are able to achieve a higher workload during exercise stress testing at an equivalent double-product (product of heart rate and systolic blood pressure), and will have less ST-segment changes and less angina [",
"    <a class=\"abstract\" href=\"UTD.htm?19/30/19946/abstract/39,40\">",
"     39,40",
"    </a>",
"    ]. Several studies have demonstrated decreased sensitivity of myocardial perfusion imaging (MPI) for the detection of ischemia in the setting of beta blocker use regardless of stress modality [",
"    <a class=\"abstract\" href=\"UTD.htm?19/30/19946/abstract/23,24,34,41-44\">",
"     23,24,34,41-44",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a study of patients undergoing exercise MPI, some perfusion defects were missed and others were smaller in patients receiving",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"       propranolol",
"      </a>",
"      even after re-exercising to the same rate-pressure product [",
"      <a class=\"abstract\" href=\"UTD.htm?19/30/19946/abstract/41\">",
"       41",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Beta blockers may also affect vasodilator stress tests. In patients with angiographically proven CHD undergoing",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/25/41366?source=see_link\">",
"       dipyridamole",
"      </a>",
"      stress MPI, beta-blocker treatment resulted in lower sensitivity for the detection of CHD as well as smaller defect size [",
"      <a class=\"abstract\" href=\"UTD.htm?19/30/19946/abstract/34\">",
"       34",
"      </a>",
"      ]. Reduction in the extent and severity of perfusion abnormalities was also demonstrated with adenosine stress MPI in a study of patients with angiographically documented CHD [",
"      <a class=\"abstract\" href=\"UTD.htm?19/30/19946/abstract/44\">",
"       44",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Studies have also shown decreased sensitivity of stress echocardiography for the detection of ischemia in patients treated with beta blockers. The antiischemic effects of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"     propranolol",
"    </a>",
"    were demonstrated in 17 patients with known reversible defects on MPI who subsequently underwent simultaneous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/57/25494?source=see_link\">",
"     dobutamine",
"    </a>",
"    stress echocardiography and technetium-99m sestamibi MPI both before and after propranolol administration [",
"    <a class=\"abstract\" href=\"UTD.htm?19/30/19946/abstract/24\">",
"     24",
"    </a>",
"    ]. Heart rate, rate-pressure product, extent and severity of perfusion defects, and the number of abnormal echocardiographic segments were smaller after propranolol administration. Additionally, in 4 of these 17 patients, no abnormalities were detected by MPI or echocardiography following propranolol administration.",
"   </p>",
"   <p>",
"    In patients who fail to achieve 85 percent of their maximal predicted heart rate during",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/57/25494?source=see_link\">",
"     dobutamine",
"    </a>",
"    stress testing,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/23/11640?source=see_link\">",
"     atropine",
"    </a>",
"    has been used to augment the heart rate response. Administration of atropine improves the hemodynamic response to dobutamine in the setting of beta-blocker administration, decreases the number of inconclusive tests [",
"    <a class=\"abstract\" href=\"UTD.htm?19/30/19946/abstract/45\">",
"     45",
"    </a>",
"    ], and increases the recognition of ischemia [",
"    <a class=\"abstract\" href=\"UTD.htm?19/30/19946/abstract/46\">",
"     46",
"    </a>",
"    ]. However, the effect of beta blockers to reduce the severity of dobutamine-induced echocardiographic segmental wall motion abnormalities is not completely abolished with atropine administration [",
"    <a class=\"abstract\" href=\"UTD.htm?19/30/19946/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6561116\">",
"    <span class=\"h3\">",
"     Calcium channel blockers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Calcium channel blockers (CCB) have effective antianginal properties that are comparable to beta blockers [",
"    <a class=\"abstract\" href=\"UTD.htm?19/30/19946/abstract/48\">",
"     48",
"    </a>",
"    ]. However, they are different in their effect on the myocardium (contractility, heart rate) and peripheral vasculature. CCBs increase coronary blood flow and reduce myocardial oxygen demand, which results in improved diastolic and systolic function [",
"    <a class=\"abstract\" href=\"UTD.htm?19/30/19946/abstract/49,50\">",
"     49,50",
"    </a>",
"    ]. CCBs should be held for 48 hours prior to stress testing performed for the diagnosis of coronary heart disease (CHD). However, if exercise testing is performed to evaluate the effectiveness of therapy in patients with known CHD, then treatment should be continued.",
"   </p>",
"   <p>",
"    The effect of CCBs on exercise stress testing in patients with stable angina has been recognized since the 1970s, while the effect of CCB administration on vasodilator stress testing with imaging has been evaluated more recently.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Several small studies compared",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/5/12377?source=see_link\">",
"       nifedipine",
"      </a>",
"      to placebo in patients with chronic stable angina [",
"      <a class=\"abstract\" href=\"UTD.htm?19/30/19946/abstract/51-53\">",
"       51-53",
"      </a>",
"      ]. Patients who received nifedipine showed improvements in exercise duration and ST segment changes during exercise stress testing.",
"     </li>",
"     <li>",
"      In patients who underwent",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/57/25494?source=see_link\">",
"       dobutamine",
"      </a>",
"      -",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/23/11640?source=see_link\">",
"       atropine",
"      </a>",
"      stress echocardiography and had angiographically documented CHD, antianginal treatment with CCBs (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/5/12377?source=see_link\">",
"       nifedipine",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/16/12554?source=see_link\">",
"       diltiazem",
"      </a>",
"      ) decreased the sensitivity of the test for detection of ischemia from 100 to 88 percent, increased the requirement for atropine administration, and reduced the severity of echocardiographic findings [",
"      <a class=\"abstract\" href=\"UTD.htm?19/30/19946/abstract/54\">",
"       54",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In patients who underwent",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/25/41366?source=see_link\">",
"       dipyridamole",
"      </a>",
"      Thallium-201 MPI with and without antiischemic treatment (serving as their own controls), treatment with antianginal drugs (CCBs in 81 percent) resulted in reduced size and severity of MPI defects [",
"      <a class=\"abstract\" href=\"UTD.htm?19/30/19946/abstract/55\">",
"       55",
"      </a>",
"      ]. This study also demonstrated a reduction in sensitivity for the detection of single vessel CHD with the use of CCBs.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6561123\">",
"    <span class=\"h3\">",
"     Nitrates",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nitrates have been shown to dilate large epicardial vessels and smaller resistance vessels and also decrease diastolic filling pressure, thereby increasing coronary perfusion, decreasing coronary steal, and improving myocardial perfusion [",
"    <a class=\"abstract\" href=\"UTD.htm?19/30/19946/abstract/40,56-58\">",
"     40,56-58",
"    </a>",
"    ]. Nitrates may also prevent exercise-induced paradoxical coronary vasoconstriction [",
"    <a class=\"abstract\" href=\"UTD.htm?19/30/19946/abstract/10\">",
"     10",
"    </a>",
"    ]. Nitrates should be held for 48 hours prior to stress testing performed for the diagnosis of coronary heart disease (CHD). However, if exercise testing is performed to evaluate the effectiveness of therapy in patients with known CHD, treatment should be continued.",
"   </p>",
"   <p>",
"    Patients with known CHD undergoing exercise stress testing have been shown to have a delay in the onset and reduced magnitude of ST-segment depression with long-acting nitrate administration [",
"    <a class=\"abstract\" href=\"UTD.htm?19/30/19946/abstract/59\">",
"     59",
"    </a>",
"    ]. Nitrate therapy has been shown to reduce the extent and severity of ischemia assessed by exercise MPI despite having no significant effect on heart rate, blood pressure or double product (product of heart rate and systolic blood pressure) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/30/19946/abstract/60,61\">",
"     60,61",
"    </a>",
"    ]. Similar results have been observed in patients receiving nitrate therapy who have undergone",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/57/25494?source=see_link\">",
"     dobutamine",
"    </a>",
"    stress echocardiography and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/25/41366?source=see_link\">",
"     dipyridamole",
"    </a>",
"    stress Thallium-201 MPI [",
"    <a class=\"abstract\" href=\"UTD.htm?19/30/19946/abstract/54,55\">",
"     54,55",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6561130\">",
"    <span class=\"h3\">",
"     Angiotensin converting enzyme inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is a paucity of data regarding the effect of angiotensin converting enzyme inhibitors (ACEI) on stress testing. As such, there is no recommendation to stop ACEI prior to stress testing.",
"   </p>",
"   <p>",
"    In animal experiments, ACEI have been shown to increase coronary blood flow at rest and during myocardial ischemia as well as to reduce experimental infarct size [",
"    <a class=\"abstract\" href=\"UTD.htm?19/30/19946/abstract/62-64\">",
"     62-64",
"    </a>",
"    ]. These beneficial effects are assumed to be secondary to nitric oxide dependent vasodilation and accumulation of bradykinin. In human studies, ACEI have demonstrated the following beneficial effects:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Attenuation of acetylcholine-induced coronary vasoconstriction [",
"      <a class=\"abstract\" href=\"UTD.htm?19/30/19946/abstract/65\">",
"       65",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Improvement in endothelium-dependent brachial artery flow-mediated vasodilation [",
"      <a class=\"abstract\" href=\"UTD.htm?19/30/19946/abstract/66\">",
"       66",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Attenuation of sympathetic coronary vasoconstriction [",
"      <a class=\"abstract\" href=\"UTD.htm?19/30/19946/abstract/67\">",
"       67",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Optimization of myocardial metabolism [",
"      <a class=\"abstract\" href=\"UTD.htm?19/30/19946/abstract/68\">",
"       68",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    How quickly ACEI can bring about beneficial hemodynamic effects remains controversial. One study in humans measuring myocardial blood flow (using positron emission tomography) in symptomatic patients with coronary heart disease (CHD) demonstrated that the acute administration of quinaprilat 10mg IV increased myocardial blood flow to ischemic regions [",
"    <a class=\"abstract\" href=\"UTD.htm?19/30/19946/abstract/69\">",
"     69",
"    </a>",
"    ]. However, other studies of patients with known myocardial ischemia and CHD treated with ACEI have shown no reduction in ischemia at one and three weeks but did demonstrate increased time to ST segment depression (ie, ischemia) only after 12 weeks of treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?19/30/19946/abstract/70,71\">",
"     70,71",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Taken together, the studies are inconclusive for an effect on stress testing. The antiischemic effects of ACEI appear independent of their hemodynamic effects and seem to require long-term administration; thus, it remains unclear whether acute discontinuation will undo this favorable effect.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6561137\">",
"    <span class=\"h3\">",
"     Angiotensin receptor blockers",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are very little data regarding the effect of angiotensin receptor blockers (ARB) on stress testing. Additionally, it remains to be determined whether acute discontinuation will reverse any antiischemic effects. Therefore, currently there is no recommendation to withhold ARBs prior to stress testing.",
"   </p>",
"   <p>",
"    ARBs may improve endothelial function, as shown by reports of their favorable effect on brachial artery flow mediated vasodilation and improvement in coronary microvascular function and flow reserve [",
"    <a class=\"abstract\" href=\"UTD.htm?19/30/19946/abstract/72,73\">",
"     72,73",
"    </a>",
"    ]. One study of myocardial blood flow (using positron emission tomography and N-13 ammonia) in 16 patients with mild stable coronary heart disease revealed improved endothelial-dependent flow increase and adenosine induced vasodilation following",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/4/31815?source=see_link\">",
"     valsartan",
"    </a>",
"    administration [",
"    <a class=\"abstract\" href=\"UTD.htm?19/30/19946/abstract/74\">",
"     74",
"    </a>",
"    ]. Notably, the improvement in coronary flow preceded any reduction in blood pressure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H653164\">",
"    <span class=\"h2\">",
"     Methylxanthines",
"    </span>",
"    &nbsp;&mdash;&nbsp;Methylated xanthines (ie, methylxanthines) include caffeine,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/19/14648?source=see_link\">",
"     aminophylline",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/31/30200?source=see_link\">",
"     theophylline",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/28/13765?source=see_link\">",
"     pentoxifylline",
"    </a>",
"    , and theobromine. Methylxanthines should be discontinued prior to stress testing. We agree with the American Society of Nuclear Cardiology guidelines that recommend the discontinuation of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/25/41366?source=see_link\">",
"     dipyridamole",
"    </a>",
"    -containing medications for 48 hours, aminophylline for 24 hours, and caffeinated foods or beverages for 12 hours [",
"    <a class=\"abstract\" href=\"UTD.htm?19/30/19946/abstract/75\">",
"     75",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Caffeine has been considered a performance-enhancing aid, especially in healthy athletes [",
"    <a class=\"abstract\" href=\"UTD.htm?19/30/19946/abstract/76-80\">",
"     76-80",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/31/30200?source=see_link\">",
"     Theophylline",
"    </a>",
"    administration increases time to the onset of angina and the rate-pressure product achieved in patients with stable coronary heart disease (CHD) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/30/19946/abstract/81,82\">",
"     81,82",
"    </a>",
"    ]. Caffeine and theophylline, additionally, have adenosine antagonist properties which may interfere with vasodilator stress testing [",
"    <a class=\"abstract\" href=\"UTD.htm?19/30/19946/abstract/83\">",
"     83",
"    </a>",
"    ]. In a canine model,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/25/41366?source=see_link\">",
"     dipyridamole",
"    </a>",
"    -induced vasodilation was prevented by pretreatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/19/14648?source=see_link\">",
"     aminophylline",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?19/30/19946/abstract/84\">",
"     84",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The ability of caffeine to prevent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/25/41366?source=see_link\">",
"     dipyridamole",
"    </a>",
"    -induced down-sloping ST depression was initially reported as a case report in 1989 [",
"    <a class=\"abstract\" href=\"UTD.htm?19/30/19946/abstract/85\">",
"     85",
"    </a>",
"    ]. Subsequently, eight patients with known CHD and ischemia on dipyridamole stress testing with myocardial perfusion imaging (MPI) underwent repeat dipyridamole MPI after administration of intravenous caffeine",
"    <span class=\"nowrap\">",
"     (4mg/Kg)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?19/30/19946/abstract/86\">",
"     86",
"    </a>",
"    ]. The repeat MPI demonstrated false negative imaging results in six of the eight patients. In contrast, however, in a study of 16 patients,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/31/30200?source=see_link\">",
"     theophylline",
"    </a>",
"    administration resolved symptoms and ischemic ECG changes during adenosine MPI without any effect on the perfusion defect [",
"    <a class=\"abstract\" href=\"UTD.htm?19/30/19946/abstract/87\">",
"     87",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A subsequent study showed that consumption of a single eight ounce cup of caffeinated coffee one hour prior to adenosine stress MPI testing did not interfere with the presence and severity of perfusion defects [",
"    <a class=\"abstract\" href=\"UTD.htm?19/30/19946/abstract/88\">",
"     88",
"    </a>",
"    ]. Critics of this study point to the relatively small amount of induced ischemia in any patient (less than 10 percent of the overall MPI defect was ischemia). However, these results were duplicated in patients undergoing vasodilator stress MPI with the selective adenosine A2a receptor agonist",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/38/23140?source=see_link\">",
"     regadenoson",
"    </a>",
"    , in whom caffeine did not affect hyperemic flow or coronary flow reserve as measured by PET imaging [",
"    <a class=\"abstract\" href=\"UTD.htm?19/30/19946/abstract/89\">",
"     89",
"    </a>",
"    ]. Despite this finding, the regadenoson package insert recommends avoidance of methylxanthine containing products for at least 12 hours prior to testing. A prospective randomized trial addressing the effect of caffeine consumption on regadenoson stress MPI is ongoing [",
"    <a class=\"abstract\" href=\"UTD.htm?19/30/19946/abstract/90\">",
"     90",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6561144\">",
"    <span class=\"h2\">",
"     Other medications",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6561152\">",
"    <span class=\"h3\">",
"     Amiodarone",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     Amiodarone",
"    </a>",
"    was initially introduced as an antianginal agent prior to emerging as a potent antiarrhythmic agent. It causes a significant decrease in heart rate at rest and with exercise without a reduction in blood pressure or functional capacity [",
"    <a class=\"abstract\" href=\"UTD.htm?19/30/19946/abstract/91\">",
"     91",
"    </a>",
"    ]. Amiodarone inhibits pacing- or exercise-induced myocardial ischemia, presumably by reducing myocardial oxygen demand [",
"    <a class=\"abstract\" href=\"UTD.htm?19/30/19946/abstract/92,93\">",
"     92,93",
"    </a>",
"    ]. Amiodarone has a terminal elimination half-life of forty days, therefore it is not possible or practical to discontinue amiodarone prior to stress testing [",
"    <a class=\"abstract\" href=\"UTD.htm?19/30/19946/abstract/94\">",
"     94",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6561160\">",
"    <span class=\"h3\">",
"     L-arginine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nitric oxide is the end product of L-arginine metabolism generated by nitric oxide synthase. L-arginine administration is usually reserved for patients with refractory angina and may be continued during stress testing to gauge the effectiveness of medical therapy. In cases where over the counter L-arginine supplementation is being used in a patient with no prior history of coronary artery disease, L-arginine should be withheld prior to stress testing.",
"   </p>",
"   <p>",
"    L-arginine administration improves brachial artery flow-mediated dilation and augments coronary endothelium-dependent vasodilation in patients with microvascular angina [",
"    <a class=\"abstract\" href=\"UTD.htm?19/30/19946/abstract/95,96\">",
"     95,96",
"    </a>",
"    ]. In a double-blind, placebo-controlled study of 22 patients with stable angina, oral supplementation of",
"    <span class=\"nowrap\">",
"     6g/day",
"    </span>",
"    of L-arginine increased exercise duration, maximum workload, and time to onset of ST-segment depression [",
"    <a class=\"abstract\" href=\"UTD.htm?19/30/19946/abstract/97\">",
"     97",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6561167\">",
"    <span class=\"h3\">",
"     Statins",
"    </span>",
"    &nbsp;&mdash;&nbsp;Statins improve endothelium function through their effect on the bioavailability of nitric oxide [",
"    <a class=\"abstract\" href=\"UTD.htm?19/30/19946/abstract/98-101\">",
"     98-101",
"    </a>",
"    ]. This effect has been demonstrated in patients with coronary disease following six months of treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/20/42312?source=see_link\">",
"     lovastatin",
"    </a>",
"    , whereas shorter-term treatment for 12 days did not demonstrate any benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?19/30/19946/abstract/102\">",
"     102",
"    </a>",
"    ]. There are no current recommendations to withhold statins prior to stress testing.",
"   </p>",
"   <p>",
"    The effect of statin treatment on stress testing results has been evaluated in multiple small studies with different statins. In patients undergoing either exercise or vasodilator stress testing with myocardial perfusion imaging (MPI), there was improved perfusion in previously ischemic areas following treatment with a statin [",
"    <a class=\"abstract\" href=\"UTD.htm?19/30/19946/abstract/103-108\">",
"     103-108",
"    </a>",
"    ]. The improvement in MPI lagged behind the reduction in serum cholesterol. Reversal of the beneficial effect of statin therapy has also been demonstrated following a 60-day washout of the statin [",
"    <a class=\"abstract\" href=\"UTD.htm?19/30/19946/abstract/108\">",
"     108",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is clear from the above studies that statins have a beneficial effect and may reduce ischemia during stress testing. However, this benefit lags behind cholesterol lowering and is probably secondary to improvement in endothelial function. It is not clear whether withholding statins for four to five half-lives will entirely reverse this effect. A longer-term washout may be required, which may not be practical or safe. Thus, we do not withhold statins prior to stress testing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6561181\">",
"    <span class=\"h1\">",
"     MEDICATIONS ASSOCIATED WITH FALSE POSITIVE STRESS TEST RESULTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;While medications that can cause false negative stress test results may do so by masking ischemic changes on the electrocardiogram (ECG)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    imaging study, medications that can produce false positive stress test results do so by causing ischemic changes on the ECG, but not the imaging test. As such, for patients taking one or more of these medications, it may be reasonable to begin with an exercise ECG and order a repeat stress test with imaging for those patients whose exercise ECG is thought to be falsely positive. This approach avoids a need to hold medications for most patients.",
"   </p>",
"   <p>",
"    Medications that can cause false positive stress test results are discussed here. Our general approach to the decision to continue or discontinue any medications prior to stress testing is discussed in more detail below. (See",
"    <a class=\"local\" href=\"#H6561212\">",
"     'Summary'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6561190\">",
"    <span class=\"h2\">",
"     Digoxin",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     Digoxin",
"    </a>",
"    is probably the most widely known medication that can cause false positive ECG changes during exercise stress testing. There is no evidence that digoxin administration affects the imaging portion of stress testing. When performing a stress test to diagnose coronary heart disease, a concomitant imaging study is usually recommended. Alternatively, it may be reasonable to begin with an exercise stress test and order an additional stress test with imaging only if the exercise ECG is thought to be falsely positive.",
"   </p>",
"   <p>",
"    While the mechanism of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    induced ST segment depression is uncertain, digoxin can induce coronary vasoconstriction leading to decreased subendocardial perfusion and may also increase intracellular calcium concentrations [",
"    <a class=\"abstract\" href=\"UTD.htm?19/30/19946/abstract/40,109\">",
"     40,109",
"    </a>",
"    ]. However, the effect on ST depression may not be due to this vasoconstriction since the administration of nitrates has been shown to reverse the vasoconstriction but not the ECG changes [",
"    <a class=\"abstract\" href=\"UTD.htm?19/30/19946/abstract/109\">",
"     109",
"    </a>",
"    ]. The effect of digoxin on",
"    <span class=\"nowrap\">",
"     Na/K",
"    </span>",
"    ATPase may change the cellular membrane depolarization and result in ECG changes in the absence of ischemia.",
"   </p>",
"   <p>",
"    Ninety-eight men with a normal initial exercise ECG result underwent repeat exercise testing after taking",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    for 14 days [",
"    <a class=\"abstract\" href=\"UTD.htm?19/30/19946/abstract/110\">",
"     110",
"    </a>",
"    ]. Digoxin induced ST depression on the ECG, resulting in a positive test, was demonstrated in 25 percent. Subsequently, digoxin was withdrawn and the exercise test was repeated daily until all had a negative test. No test was positive 12 days after digoxin was withdrawn. In a separate study, treadmill stress testing had lower specificity in patients with chest pain receiving digoxin therapy compared to patients who did not take digoxin [",
"    <a class=\"abstract\" href=\"UTD.htm?19/30/19946/abstract/111\">",
"     111",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6561197\">",
"    <span class=\"h2\">",
"     Estrogens",
"    </span>",
"    &nbsp;&mdash;&nbsp;Estrogen, whose chemical structure has some similarities to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    , can cause false positive ECG changes during exercise stress testing. As with other medications that may cause false positive results, we begin with an exercise ECG and order a repeat stress test with imaging for those patients whose exercise ECG is thought to be falsely positive. If estrogen therapy were to be held, the optimum timing is not clear, although in one crossover study a six-week washout period was used [",
"    <a class=\"abstract\" href=\"UTD.htm?19/30/19946/abstract/112\">",
"     112",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is a paucity of data regarding the effects of estrogen on stress testing. In premenopausal women, the accuracy of the exercise ECG has been shown to vary with estrogen levels during the menstrual cycle [",
"    <a class=\"abstract\" href=\"UTD.htm?19/30/19946/abstract/113\">",
"     113",
"    </a>",
"    ]. One study demonstrated more ST segment depression in 90 percent of patients with established CAD after two weeks of treatment with estrogens [",
"    <a class=\"abstract\" href=\"UTD.htm?19/30/19946/abstract/114\">",
"     114",
"    </a>",
"    ]. In another study, normalization of an abnormal ST segment response to exercise was seen in women undergoing repeat exercise testing following an intervening oophorectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?19/30/19946/abstract/115\">",
"     115",
"    </a>",
"    ]. Another study of 404 women with normal myocardial perfusion imaging following exercise stress testing reported a significantly higher rate of ECG positivity in women taking hormone replacement therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?19/30/19946/abstract/116\">",
"     116",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6561205\">",
"    <span class=\"h2\">",
"     Diuretics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diuretics can be associated with ECG changes due to electrolyte imbalances. In patients with documented hypokalemia on diuretic therapy, exercise testing should be delayed, if possible, until adequate potassium repletion has occurred. If the stress test cannot be delayed, or if a false positive result from exercise testing is suspected in a patient taking a diuretic, the stress test should be performed with concomitant myocardial imaging.",
"   </p>",
"   <p>",
"    Diuretics are associated with false positive exercise stress testing secondary to ST-segment depression. This is related to diuretic-induced hypokalemia, especially if the serum potassium is below 3",
"    <span class=\"nowrap\">",
"     mEq/L",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?19/30/19946/abstract/117\">",
"     117",
"    </a>",
"    ]. The ECG changes are less prominent at potassium levels between 3 and 4",
"    <span class=\"nowrap\">",
"     mEq/L.",
"    </span>",
"    No false positive ECG changes with exercise stress testing were seen in one study of normokalemic, healthy young males taking diuretics [",
"    <a class=\"abstract\" href=\"UTD.htm?19/30/19946/abstract/118\">",
"     118",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6561212\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Medications and dietary ingestions have a substantial impact on the accuracy of stress testing for determining the presence of significant coronary heart disease (CHD). Medications that can cause false negative stress test results may do so by masking ischemic changes on the electrocardiogram (ECG)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    imaging study (eg, myocardial perfusion imaging, echocardiographic imaging). In contrast, medications that can produce false positive stress test results do so by causing ischemic changes on the ECG, but not the imaging test. (See",
"    <a class=\"local\" href=\"#H6561092\">",
"     'False stress test results'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The decision to continue or withhold any medications prior to stress testing is dependent upon a number of patient-specific factors, most important being the indication for stress testing. It may often be necessary to discuss the specific indications for stress testing with the ordering physician to ensure optimal testing conditions:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If the stress test is being performed primarily to diagnose the presence",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      extent of CHD, withholding medical therapy prior to testing should be highly considered in order to optimize the sensitivity and specificity of the test (",
"      <a class=\"graphic graphic_table graphicRef53174 \" href=\"UTD.htm?36/35/37436\">",
"       table 1",
"      </a>",
"      ). This is especially important if the fate of the particular medical therapy or the administration of further therapies is affected by stress testing.",
"     </li>",
"     <li>",
"      If exercise testing is performed to evaluate the effectiveness of therapy in patients with known CHD, then treatment should be continued.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    To obtain the maximal benefit of stopping any medication(s), the medication(s) should be withheld for four to five half-lives",
"    <strong>",
"     prior to",
"    </strong>",
"    the stress test being performed. This will reverse the hemodynamic impact of antianginal treatment with nitrates, beta blockers, and calcium channel blockers. This can be accomplished for most medications by withholding them for at least 48 hours prior to a diagnostic stress test. Before stopping any medications, physicians should consider the appropriate risks and benefits of interrupting therapy with a given medication. (See",
"    <a class=\"local\" href=\"#H653329\">",
"     'Medications associated with false negative stress test results'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H254516\">",
"    <span class=\"h2\">",
"     Our approach to antihypertensive medications",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beta blockers &ndash; Available data suggest that beta-blocker therapy affects exercise and pharmacologic stress testing including vasodilator and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/57/25494?source=see_link\">",
"       dobutamine",
"      </a>",
"      testing. Thus, beta blockers should be withheld for 48 hours prior to stress testing performed for the diagnosis of CHD. However, if testing is performed to evaluate the effectiveness of therapy in patients with known CHD, then treatment should be continued. (See",
"      <a class=\"local\" href=\"#H6561108\">",
"       'Beta blockers'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Calcium channel blockers &ndash; Available data suggest a significant impact of calcium channel blocker therapy on exercise and pharmacologic stress testing including vasodilator and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/57/25494?source=see_link\">",
"       dobutamine",
"      </a>",
"      testing. Thus, calcium channel blockers should be held for 48 hours prior to stress testing performed for the diagnosis of CHD. However, if testing is performed to evaluate the effectiveness of therapy in patients with known CHD, then treatment should be continued. (See",
"      <a class=\"local\" href=\"#H6561116\">",
"       'Calcium channel blockers'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Nitrates &ndash; Studies have demonstrated that long-acting nitrates affect exercise, vasodilator and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/57/25494?source=see_link\">",
"       dobutamine",
"      </a>",
"      stress testing by reducing ischemia. Thus, nitrates should be held for 48 hours prior to stress testing performed for the diagnosis of CHD. However, if testing is performed to evaluate the effectiveness of therapy in patients with known CHD, then treatment should be continued. (See",
"      <a class=\"local\" href=\"#H6561123\">",
"       'Nitrates'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Angiotensin converting enzyme inhibitors (ACEI) and angiotensin receptor blockers (ARBs) &ndash; Limited available data on stress testing in patients taking ACEI and ARBs are inconclusive regarding their effect on the results. Therefore, there is currently no recommendation to stop ACEI or ARBs prior to stress testing. (See",
"      <a class=\"local\" href=\"#H6561130\">",
"       'Angiotensin converting enzyme inhibitors'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H6561137\">",
"       'Angiotensin receptor blockers'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Multiple medications &ndash; If a patient is receiving multiple medical therapies for hypertension and withholding therapies is considered, it may be reasonable to continue diuretics (assuming serum potassium levels are normal), ACEI, and ARBs and to discontinue nitrates, beta blockers and calcium channel blockers.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H254523\">",
"    <span class=\"h2\">",
"     Our approach to methylxanthines",
"    </span>",
"    &nbsp;&mdash;&nbsp;As recommended by current guidelines, we ask patients to withhold caffeine 12 hours prior to vasodilator stress testing. If caffeine has been consumed, then a two day rest-stress protocol can be used by performing the resting imaging on day one and delaying the stress testing for at least 12 hours. (See",
"    <a class=\"local\" href=\"#H653164\">",
"     'Methylxanthines'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H254531\">",
"    <span class=\"h2\">",
"     Our approach to other medications",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"       Amiodarone",
"      </a>",
"      &ndash; Because of a half-life of approximately 40 days, it is not possible or practical to discontinue amiodarone prior to stress testing. (See",
"      <a class=\"local\" href=\"#H6561152\">",
"       'Amiodarone'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      L-arginine &ndash; Since L-arginine is usually prescribed only for patients with angina to other medical therapies, we continue it during stress testing to gauge the effectiveness of medical therapy. However, in cases where over the counter L-arginine supplementation is being used by a patient with no prior history of CHD, L-arginine should be withheld prior to stress testing. (See",
"      <a class=\"local\" href=\"#H6561160\">",
"       'L-arginine'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Statins &ndash; Studies have shown that statins may reduce ischemia during stress testing. However, this benefit lags behind cholesterol lowering and is probably secondary to improvement in endothelial function, and it is not clear whether withholding statins for four to five half-lives will entirely reverse this effect. Therefore, we do not withhold statins prior to stress testing. (See",
"      <a class=\"local\" href=\"#H6561167\">",
"       'Statins'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"       Digoxin",
"      </a>",
"      &ndash; Digoxin is probably the most widely known medication which can cause false positive ECG changes during exercise stress testing; however, there is no evidence that digoxin alters the imaging portion of stress testing. If the goal of stress testing is to diagnose CHD, then a concomitant imaging study is usually recommended. However, it may be reasonable to begin with an exercise stress test and order an additional stress test with imaging only if the exercise testing is positive. (See",
"      <a class=\"local\" href=\"#H6561190\">",
"       'Digoxin'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Estrogen therapy &ndash; Women taking hormone-replacement therapy containing estrogen have a significantly higher rate of false positive ECG findings on exercise treadmill testing. If the goal of stress testing is to diagnose CHD, then a concomitant imaging study is usually recommended. However, it may be reasonable to begin with an exercise stress test and order an additional stress test with imaging only if the exercise testing is positive. (See",
"      <a class=\"local\" href=\"#H6561197\">",
"       'Estrogens'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Diuretics &ndash; Diuretics can cause hypokalemia, which is known to cause false positive exercise stress testing results. In patients with documented hypokalemia, exercise testing should be delayed, if possible, until adequate potassium repletion has occurred. If the stress test cannot be delayed, or if a false positive result from exercise testing is suspected in a patient taking a diuretic, the stress test should be performed with concomitant myocardial imaging. (See",
"      <a class=\"local\" href=\"#H6561205\">",
"       'Diuretics'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Udelson JE, Dilsizian V, Bonow RO. Nuclear Cardiology. In: Braunwald's Heart Disease, 7th ed, Zipes DP, Libby P, Bonow RO, Braunwald E (Eds), Elsevier Saunders, Philadelphia 2005. p.287.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/30/19946/abstract/2\">",
"      Gielen S, Schuler G, Hambrecht R. Exercise training in coronary artery disease and coronary vasomotion. Circulation 2001; 103:E1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/30/19946/abstract/3\">",
"      Sambuceti G, Marzilli M, Marraccini P, et al. Coronary vasoconstriction during myocardial ischemia induced by rises in metabolic demand in patients with coronary artery disease. Circulation 1997; 95:2652.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/30/19946/abstract/4\">",
"      Bogaty P, Hackett D, Davies G, Maseri A. Vasoreactivity of the culprit lesion in unstable angina. Circulation 1994; 90:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/30/19946/abstract/5\">",
"      Frielingsdorf J, Seiler C, Kaufmann P, et al. Normalization of abnormal coronary vasomotion by calcium antagonists in patients with hypertension. Circulation 1996; 93:1380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/30/19946/abstract/6\">",
"      Chierchia S, Muiesan L, Davies A, et al. Role of the sympathetic nervous system in the pathogenesis of chronic stable angina. Implications for the mechanism of action of beta-blockers. Circulation 1990; 82:II71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/30/19946/abstract/7\">",
"      Bortone AS, Hess OM, Gaglione A, et al. Effect of intravenous propranolol on coronary vasomotion at rest and during dynamic exercise in patients with coronary artery disease. Circulation 1990; 81:1225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/30/19946/abstract/8\">",
"      Nabel EG, Selwyn AP, Ganz P. Paradoxical narrowing of atherosclerotic coronary arteries induced by increases in heart rate. Circulation 1990; 81:850.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/30/19946/abstract/9\">",
"      Bache RJ. Effects of calcium entry blockade on myocardial blood flow. Circulation 1989; 80:IV40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/30/19946/abstract/10\">",
"      Bortone AS, Hess OM, Eberli FR, et al. Abnormal coronary vasomotion during exercise in patients with normal coronary arteries and reduced coronary flow reserve. Circulation 1989; 79:516.",
"     </a>",
"    </li>",
"    <li>",
"     Zoghbi GJ, Iskandrian AE. Coronary Artery Disease Detection: Pharmacologic Stress. In: Clinical Nuclear Cardiology State of the Art and Future Directions, 3rd ed, Zaret BL, Beller GA (Eds), Elsevier Mosby, 2005. p.233.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/30/19946/abstract/12\">",
"      Gould KL. Noninvasive assessment of coronary stenoses by myocardial perfusion imaging during pharmacologic coronary vasodilatation. I. Physiologic basis and experimental validation. Am J Cardiol 1978; 41:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/30/19946/abstract/13\">",
"      Hauser AM, Gangadharan V, Ramos RG, et al. Sequence of mechanical, electrocardiographic and clinical effects of repeated coronary artery occlusion in human beings: echocardiographic observations during coronary angioplasty. J Am Coll Cardiol 1985; 5:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/30/19946/abstract/14\">",
"      Nesto RW, Kowalchuk GJ. The ischemic cascade: temporal sequence of hemodynamic, electrocardiographic and symptomatic expressions of ischemia. Am J Cardiol 1987; 59:23C.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/30/19946/abstract/15\">",
"      Diaz LA, Brunken RC, Blackstone EH, et al. Independent contribution of myocardial perfusion defects to exercise capacity and heart rate recovery for prediction of all-cause mortality in patients with known or suspected coronary heart disease. J Am Coll Cardiol 2001; 37:1558.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/30/19946/abstract/16\">",
"      Iskandrian AS, Chae SC, Heo J, et al. Independent and incremental prognostic value of exercise single-photon emission computed tomographic (SPECT) thallium imaging in coronary artery disease. J Am Coll Cardiol 1993; 22:665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/30/19946/abstract/17\">",
"      Snader CE, Marwick TH, Pashkow FJ, et al. Importance of estimated functional capacity as a predictor of all-cause mortality among patients referred for exercise thallium single-photon emission computed tomography: report of 3,400 patients from a single center. J Am Coll Cardiol 1997; 30:641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/30/19946/abstract/18\">",
"      Travin MI, Boucher CA, Newell JB, et al. Variables associated with a poor prognosis in patients with an ischemic thallium-201 exercise test. Am Heart J 1993; 125:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/30/19946/abstract/19\">",
"      Lauer MS, Mehta R, Pashkow FJ, et al. Association of chronotropic incompetence with echocardiographic ischemia and prognosis. J Am Coll Cardiol 1998; 32:1280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/30/19946/abstract/20\">",
"      Iskandrian AS, Heo J, Kong B, Lyons E. Effect of exercise level on the ability of thallium-201 tomographic imaging in detecting coronary artery disease: analysis of 461 patients. J Am Coll Cardiol 1989; 14:1477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/30/19946/abstract/21\">",
"      Heller GV, Ahmed I, Tilkemeier PL, et al. Influence of exercise intensity on the presence, distribution, and size of thallium-201 defects. Am Heart J 1992; 123:909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/30/19946/abstract/22\">",
"      Heller GV, Ahmed I, Tilkemeier PL, et al. Comparison of chest pain, electrocardiographic changes and thallium-201 scintigraphy during varying exercise intensities in men with stable angina pectoris. Am J Cardiol 1991; 68:569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/30/19946/abstract/23\">",
"      Steele P, Sklar J, Kirch D, et al. Thallium-201 myocardial imaging during maximal and submaximal exercise: comparison of submaximal exercise with propranolol. Am Heart J 1983; 106:1353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/30/19946/abstract/24\">",
"      Shehata AR, Gillam LD, Mascitelli VA, et al. Impact of acute propranolol administration on dobutamine-induced myocardial ischemia as evaluated by myocardial perfusion imaging and echocardiography. Am J Cardiol 1997; 80:268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/30/19946/abstract/25\">",
"      Navare SM, Katten D, Johnson LL, et al. Risk stratification with electrocardiographic-gated dobutamine stress technetium-99m sestamibi single-photon emission tomographic imaging: value of heart rate response and assessment of left ventricular function. J Am Coll Cardiol 2006; 47:781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/30/19946/abstract/26\">",
"      Sicari R, Cortigiani L, Bigi R, et al. Prognostic value of pharmacological stress echocardiography is affected by concomitant antiischemic therapy at the time of testing. Circulation 2004; 109:2428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/30/19946/abstract/27\">",
"      Brown KA, Rowen M. Impact of antianginal medications, peak heart rate and stress level on the prognostic value of a normal exercise myocardial perfusion imaging study. J Nucl Med 1993; 34:1467.",
"     </a>",
"    </li>",
"    <li>",
"     In: Imaging Guidelines for Nuclear Cardiology Procedures. A Report of The American Society of Nuclear Cardiology Quality Assurance Committee. DePuey EG (Ed), American Society of Nuclear Cardiology 2006.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/30/19946/abstract/29\">",
"      Moir TW. Subendocardial distribution of coronary blood flow and the effect of antianginal drugs. Circ Res 1972; 30:621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/30/19946/abstract/30\">",
"      Jackson G, Atkinson L, Oram S. Improvement of myocardial metabolism in coronary arterial disease by beta-blockade. Br Heart J 1977; 39:829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/30/19946/abstract/31\">",
"      Kern MJ, Ganz P, Horowitz JD, et al. Potentiation of coronary vasoconstriction by beta-adrenergic blockade in patients with coronary artery disease. Circulation 1983; 67:1178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/30/19946/abstract/32\">",
"      Vatner SF, Hintze TH. Mechanism of constriction of large coronary arteries by beta-adrenergic receptor blockade. Circ Res 1983; 53:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/30/19946/abstract/33\">",
"      Picano E. Dipyridamole-echocardiography test: historical background and physiologic basis. Eur Heart J 1989; 10:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/30/19946/abstract/34\">",
"      Taillefer R, Ahlberg AW, Masood Y, et al. Acute beta-blockade reduces the extent and severity of myocardial perfusion defects with dipyridamole Tc-99m sestamibi SPECT imaging. J Am Coll Cardiol 2003; 42:1475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/30/19946/abstract/35\">",
"      Vatner SF, Hintze TH, Macho P. Regulation of large coronary arteries by beta-adrenergic mechanisms in the conscious dog. Circ Res 1982; 51:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/30/19946/abstract/36\">",
"      Hodgson JM, Cohen MD, Szentpetery S, Thames MD. Effects of regional alpha- and beta-blockade on resting and hyperemic coronary blood flow in conscious, unstressed humans. Circulation 1989; 79:797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/30/19946/abstract/37\">",
"      Ferro A, Kaumann AJ, Brown MJ. Beta-adrenoceptor subtypes in human coronary artery: desensitization of beta 2-adrenergic vasorelaxation by chronic beta 1-adrenergic stimulation in vitro. J Cardiovasc Pharmacol 1995; 25:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/30/19946/abstract/38\">",
"      Egstrup K, Andersen PE Jr. Transient myocardial ischemia during nifedipine therapy in stable angina pectoris, and its relation to coronary collateral flow and comparison with metoprolol. Am J Cardiol 1993; 71:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/30/19946/abstract/39\">",
"      Jorgensen CR, Wang K, Wang Y, et al. Effect of propranolol on myocardial oxygen consumption and its hemodynamic correlates during upright exercise. Circulation 1973; 48:1173.",
"     </a>",
"    </li>",
"    <li>",
"     Ellestad M. Stress Testing Principles and Practice, Oxford University Press, Inc, New York 2003.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/30/19946/abstract/41\">",
"      Hockings B, Saltissi S, Croft DN, Webb-Peploe MM. Effect of beta adrenergic blockade on thallium-201 myocardial perfusion imaging. Br Heart J 1983; 49:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/30/19946/abstract/42\">",
"      Martin GJ, Henkin RE, Scanlon PJ. Beta blockers and the sensitivity of the thallium treadmill test. Chest 1987; 92:486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/30/19946/abstract/43\">",
"      Narahara KA, Thompson CJ, Hazen JF, et al. The effect of beta blockade on single photon emission computed tomographic (SPECT) thallium-201 images in patients with coronary disease. Am Heart J 1989; 117:1030.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/30/19946/abstract/44\">",
"      Reyes E, Stirrup J, Roughton M, et al. Attenuation of adenosine-induced myocardial perfusion heterogeneity by atenolol and other cardioselective beta-adrenoceptor blockers: a crossover myocardial perfusion imaging study. J Nucl Med 2010; 51:1036.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/30/19946/abstract/45\">",
"      Camarozano AC, Siqueira-Filho AG, Weitzel LH, et al. The effects of early administration of atropine during dobutamine stress echocardiography: advantages and disadvantages of early dobutamine-atropine protocol. Cardiovasc Ultrasound 2006; 4:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/30/19946/abstract/46\">",
"      Ling LH, Pellikka PA, Mahoney DW, et al. Atropine augmentation in dobutamine stress echocardiography: role and incremental value in a clinical practice setting. J Am Coll Cardiol 1996; 28:551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/30/19946/abstract/47\">",
"      Chen L, Ma L, de Prada VA, et al. Effects of beta-blockade and atropine on ischemic responses in left ventricular regions subtending coronary stenosis during dobutamine stress echocardiography. J Am Coll Cardiol 1996; 28:1866.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/30/19946/abstract/48\">",
"      Follath F. The role of calcium antagonists in the treatment of myocardial ischemia. Am Heart J 1989; 118:1093.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/30/19946/abstract/49\">",
"      Pepine CJ, Lambert CR. Effects of nicardipine on coronary blood flow. Am Heart J 1988; 116:248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/30/19946/abstract/50\">",
"      Chaffman M, Brogden RN. Diltiazem. A review of its pharmacological properties and therapeutic efficacy. Drugs 1985; 29:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/30/19946/abstract/51\">",
"      Moskowitz RM, Piccini PA, Nacarelli GV, Zelis R. Nifedipine therapy for stable angina pectoris: preliminary results of effects on angina frequency and treadmill exercise response. Am J Cardiol 1979; 44:811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/30/19946/abstract/52\">",
"      Fox KM, Deanfield J, Jonathan A, Selwyn A. The dose-response effects of nifedipine of ST-segment changes in exercise testing: preliminary studies. Cardiology 1981; 68 Suppl 2:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/30/19946/abstract/53\">",
"      Rice KR, Gervino E, Jarisch WR, Stone PH. Effects of nifedipine on myocardial perfusion during exercise in chronic stable angina pectoris. Am J Cardiol 1990; 65:1097.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/30/19946/abstract/54\">",
"      Dodi C, Pingitore A, Sicari R, et al. Effects of antianginal therapy with a calcium antagonist and nitrates on dobutamine-atropine stress echocardiography. Comparison with exercise electrocardiography. Eur Heart J 1997; 18:242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/30/19946/abstract/55\">",
"      Sharir T, Rabinowitz B, Livschitz S, et al. Underestimation of extent and severity of coronary artery disease by dipyridamole stress thallium-201 single-photon emission computed tomographic myocardial perfusion imaging in patients taking antianginal drugs. J Am Coll Cardiol 1998; 31:1540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/30/19946/abstract/56\">",
"      Hintze TH, Vatner SF. Comparison of effects of nifedipine and nitroglycerin on large and small coronary arteries and cardiac function in conscious dogs. Circ Res 1983; 52:I139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/30/19946/abstract/57\">",
"      Nagao T, Murata S, Sato M. Effects of diltiazem (CRD-401) on developed coronary collaterals in the dog. Jpn J Pharmacol 1975; 25:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/30/19946/abstract/58\">",
"      Fallen EL, Nahmias C, Scheffel A, et al. Redistribution of myocardial blood flow with topical nitroglycerin in patients with coronary artery disease. Circulation 1995; 91:1381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/30/19946/abstract/59\">",
"      Wayne VS, Fagan ET, McConachy DL. The Effects of Isosorbide Dinitrate on the Exercise Test. J Cardiopulm Rehabil Prev 1987; 7:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/30/19946/abstract/60\">",
"      Mahmarian JJ, Fenimore NL, Marks GF, et al. Transdermal nitroglycerin patch therapy reduces the extent of exercise-induced myocardial ischemia: results of a double-blind, placebo-controlled trial using quantitative thallium-201 tomography. J Am Coll Cardiol 1994; 24:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/30/19946/abstract/61\">",
"      Tono I, Satoh S, Kanaya T, et al. Alterations in myocardial perfusion during exercise after isosorbide dinitrate infusion in patients with coronary disease: assessment by thallium-201 scintigraphy. Am Heart J 1986; 111:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/30/19946/abstract/62\">",
"      Sudhir K, Chou TM, Hutchison SJ, Chatterjee K. Coronary vasodilation induced by angiotensin-converting enzyme inhibition in vivo: differential contribution of nitric oxide and bradykinin in conductance and resistance arteries. Circulation 1996; 93:1734.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/30/19946/abstract/63\">",
"      Kitakaze M, Minamino T, Node K, et al. Beneficial effects of inhibition of angiotensin-converting enzyme on ischemic myocardium during coronary hypoperfusion in dogs. Circulation 1995; 92:950.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/30/19946/abstract/64\">",
"      Ertl G, Kloner RA, Alexander RW, Braunwald E. Limitation of experimental infarct size by an angiotensin-converting enzyme inhibitor. Circulation 1982; 65:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/30/19946/abstract/65\">",
"      Mancini GB, Henry GC, Macaya C, et al. Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND (Trial on Reversing ENdothelial Dysfunction) Study. Circulation 1996; 94:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/30/19946/abstract/66\">",
"      Anderson TJ, Elstein E, Haber H, Charbonneau F. Comparative study of ACE-inhibition, angiotensin II antagonism, and calcium channel blockade on flow-mediated vasodilation in patients with coronary disease (BANFF study). J Am Coll Cardiol 2000; 35:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/30/19946/abstract/67\">",
"      Perondi R, Saino A, Tio RA, et al. ACE inhibition attenuates sympathetic coronary vasoconstriction in patients with coronary artery disease. Circulation 1992; 85:2004.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/30/19946/abstract/68\">",
"      Kiowski W, Zuber M, Elsasser S, et al. Coronary vasodilatation and improved myocardial lactate metabolism after angiotensin converting enzyme inhibition with cilazapril in patients with congestive heart failure. Am Heart J 1991; 122:1382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/30/19946/abstract/69\">",
"      Schneider CA, Voth E, Moka D, et al. Improvement of myocardial blood flow to ischemic regions by angiotensin-converting enzyme inhibition with quinaprilat IV: a study using [15O] water dobutamine stress positron emission tomography. J Am Coll Cardiol 1999; 34:1005.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/30/19946/abstract/70\">",
"      van den Heuvel AF, Dunselman PH, Kingma T, et al. Reduction of exercise-induced myocardial ischemia during add-on treatment with the angiotensin-converting enzyme inhibitor enalapril in patients with normal left ventricular function and optimal beta blockade. J Am Coll Cardiol 2001; 37:470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/30/19946/abstract/71\">",
"      Longobardi G, Ferrara N, Leosco D, et al. Failure of protective effect of captopril and enalapril on exercise and dipyridamole-induced myocardial ischemia. Am J Cardiol 1995; 76:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/30/19946/abstract/72\">",
"      Benndorf RA, Appel D, Maas R, et al. Telmisartan improves endothelial function in patients with essential hypertension. J Cardiovasc Pharmacol 2007; 50:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/30/19946/abstract/73\">",
"      Tom&aacute;s JP, Moya JL, Barrios V, et al. Effect of candesartan on coronary flow reserve in patients with systemic hypertension. J Hypertens 2006; 24:2109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/30/19946/abstract/74\">",
"      Higuchi T, Abletshauser C, Nekolla SG, et al. Effect of the angiotensin receptor blocker Valsartan on coronary microvascular flow reserve in moderately hypertensive patients with stable coronary artery disease. Microcirculation 2007; 14:805.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/30/19946/abstract/75\">",
"      Henzlova MJ, Cerqueira MD, Mahmarian JJ, et al. Stress protocols and tracers. J Nucl Cardiol 2006; 13:e80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/30/19946/abstract/76\">",
"      Costill DL, Dalsky GP, Fink WJ. Effects of caffeine ingestion on metabolism and exercise performance. Med Sci Sports 1978; 10:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/30/19946/abstract/77\">",
"      Ivy JL, Costill DL, Fink WJ, Lower RW. Influence of caffeine and carbohydrate feedings on endurance performance. Med Sci Sports 1979; 11:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/30/19946/abstract/78\">",
"      Bruce CR, Anderson ME, Fraser SF, et al. Enhancement of 2000-m rowing performance after caffeine ingestion. Med Sci Sports Exerc 2000; 32:1958.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/30/19946/abstract/79\">",
"      Schneiker KT, Bishop D, Dawson B, Hackett LP. Effects of caffeine on prolonged intermittent-sprint ability in team-sport athletes. Med Sci Sports Exerc 2006; 38:578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/30/19946/abstract/80\">",
"      Am J Clin Nutr 1980; 33:989.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/30/19946/abstract/81\">",
"      Barbour MM, Garber CE, Ahlberg AW, et al. Effects of intravenous theophylline on exercise-induced myocardial ischemia: II. A concentration-dependent phenomenon. J Am Coll Cardiol 1993; 22:1155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/30/19946/abstract/82\">",
"      Heller GV, Barbour MM, Dweik RB, et al. Effects of intravenous theophylline on exercise-induced myocardial ischemia. I. Impact on the ischemic threshold. J Am Coll Cardiol 1993; 21:1075.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/30/19946/abstract/83\">",
"      Smits P, Boekema P, De Abreu R, et al. Evidence for an antagonism between caffeine and adenosine in the human cardiovascular system. J Cardiovasc Pharmacol 1987; 10:136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/30/19946/abstract/84\">",
"      Granato JE, Watson DD, Belardinelli L, et al. Effects of dipyridamole and aminophylline on hemodynamics, regional myocardial blood flow and thallium-201 washout in the setting of a critical coronary stenosis. J Am Coll Cardiol 1990; 16:1760.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/30/19946/abstract/85\">",
"      Smits P, Aengevaeren WR, Corstens FH, Thien T. Caffeine reduces dipyridamole-induced myocardial ischemia. J Nucl Med 1989; 30:1723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/30/19946/abstract/86\">",
"      Smits P, Corstens FH, Aengevaeren WR, et al. False-negative dipyridamole-thallium-201 myocardial imaging after caffeine infusion. J Nucl Med 1991; 32:1538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/30/19946/abstract/87\">",
"      Heller GV, Dweik RB, Barbour MM, et al. Pretreatment with theophylline does not affect adenosine-induced thallium-201 myocardial imaging. Am Heart J 1993; 126:1077.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/30/19946/abstract/88\">",
"      Zoghbi GJ, Htay T, Aqel R, et al. Effect of caffeine on ischemia detection by adenosine single-photon emission computed tomography perfusion imaging. J Am Coll Cardiol 2006; 47:2296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/30/19946/abstract/89\">",
"      Gaemperli O, Schepis T, Koepfli P, et al. Interaction of caffeine with regadenoson-induced hyperemic myocardial blood flow as measured by positron emission tomography: a randomized, double-blind, placebo-controlled crossover trial. J Am Coll Cardiol 2008; 51:328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/30/19946/abstract/90\">",
"      Tejani FH, Thompson RC, Iskandrian AE, et al. Effect of caffeine on SPECT myocardial perfusion imaging during regadenoson pharmacologic stress: rationale and design of a prospective, randomized, multicenter study. J Nucl Cardiol 2011; 18:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/30/19946/abstract/91\">",
"      Rod JL, Shenasa M. Functional significance of chronotropic response during chronic amiodarone therapy. Cardiology 1984; 71:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/30/19946/abstract/92\">",
"      Remme WJ, Van Hoogenhuyze DC, Krauss XH, et al. Acute hemodynamic and antiischemic effects of intravenous amiodarone. Am J Cardiol 1985; 55:639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/30/19946/abstract/93\">",
"      Pfisterer M, Burkart F. Effect of short and long term administration of amiodarone on ischaemia-induced left ventricular dysfunction. Implications for combined antianginal drug therapy. Drugs 1985; 29 Suppl 3:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/30/19946/abstract/94\">",
"      Holt DW, Tucker GT, Jackson PR, Storey GC. Amiodarone pharmacokinetics. Am Heart J 1983; 106:840.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/30/19946/abstract/95\">",
"      Thorne S, Mullen MJ, Clarkson P, et al. Early endothelial dysfunction in adults at risk from atherosclerosis: different responses to L-arginine. J Am Coll Cardiol 1998; 32:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/30/19946/abstract/96\">",
"      Egashira K, Hirooka Y, Kuga T, et al. Effects of L-arginine supplementation on endothelium-dependent coronary vasodilation in patients with angina pectoris and normal coronary arteriograms. Circulation 1996; 94:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/30/19946/abstract/97\">",
"      Ceremuzyski L, Chamiec T, Herbaczyska-Cedro K. Effect of supplemental oral L-arginine on exercise capacity in patients with stable angina pectoris. Am J Cardiol 1997; 80:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/30/19946/abstract/98\">",
"      Egashira K, Hirooka Y, Kai H, et al. Reduction in serum cholesterol with pravastatin improves endothelium-dependent coronary vasomotion in patients with hypercholesterolemia. Circulation 1994; 89:2519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/30/19946/abstract/99\">",
"      Boodhwani M, Nakai Y, Voisine P, et al. High-dose atorvastatin improves hypercholesterolemic coronary endothelial dysfunction without improving the angiogenic response. Circulation 2006; 114:I402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/30/19946/abstract/100\">",
"      Jones SP, Gibson MF, Rimmer DM 3rd, et al. Direct vascular and cardioprotective effects of rosuvastatin, a new HMG-CoA reductase inhibitor. J Am Coll Cardiol 2002; 40:1172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/30/19946/abstract/101\">",
"      Laufs U, La Fata V, Plutzky J, Liao JK. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation 1998; 97:1129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/30/19946/abstract/102\">",
"      Treasure CB, Klein JL, Weintraub WS, et al. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N Engl J Med 1995; 332:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/30/19946/abstract/103\">",
"      Eichst&auml;dt HW, Esk&ouml;tter H, Hoffman I, et al. Improvement of myocardial perfusion by short-term fluvastatin therapy in coronary artery disease. Am J Cardiol 1995; 76:122A.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/30/19946/abstract/104\">",
"      Eichst&auml;dt HW, Abletshauser CB, St&ouml;rk T, Weidinger G. Beneficial effects of fluvastatin on myocardial blood flow at two time-points in hypercholesterolemic patients with coronary artery disease. J Cardiovasc Pharmacol 2000; 35:735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/30/19946/abstract/105\">",
"      Manfrini O, Pizzi C, Morgagni G, et al. Effect of pravastatin on myocardial perfusion after percutaneous transluminal coronary angioplasty. Am J Cardiol 2004; 93:1391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/30/19946/abstract/106\">",
"      Hosokawa R, Nohara R, Linxue L, et al. Effect of long-term cholesterol-lowering treatment with HMG-CoA reductase inhibitor (simvastatin) on myocardial perfusion evaluated by thallium-201 single photon emission computed tomography. Jpn Circ J 2000; 64:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/30/19946/abstract/107\">",
"      Schwartz RG, Pearson TA, Kalaria VG, et al. Prospective serial evaluation of myocardial perfusion and lipids during the first six months of pravastatin therapy: coronary artery disease regression single photon emission computed tomography monitoring trial. J Am Coll Cardiol 2003; 42:600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/30/19946/abstract/108\">",
"      Gould KL, Martucci JP, Goldberg DI, et al. Short-term cholesterol lowering decreases size and severity of perfusion abnormalities by positron emission tomography after dipyridamole in patients with coronary artery disease. A potential noninvasive marker of healing coronary endothelium. Circulation 1994; 89:1530.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/30/19946/abstract/109\">",
"      Indolfi C, Piscione F, Russolillo E, et al. Digoxin-induced vasoconstriction of normal and atherosclerotic epicardial coronary arteries. Am J Cardiol 1991; 68:1274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/30/19946/abstract/110\">",
"      Sketch MH, Mooss AN, Butler ML, et al. Digoxin-induced positive exercise tests: their clinical and prognostic significance. Am J Cardiol 1981; 48:655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/30/19946/abstract/111\">",
"      Nasrallah AT, Garcia E, Benry J, Hall RJ. Treadmill exercise testing in the presence of digitals therapy or nonspecific ST-T changes: correlation with coronary angiography. Cathet Cardiovasc Diagn 1975; 1:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/30/19946/abstract/112\">",
"      Rovang KS, Arouni AJ, Mohiuddin SM, et al. Effect of estrogen on exercise electrocardiograms in healthy postmenopausal women. Am J Cardiol 2000; 86:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/30/19946/abstract/113\">",
"      Clark PI, Glasser SP, Lyman GH, et al. Relation of results of exercise stress tests in young women to phases of the menstrual cycle. Am J Cardiol 1988; 61:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/30/19946/abstract/114\">",
"      Jaffe MD. Effect of oestrogens on postexercise electrocardiogram. Br Heart J 1976; 38:1299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/30/19946/abstract/115\">",
"      Marmor A, Zeira M, Zohar S. Effects of bilateral hystero-salpingo-oophorectomy on exercise-induced ST-segment abnormalities in young women. Am J Cardiol 1993; 71:1118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/30/19946/abstract/116\">",
"      Henzlova MJ, Croft LB, Diamond JA. Effect of hormone replacement therapy on the electrocardiographic response to exercise. J Nucl Cardiol 2002; 9:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/30/19946/abstract/117\">",
"      Surawicz B. Relationship between electrocardiogram and electrolytes. Am Heart J 1967; 73:814.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/30/19946/abstract/118\">",
"      Pascual EE, Cintron GB, Valdez MG, Clark PI. Effect of diuretic therapy on the electrocardiographic response to exercise. Clin Cardiol 1992; 15:93.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5305 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.247-6C4A8C19E1-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_30_19946=[""].join("\n");
var outline_f19_30_19946=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H6561212\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6560911\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6561092\">",
"      FALSE STRESS TEST RESULTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H653040\">",
"      Mechanisms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H653047\">",
"      Effect of medications on prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H653329\">",
"      MEDICATIONS ASSOCIATED WITH FALSE NEGATIVE STRESS TEST RESULTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6561099\">",
"      Medications with antihypertensive and anti-ischemic properties",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6561108\">",
"      - Beta blockers",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6561116\">",
"      - Calcium channel blockers",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6561123\">",
"      - Nitrates",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6561130\">",
"      - Angiotensin converting enzyme inhibitors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6561137\">",
"      - Angiotensin receptor blockers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H653164\">",
"      Methylxanthines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6561144\">",
"      Other medications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6561152\">",
"      - Amiodarone",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6561160\">",
"      - L-arginine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6561167\">",
"      - Statins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6561181\">",
"      MEDICATIONS ASSOCIATED WITH FALSE POSITIVE STRESS TEST RESULTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6561190\">",
"      Digoxin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6561197\">",
"      Estrogens",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6561205\">",
"      Diuretics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6561212\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H254516\">",
"      Our approach to antihypertensive medications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H254523\">",
"      Our approach to methylxanthines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H254531\">",
"      Our approach to other medications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/5305\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/5305|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?32/60/33741\" title=\"figure 1\">",
"      Time course cardiac ischemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?16/29/16862\" title=\"figure 2\">",
"      Effect of heart rate on exercise MPI defect size",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/5305|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?36/35/37436\" title=\"table 1\">",
"      Impact of medications and methylxanthines on stress testing",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/9/42134?source=related_link\">",
"      Dobutamine stress radionuclide myocardial perfusion imaging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/28/29129?source=related_link\">",
"      Exercise ECG testing to determine prognosis of coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/24/24970?source=related_link\">",
"      Exercise radionuclide myocardial perfusion imaging in the diagnosis and prognosis of coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/6/35945?source=related_link\">",
"      Performance of exercise ECG testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/31/35319?source=related_link\">",
"      Protocols for stress echocardiography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/30/44520?source=related_link\">",
"      Selecting the optimal cardiac stress test",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/52/27466?source=related_link\">",
"      Stress echocardiography in the diagnosis and prognosis of coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/5/41048?source=related_link\">",
"      Stress echocardiography: Indications, imaging techniques and safety",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/57/26521?source=related_link\">",
"      Stress testing for the diagnosis of coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/58/2986?source=related_link\">",
"      Stress testing to determine prognosis and management of patients with known or suspected coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/5/10330?source=related_link\">",
"      Vasodilator stress radionuclide myocardial perfusion imaging: Testing methodologies and safety",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_30_19947="Pediatric appendicitis score";
var content_f19_30_19947=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F62136&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F62136&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    The Pediatric Appendicitis Score",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Item",
"      </td>",
"      <td class=\"subtitle1\">",
"       Score (point)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Anorexia",
"      </td>",
"      <td>",
"       1",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Nausea or vomiting",
"      </td>",
"      <td>",
"       1",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Migration of pain",
"      </td>",
"      <td>",
"       1",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Fever &gt;38&deg;C (100.5&deg;F)",
"      </td>",
"      <td>",
"       1",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Pain with cough, percussion or hopping",
"      </td>",
"      <td>",
"       2",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Right lower quadrant tenderness",
"      </td>",
"      <td>",
"       2",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       White blood cell count &gt;10,000 cells/microL",
"      </td>",
"      <td>",
"       1",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Neutrophils plus band forms &gt;7500 cells/microL",
"      </td>",
"      <td>",
"       1",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <strong>",
"        Total",
"       </strong>",
"      </td>",
"      <td>",
"       <strong>",
"        10 points",
"       </strong>",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     C: Centigrade; F: Fahrenheit.",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Samuel, M. Pediatric appendicitis score. J Pediatr Surg 2002; 37:877.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_30_19947=[""].join("\n");
var outline_f19_30_19947=null;
var title_f19_30_19948="Cytogenetics in AML subsets";
var content_f19_30_19948=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F51764&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F51764&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Correlation between morphologic subtypes of acute myeloid leukemia (AML) and recurring chromosomal translocations",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        FAB subtype",
"       </td>",
"       <td class=\"subtitle1\">",
"        Cytogenetic aberration",
"       </td>",
"       <td class=\"subtitle1\">",
"        Molecular aberration",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        M0, M1, and ALL",
"       </td>",
"       <td>",
"        t(10;11)",
"       </td>",
"       <td>",
"        CALM-AF10",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        M1",
"       </td>",
"       <td>",
"        Trisomy (11)",
"       </td>",
"       <td>",
"        Partial duplication of MLL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        M2",
"       </td>",
"       <td>",
"        t(8;21)",
"       </td>",
"       <td>",
"        AML1-ETO",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        M3",
"       </td>",
"       <td>",
"        t(15;17), t(11;17), t(5;17)",
"       </td>",
"       <td>",
"        PML-RAR &alpha;,",
"PLZF-RAR &alpha;, NPM-RAR &alpha;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        M4E0",
"       </td>",
"       <td>",
"        inv(16)",
"       </td>",
"       <td>",
"        CBF&beta;-MYH11",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        M4 with erythrophagocytosis",
"       </td>",
"       <td>",
"        t(8;16)",
"       </td>",
"       <td>",
"        MOZ-CBP",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        M5",
"       </td>",
"       <td>",
"        11q23 translocations",
"       </td>",
"       <td>",
"        MLL fused to one of its partner genes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        M6",
"       </td>",
"       <td>",
"        t(3;5)",
"       </td>",
"       <td>",
"        NPM-MLF1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        M1, M2, M4 and MDS",
"       </td>",
"       <td>",
"        t(6;9), t(9;9)",
"       </td>",
"       <td>",
"        DEK-CAN, SET-CAN",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Multiple FAB subtypes, MDS, and CML",
"       </td>",
"       <td>",
"        t(16;21)",
"       </td>",
"       <td>",
"        TLS/FUS-ERG",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        M2, M4, CML",
"       </td>",
"       <td>",
"        t(7;11)",
"       </td>",
"       <td>",
"        NUP98-HOXA9",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        MDS, de novo/t-AML",
"       </td>",
"       <td>",
"        inv(11)",
"       </td>",
"       <td>",
"        NUP98-DDX10",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        MDS, t-AML, CML",
"       </td>",
"       <td>",
"        t(3,21)",
"       </td>",
"       <td>",
"        AML1-EAP/MDS1/EVI1",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Stock, W, Thirman, MJ. Patholoogy of acute myeloid leukemia. In: Hematology: Basic principles and practice, 3rd edition, Hoffman, R, benz, EJ Jr, Shattil, SJ, et al, Churchville Livingstone, New York 2000. table 52-1, p. 980.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_30_19948=[""].join("\n");
var outline_f19_30_19948=null;
var title_f19_30_19949="Modes of mechanical ventilation";
var content_f19_30_19949=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F77391&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F77391&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Modes of mechanical ventilation",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"8\" width=\"12%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Mode",
"       </td>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Breath strategy",
"        <br/>",
"        (target)",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Trigger",
"       </td>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Cycle",
"        <br/>",
"        (breath termination)",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"3\">",
"        Types of breaths",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Ventilator",
"       </td>",
"       <td class=\"subtitle2\">",
"        Patient",
"       </td>",
"       <td class=\"subtitle2\">",
"        Mandatory",
"       </td>",
"       <td class=\"subtitle2\">",
"        Assisted",
"       </td>",
"       <td class=\"subtitle2\">",
"        Spontaneous",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        CMV",
"       </td>",
"       <td>",
"        Volume-limited",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        Volume",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        No",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pressure-limited",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        Time",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        No",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        AC",
"       </td>",
"       <td>",
"        Volume-limited",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        Volume",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        No",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pressure-limited",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        Time",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        No",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        IMV",
"       </td>",
"       <td>",
"        Volume-limited",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        Volume",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        Yes*",
"       </td>",
"       <td>",
"        Yes*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pressure-limited (also called APRV)",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        Time",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        Yes*",
"       </td>",
"       <td>",
"        Yes*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        PSV",
"       </td>",
"       <td>",
"        Pressure-limited",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        Flow, pressure, or time",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        No",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        CPAP",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        Flow",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        No",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tube compensation",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        Flow",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"8\">",
"        Types of breaths:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"8\">",
"        Mandatory: Breaths are initiated by the ventilator and the ventilator performs the work of inspiration during those breaths",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"8\">",
"        Assisted: Breaths are initiated by the patient, but the ventilator performs at least some of the work of inspiration for those patient initiated breaths",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"8\">",
"        Spontaneous: Breaths are initiated by the patient and the patient performs the entire work of inspiration for those patient initiated breaths",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     CMV: controlled mechanical ventilation; AC: assist control; IMV: intermittent mandatory ventilation; PSV: pressure support ventilation; CPAP: continuous positive airway pressure; APRV: airway pressure release ventilation; BPAP: bilevel positive airway pressure.",
"     <br/>",
"     * Note that there is overlap between the types of breaths that can be generated during various modes of ventilation. This overlap is dependent on the ventilator settings. As examples, APRV and IMV are capable of assisted breaths (pressure support added) or spontaneous breaths (no pressure support added). Both assisted and spontaneous breaths depend on the patient's ability to trigger the ventilator.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_30_19949=[""].join("\n");
var outline_f19_30_19949=null;
var title_f19_30_19950="IgG structure";
var content_f19_30_19950=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F71452&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F71452&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Immunoglobulin G structure",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 335px; height: 229px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The four main chains comprising each IgG molecule are shown, each immunoglobulin domain is represented as a circle and contains an internal disulfide bond (not shown). There are usually multiple disulfide bonds linking the two H chains in the hinge region, and also a disulfide linking the H and L chains.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_30_19950=[""].join("\n");
var outline_f19_30_19950=null;
var title_f19_30_19951="Infant hip imaging overview";
var content_f19_30_19951=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F53048%7EPEDS%2F64344%7EPEDS%2F72030&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=10\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F53048%7EPEDS%2F64344%7EPEDS%2F72030&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=10\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Use of various imaging modalities in the evaluation and management of selected hip problems in infants",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Plain radiograph",
"       </td>",
"       <td class=\"subtitle1\">",
"        Ultrasonography",
"       </td>",
"       <td class=\"subtitle1\">",
"        Computed tomography",
"       </td>",
"       <td class=\"subtitle1\">",
"        Magnetic resonance imaging",
"       </td>",
"       <td class=\"subtitle1\">",
"        Conventional arthrography",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"3\">",
"        <strong>",
"         Developmental dysplasia of the hip",
"        </strong>",
"       </td>",
"       <td rowspan=\"3\">",
"        <p>",
"         Diagnosis in children &gt;4 months",
"        </p>",
"        Findings:",
"        <br/>",
"        <ul>",
"         <li>",
"          Superolateral displacement of the femur",
"         </li>",
"        </ul>",
"       </td>",
"       <td>",
"        <p>",
"         Evaluation of infants &lt;4 months who are high risk or have equivocal clinical findings",
"        </p>",
"        Findings:",
"        <br/>",
"        <ul>",
"         <li>",
"          Superolateral displacement of the femoral head",
"         </li>",
"         <li>",
"          Alpha angle less than 60 degrees",
"         </li>",
"         <li>",
"          Instability of hip (able to move in and out of socket)",
"         </li>",
"        </ul>",
"       </td>",
"       <td>",
"        Preoperative assessment",
"       </td>",
"       <td>",
"        Preoperative assessment",
"       </td>",
"       <td>",
"        Intraoperative confirmation of femoral head position",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Monitoring treatment",
"       </td>",
"       <td>",
"        Postoperative follow-up",
"       </td>",
"       <td>",
"        Evaluation of postsurgical reduction",
"       </td>",
"       <td>",
"        Intraoperative visualization of structures interfering with reduction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Follow-up of patients treated with abduction splints (eg, Pavlik harness)",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Monitoring for long-term sequelae",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <strong>",
"         Proximal femoral focal deficiency",
"        </strong>",
"       </td>",
"       <td>",
"        <p>",
"         Diagnosis",
"        </p>",
"        Findings:",
"        <br/>",
"        <ul>",
"         <li>",
"          Short femur with dysmorphic or absent head and neck",
"         </li>",
"         <li>",
"          Delayed appearance or non-appearance of the femoral capital ossification center",
"         </li>",
"        </ul>",
"       </td>",
"       <td>",
"        NA",
"       </td>",
"       <td>",
"        NA",
"       </td>",
"       <td>",
"        <p>",
"         Early diagnosis, extent of involvement",
"        </p>",
"        Findings:",
"        <br/>",
"        <ul>",
"         <li>",
"          Incompletely ossified femoral head",
"         </li>",
"         <li>",
"          Demonstrates cartilage structure of acetabulum and upper femur",
"         </li>",
"        </ul>",
"       </td>",
"       <td>",
"        NA",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     NA: not applicable.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Overview of the use of various imaging modalities in the evaluation and management of common hip problems in young children (toddlers to 10 years)*",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Plain radiograph",
"       </td>",
"       <td class=\"subtitle1\">",
"        Ultrasonography",
"       </td>",
"       <td class=\"subtitle1\">",
"        Computed tomography",
"       </td>",
"       <td class=\"subtitle1\">",
"        Magnetic resonance imaging",
"       </td>",
"       <td class=\"subtitle1\">",
"        Radionuclide bone scan",
"       </td>",
"       <td class=\"subtitle1\">",
"        Arthrography",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Acute transient synovitis",
"        </strong>",
"       </td>",
"       <td>",
"        May demonstrate effusion",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        May demonstrate effusion",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        NA",
"       </td>",
"       <td>",
"        May demonstrate joint effusion and synovial inflammation (with contrast enhancement)",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        NA",
"       </td>",
"       <td>",
"        NA",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <strong>",
"         Septic arthritis",
"        </strong>",
"       </td>",
"       <td>",
"        May demonstrate effusion",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        <p>",
"         May demonstrate effusion",
"         <sup>",
"          &bull;",
"         </sup>",
"        </p>",
"        <p>",
"         May guide aspiration",
"        </p>",
"       </td>",
"       <td>",
"        NA",
"       </td>",
"       <td>",
"        <p>",
"         May demonstrate joint effusion and synovial inflammation (with contrast enhancement)",
"         <sup>",
"          &bull;",
"         </sup>",
"        </p>",
"        <p>",
"         Bone marrow edema is suggestive of septic arthritis but not always present",
"        </p>",
"        <p>",
"         May identify adjacent osteomyelitis",
"        </p>",
"       </td>",
"       <td>",
"        May suggest adjacent osteomyelitis",
"       </td>",
"       <td>",
"        NA",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <strong>",
"         Osteomyelitis",
"        </strong>",
"       </td>",
"       <td>",
"        <p>",
"         Usually normal in the early stages",
"        </p>",
"        <p>",
"         Bone destruction and/or joint effusion in advanced cases",
"        </p>",
"       </td>",
"       <td>",
"        NA",
"       </td>",
"       <td>",
"        NA",
"       </td>",
"       <td>",
"        May demonstrate bone marrow edema and joint effusion",
"       </td>",
"       <td>",
"        May facilitate diagnosis in children with normal plain films and poorly localized symptoms",
"       </td>",
"       <td>",
"        NA",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <strong>",
"         Developmental coxa vara",
"        </strong>",
"       </td>",
"       <td>",
"        Demonstrates decreased femoral neck-shaft angle (&lt;120&deg;), vertical orientation, and widening of the physis",
"       </td>",
"       <td>",
"        NA",
"       </td>",
"       <td>",
"        NA",
"       </td>",
"       <td>",
"        Preoperative planning (demonstrates the relationship between the acetabulum and femoral head, neck and shaft)",
"       </td>",
"       <td>",
"        NA",
"       </td>",
"       <td>",
"        NA",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <strong>",
"         Legg-Calv&eacute;-Perthes disease",
"        </strong>",
"       </td>",
"       <td>",
"        <p>",
"         Diagnosis, classification, and follow-up",
"        </p>",
"        <p>",
"         May be normal early in disease, but subsequently demonstrates sclerosis, fragmentation, and subchondral collapse of the ossification center of the femoral head",
"        </p>",
"       </td>",
"       <td>",
"        Adjunct to other imaging modalities",
"       </td>",
"       <td>",
"        Early diagnosis of bone collapse and definition of anatomy",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        <p>",
"         Facilitates early diagnosis (bone marrow edema)",
"        </p>",
"        <p>",
"         Evaluation of complications (femoral head subluxation; physeal abnormalities)",
"        </p>",
"        <p>",
"         Contrast enhanced MRI facilitates staging (avascular or revascularization and reparative)",
"        </p>",
"       </td>",
"       <td>",
"        May facilitate early diagnosis if plain films are normal; scintigraphic changes (decreased uptake in the femoral head) precede plain radiographic findings by about 3 months",
"       </td>",
"       <td>",
"        <p>",
"         Conventional arthrography: surgical planning in advanced disease",
"        </p>",
"        <p>",
"         MRA: assessment for complications",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <strong>",
"         Neuromuscular hip dysplasia",
"        </strong>",
"       </td>",
"       <td>",
"        Demonstrates valgus deformity, abnormal shape and location of the femoral head, and dysplastic changes in acetabulum",
"       </td>",
"       <td>",
"        NA",
"       </td>",
"       <td>",
"        Preoperative planning",
"       </td>",
"       <td>",
"        NA",
"       </td>",
"       <td>",
"        NA",
"       </td>",
"       <td>",
"        NA",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     NA: not applicable; MRI: magnetic resonance imaging; MRA: magnetic resonance arthrography.",
"     <br>",
"      * This age range is approximate; these problems may occur in children outside this age group.",
"      <br>",
"       <span class=\"bullet\">",
"        &bull;",
"       </span>",
"       Cannot differentiate between acute transient synovitis and septic arthritis of the hip.",
"       <br>",
"        &Delta; Use of computed tomography is limited because of the risk of radiation exposure.",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Overview of the use of various imaging modalities in the evaluation and management of common hip problems in children older than 10 years*",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Plain radiograph",
"       </td>",
"       <td class=\"subtitle1\">",
"        Ultrasonography",
"       </td>",
"       <td class=\"subtitle1\">",
"        Computed tomography",
"       </td>",
"       <td class=\"subtitle1\">",
"        Magnetic resonance imaging",
"       </td>",
"       <td class=\"subtitle1\">",
"        Radionuclide bone scan",
"       </td>",
"       <td class=\"subtitle1\">",
"        Arthrography",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Slipped capital femoral epiphysis",
"        </strong>",
"       </td>",
"       <td>",
"        Diagnosis:",
"        <ul>",
"         <li>",
"          Stable: widening and irregularity of the capital femoral physis, osteopenia, increased density of metaphysis",
"         </li>",
"         <li>",
"          Unstable: displacement of the capital femoral epiphysis",
"         </li>",
"        </ul>",
"       </td>",
"       <td>",
"        NA",
"       </td>",
"       <td>",
"        Treatment planning in advanced disease",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        <p>",
"         Early diagnosis (demonstrates physeal widening before apparent on plain films)",
"        </p>",
"        <p>",
"         Detection of complications (eg, avascular necrosis)",
"        </p>",
"       </td>",
"       <td>",
"        Detection of complications (eg, avascular necrosis)",
"       </td>",
"       <td>",
"        NA",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <strong>",
"         Pelvic apophyseal avulsions",
"        </strong>",
"       </td>",
"       <td>",
"        Displacement of the apophyseal center from its normal position, callus formation, bony reaction",
"       </td>",
"       <td>",
"        NA",
"       </td>",
"       <td>",
"        NA",
"       </td>",
"       <td>",
"        <p>",
"         Useful in suspected avulsion injuries with negative radiographs",
"        </p>",
"        <p>",
"         Demonstrates bone marrow edema and soft tissue injuries at the site of avulsion; also may demonstrate physeal widening",
"        </p>",
"       </td>",
"       <td>",
"        NA",
"       </td>",
"       <td>",
"        NA",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <strong>",
"         Iliopsoas tendinosis and bursitis",
"        </strong>",
"       </td>",
"       <td>",
"        NA",
"       </td>",
"       <td>",
"        <p>",
"         Demonstrates enlarged bursa",
"        </p>",
"        <p>",
"         May guide bursal aspiration",
"        </p>",
"       </td>",
"       <td>",
"        NA",
"       </td>",
"       <td>",
"        Thickening with increased signal in the iliopsoas tendon with increased synovial fluid or hypertrophy of the bursa",
"       </td>",
"       <td>",
"        NA",
"       </td>",
"       <td>",
"        NA",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <strong>",
"         Snapping hip syndrome",
"        </strong>",
"       </td>",
"       <td>",
"        NA",
"       </td>",
"       <td>",
"        <p>",
"         Dynamic sonography can confirm the diagnosis",
"        </p>",
"        <p>",
"         In external snapping hip, the posterior iliotibial band or anterior portion of the gluteus maximus muscle catches over the greater trochanter",
"        </p>",
"        <p>",
"         In internal snapping hip the iliopsoas tendon moves over the lesser trochanter",
"        </p>",
"       </td>",
"       <td>",
"        NA",
"       </td>",
"       <td>",
"        NA",
"       </td>",
"       <td>",
"        NA",
"       </td>",
"       <td>",
"        NA",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <strong>",
"         Athletic pubalgia",
"        </strong>",
"       </td>",
"       <td>",
"        Symmetric sclerosis of the pubic symphysis",
"       </td>",
"       <td>",
"        NA",
"       </td>",
"       <td>",
"        NA",
"       </td>",
"       <td>",
"        <p>",
"         Edema of the pubic body",
"        </p>",
"        <p>",
"         Injury to the insertion of the rectus abdominus muscle",
"        </p>",
"       </td>",
"       <td>",
"        NA",
"       </td>",
"       <td>",
"        NA",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <strong>",
"         Stress fractures",
"        </strong>",
"       </td>",
"       <td>",
"        Chronic stress reaction (may be normal in the early stage)",
"       </td>",
"       <td>",
"        NA",
"       </td>",
"       <td>",
"        NA",
"       </td>",
"       <td>",
"        Early detection (demonstrates bone marrow edema)",
"       </td>",
"       <td>",
"        Early detection (demonstrates increased uptake)",
"       </td>",
"       <td>",
"        NA",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <strong>",
"         Acetabular labral tear",
"        </strong>",
"       </td>",
"       <td>",
"        NA",
"       </td>",
"       <td>",
"        NA",
"       </td>",
"       <td>",
"        NA",
"       </td>",
"       <td>",
"        MR arthrography shows the labral tear",
"       </td>",
"       <td>",
"        NA",
"       </td>",
"       <td>",
"        Demonstrates the labral tear; however, conventional arthrography has been replaced by MR arthrography",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <strong>",
"         Femoroacetabular impingement",
"        </strong>",
"       </td>",
"       <td>",
"        <p>",
"         Cam-type: demonstrates a non-spherical femoral head or lack of femoral head-neck offset",
"        </p>",
"        <p>",
"         Pincer type: acetabular over-coverage",
"        </p>",
"       </td>",
"       <td>",
"        NA",
"       </td>",
"       <td>",
"        NA",
"       </td>",
"       <td>",
"        Facilitates diagnosis of the type (cam or pincer) and demonstrates abnormalities of the femoral head, neck, and acetabulum",
"       </td>",
"       <td>",
"        NA",
"       </td>",
"       <td>",
"        NA",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <strong>",
"         Idiopathic chondrolysis of the hip",
"        </strong>",
"       </td>",
"       <td>",
"        Joint space narrowing and osteopenia, protrusion acetabuli, osteophyte formation, premature physeal fusion",
"       </td>",
"       <td>",
"        NA",
"       </td>",
"       <td>",
"        NA",
"       </td>",
"       <td>",
"        Early detection (shows cartilage loss, geometric abnormal signal in the proximal femoral epiphysis, acetabular bone marrow edema, synovial hypertrophy or enhancement, and minimal joint fluid)",
"       </td>",
"       <td>",
"        NA",
"       </td>",
"       <td>",
"        NA",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     NA: not applicable.",
"     <br>",
"      * This age range is approximate; these problems may occur in children outside this age group.",
"      <br>",
"       &Delta; Use of computed tomography is limited because of the risk of radiation exposure.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_30_19951=[""].join("\n");
var outline_f19_30_19951=null;
